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ABSTRACT OF DISSERTATION 
MECHANISMS OF THERAPEUTIC RESISTANCE IN 
CASTRATION RESISTANT PROSTATE CANCER 
Taxane based chemotherapy is an effective treatment for castration-resistant prostate 
cancer (CRPC) via stabilization of microtubules. Progression to castration-resistant 
prostate cancer is characterized by increased androgen receptor (AR), elevated intra-
prostatic androgens and activated AR signaling despite castrate levels of androgens. 
Previous studies identified that the inhibitory effect of microtubule targeting 
chemotherapy on AR activity was conferred by interfering with AR intracellular 
trafficking. The N-terminal domain (NTD) of AR was identified as a tubulin interacting 
domain that can be effectively targeted by the novel small molecular inhibitor, EPI. 
Taken together, this evidence provided the rationale that targeting AR nuclear 
translocation and activity via a combination of an antagonist of the AR NTD and taxane 
based chemotherapy may enhance the therapeutic response in CRPC. This study 
investigated the anti-tumor efficacy of a combination of EPI with Docetaxel 
chemotherapy, in cell models of CRPC, harboring AR splice variants in addition to full 
length AR.  Our findings demonstrate there was no significant effect on androgen-
mediated nuclear transport of AR variants and transcriptional activity by Docetaxel. The 
therapeutic response to Docetaxel was enhanced by inhibition of the NTD of AR (by EPI) 
through cycling of epithelial-mesenchymal transition (EMT) to mesenchymal–epithelial 
transition (MET) among prostate cancer epithelial cells. These results support that 
transient programming of EMT by the AR NTD inhibitor, potentially drives sensitivity of 
prostate tumors with differential distribution of AR variants to microtubule targeting 
chemotherapy.  
The FDA-approved next-generation taxane, Cabazitaxel (CBZ) and the anti-androgen 
Enzalutamide (MDV3100) have demonstrated additional survival benefits for patients 
with advanced CRPC. The present study pursued the mechanism of therapeutic 
resistance to Cabazitaxel and anti-androgen treatment in vitro and in vivo models of 
CRPC. The findings support the ability of Cabazitaxel to target pro-mitotic kinesins, 
providing an insight into a new mechanism of action of this chemotherapy. Moreover, the 
in vivo evidence identified that Cabazitaxel chemotherapy has novel effects beyond 
suppressing tumor growth, by inducing prostate glandular differentiation. Our results are 
of translational significance in introducing a novel mechanism for cross-resistance to 
Cabazitaxel chemotherapy and anti-androgen therapy and a potential targeting platform 
to overcome such resistance in advanced CRPC.   
KEYWORDS:  Prostate Cancer, Androgen Receptor, 
Microtubules, Taxanes, Anti-Androgens 
_________Sarah Katherine Martin__ 
Student’s Signature 
_________________04/27/2015____ 
Date 
MECHANISMS OF THERAPEUTIC RESISTANCE 
IN CASTRATION RESISTANT PROSTATE CANCER 
By 
Sarah Katherine Martin, M.S. 
_____Dr. Natasha Kyprianou_________ 
Director of Dissertation 
_____Dr. Michael Mendenhall________ 
Director of Graduate Studies 
___________01/09/2015____________ 
ACKNOWLEDGEMENTS 
The following dissertation was an individual effort but benefitted from the insights 
and directions of several people. First, my Dissertation Chair, Mentor, Advisor, and 
Friend, Natasha Kyprianou exemplifies the high quality scholarship to which I aspire. I 
sincerely appreciate her diligent mentorship which brought me to this point in my 
education. Furthermore, I have great admiration for her commitment to scientific 
excellence, fierce capacity for friendship, and endless personal style. Next, I wish to 
thank the complete Dissertation Committee: Drs. Craig Vander Kooi, Haining, Zhu, and 
Rina Plattner as well as the outside examiner, Dr. Chang-Guo Zhan. Each individual 
provided insights that guided and challenged my thinking, substantially improving the 
finished product.  I appreciate Dr. Marianne Sadar for contributing to this work as an 
expert collaborator. I would like to express appreciation to past and present members of 
the Kyprianou Laboratory; to Drs. Joanne Collazo Santiago and Michael Fiandalo, I 
express my deepest appreciation for mentoring me in all scientific techniques used to 
complete this dissertation and endless understanding of the frustrations of working in a 
scientific laboratory. To Patrick Hensley, I recognize his contribution to this research by 
serving as a trustworthy steward of my cell culture at times when I must be away from 
the laboratory. I would like to recognize the tireless efforts of medical student researcher, 
Justin Penticuff, whose contributions to this work were essential to its completion.   To 
Drs. Hong Pu and Zheng Cao, I recognize their contributions to this dissertation with 
expertise in transgenic mouse work and execution of experiments.  
In addition to the technical and instrumental assistance above, I received equally 
important assistance from my family and friends. My husband, Jack Spaulding, provided 
on-going support throughout the dissertation process, as well as technical assistance 
critical for completing the project in a timely manner. Without his encouragement, I would 
never have attempted this program of study, let alone finish it.  My mother, Karen Martin, 
instilled in me, from an early age, the desire and skills to obtain this Ph.D. and she 
remains, as always, my biggest fan. My father, Keith Martin, deserves recognition for 
always encouraging my interests in science. My grandparents, Edsel and Ardath Rohm, 
are among the greatest influences in my life and who taught me that a job is not finished 
until every aspect is done and your tools are put away: a lesson that has literally carried 
me through the production of this dissertation document.  I would like to recognize my 
equestrian mentor, Adrienne Hancock-Leong, who instilled in me the importance of 
higher education and an unrelenting quest for perfection in all things. Lastly, I would like 
to recognize my non-human family members:  thank you to my horse and dogs. SRC 
Parrot Bay** provided daily reminder that humility is essential in every pursuit but also 
brought me great personal triumph. Fleetwood Farm’s Despicable Me for reminding me 
that life is not really that complicated,  Lunn’s Ultra Violet for reminding me that life is 
more complicated than you think, and GTF Last Mango in Paris for teaching me that life 
is precious and gone too quickly. 
iii 
TABLE OF CONTENTS 
Acknowledgements……………………………………………………………………………iii 
List of Figures………..…………………………………………………………………………vi 
Chapter One: Introduction 
The Clinical Challenge for Treatment of Advanced Prostate Cancer……………..1 
Androgen Receptor Signaling……………………………………………….……...…2 
Epithelial – Mesenchymal Transition (EMT) in Prostate Cancer Progression……7 
AR Cross-Talk with Growth Factor Signaling……………………………………….14 
Androgen Deprivation Therapy………………………………………………………20 
Abiraterone……………………………………………………………….……22 
Enzalutamide (MDV3100)……………………………………………………22 
N terminal domain targeting EPI-002………………………………….……23 
Classical Taxane Action………………………………………………………………24 
Cabazitaxel……………………………………………………………….……25 
Beyond Microtubule Stabilization……………………………………………….……26 
Mechanisms of Therapeutic Resistance…………………………………………….30 
EMT as a mechanism of resistance………………………………………...34 
Overcoming Taxane Resistance in Clinical Setting……………………….35 
Combination Strategies……………………………………………………………….37 
Platinum Based Therapy……………………………………………………..37 
Abiraterone Acetate…………………………………………………………..37 
Enzalutamide…………………………………………………………….…….37 
Radio-pharmaceuticals……………………………………………………….38 
Clusterin targeting (OGX-011)……………………………………………….39 
Other combinations…………………………………………………………...39 
Docetaxel to Cabazitaxel…………………………………………………….40 
Conclusions………………………………………………………………………….…41 
Chapter Two: N-Terminal Targeting of AR Variant Enhances Response of Castration 
Resistant Prostate Cancer to Taxane Chemotherapy 
Background and Significance……………………………………...…………………55 
Approach………………………………………………………………………………..57 
Cell Lines………………………………………………………………………57 
Antibodies……………………………………………………………………...58 
Cell Viability Assay……………………………………………………………58 
Cell Proliferation……………………………………………………………….58 
Western Blot Analysis………………………………………………………...59 
Quantitative RT-PCR Analysis………………………………………………59 
Luciferase Reporter Gene Assays…………………………………………..60 
Immunofluorescent Confocal Microscopy………………………………….60 
In Vivo Tumor Targeting Studies……………………………………………61 
Immunohistochemical Analysis……………………………………………...61 
Statistical Analysis…………………………………………………………….62 
Results 
Combination of Docetaxel and EPI Maximizes Blockade of AR Activity 
and Impairs Human Castration Resistant Prostate Cancer Growth in vitro 
and in vivo……………………………………………………………………...62 
Impact of AR Variants on Taxane-Mediated AR Trafficking……………...64 
iv 
Differential Effect of Taxane and EPI  
Treatment on AR vs AR-V7 Target Genes…………………………………66 
Role of EMT in Therapeutic Response of  
CRPC to Combined Targeting of AR NTD and 
Microtubules…………………………………………………………………...67 
 Conclusions………………………………………………………………………….…69 
 
Chapter Three: Cabazitaxel Induces Mesenchymal Epithelial Transition (MET) and 
Overcomes Phenotypic Resistance in Advanced Prostate Cancer 
 Background and Significance………………………………………………….……..92 
 Approach………………………………………………………………………….…….95 
  Cell Lines and Transfections………………………………………….……..95 
  Drugs…………………………………………………………………….……..95 
  Antibodies…………………………………………………………..………….96 
  Western Blot Analysis………………………………………..……………….96 
  Cell Viability Assay……………………………………………………………96 
  Migration Assays…………………………………………...…………………97 
  Quantitative RT-PCR Analysis………………………………………………97 
  Immunofluorescent Confocal Microscopy………………………………….97 
  Flow Cytometric Analysis…………………………………………………….98 
  In Vivo Tumor Targeting Studies……………………………………………98 
  Transgenic Mouse Model of Prostate Cancer Progression………………99 
  Immunohistochemical Analysis……………………………………………...99 
  Statistical Analysis…………………………………………………………..100 
 Results 
Significance of AR Status in Prostate Cancer Cell Response to 
Cabazitaxel…………………………………………………………………...100 
  Effect of Cabazitaxel Treatment on AR Expression, Localization 
and Activity………….………………………………………………………..102 
Cabazitaxel Causes Multi-nucleation in Prostate Cancer Cells by 
Targeting Kinesins…………………………… ……………………..……...105 
In Vivo Novel Action of Cabazitaxel in Models of Advanced Prostate 
Cancer via Induction of Mesenchymal Epithelial Transition (MET) and 
Glandular Differentiation………………………………………………..…..106 
 
 Conclusions…………………………………………………………………………...111 
 
Chapter Four: Discussion……………………………………………………………….……143 
 
References…………………………………………………………………………………….155 
 
Vita……………………………………………………………………………….……………..175 
 
v 
LIST OF FIGURES 
Figure 1.1, The Androgen Receptor (AR)……………………………………………………44 
Figure 1.1a, AR Structure……………………………………………………………………..44 
Figure 1.1b, Targeting AR translocation to the nucleus in prostate cancer……………...45 
Figure 1.2, Role of AR in Prostate Cancer and EMT……………………………………….46 
Figure 1.3, Therapeutic Targeting of Hormonally Dependent Prostate Cancer…………48 
Figure 1.4, Taxane Mechanism of Action……………………………………………………50 
Figure 1.5, Mechanisms of Taxane Resistance in CRPC………………………..………..52 
Figure 1.6, Differential Effect of Docetaxel (DOC) and Cabazitaxel (CBZ) on ATP-
dependent Motor Proteins Driving Therapeutic Response………………………………...54 
Figure 2.1, Combination of an AR NTD Inhibitor and Docetaxel Impairs Growth of 
Castration Resistant Prostate Cancer in vitro and in vivo…………………………….……74 
Figure 2.2, Effect of DOC and EPI Combination on Apoptosis and Vascularity of CRPC 
Xenografts……………………………………………………………………………………….76 
Figure 2.3, Effect of Microtubule and NTD AR Targeting on AR and Cytoskeleton in 
CRPC…………………………………………………………………………………………….77 
Figure 2.4, Impact of Androgens on the Effect of Taxane Monotherapy on AR 
Localization………………………………………………………………...............................80 
Figure 2.5, Cell Death in Response to Microtubule Targeting (Taxane), N-terminal 
Targeting of AR or the Combination in the Androgen-Sensitive Human Prostate Cancer 
Cells, LNCaP……………………………………………………………………………………81 
Figure 2.6, Effect of Targeting Microtubules and N-terminal AR on Cytosolic Protein 
Association and Nuclear Localization / Activity in 22Rv1 Prostate Cancer Cells………..83 
Figure 2.7, Effect of Combined Targeting of Microtubules and AR NTD in Androgen-
Sensitive LNCaP95 Cell Growth and AR Activity…………………………………………...85 
Figure 2.8, Impact of AR Variant on EMT in CRPC 22Rv1 Cells in Response to 
Combination Targeting of the AR NTD and Microtubules………………………………….87 
Figure 3.1, Human Prostate Cancer Cell Response  
to Cabazitaxel and AR Targeting……………………………………………………………116 
Figure 3.2, Dose Response Analysis of Human Prostate Cancer Cells to Antiandrogen 
Enzalutamide (MDV3100) and Docetaxel …………………………………………………118 
Figure 3.3, Effect of Cabazitaxel on AR Localization and Gene Expression in Prostate 
Cancer Cells…………………………………………………………………………………...120 
Figure 3.4, Combined Effect of Cabazitaxel and Enzalutamide on AR Expression and 
Localization in VCaP Cells…………………………………………………………………...122 
Figure 3.5, AR Variant Localization and Tubulin Expression in CBZ Resistant 
PC3v567es Cells……………………………………………………………………………...124 
Figure 3.6, Cabazitaxel Results in Multi-nucleation and Centrosome Clustering in 
Prostate Cancer Cells by Targeting Kinesins……………………………………………...126 
Figure 3.7, Effect of Cabazitaxel on Kinesin Expression in VCaP Cells………………..128 
Figure 3.8, Effect of Cabazitaxel on Centrosomal Amplification in  
CRPC 22Rv1 cells……………..……………………………………………………………..129 
Figure 3.9, In Vivo Therapeutic Regimen of Cabazitaxel in a Transgenic  
Mouse Model of Aggressive Prostate Tumor Progression……..………………………...130 
Figure 3.10, In Vivo Effect of Cabazitaxel on an Androgen-responsive  
Prostate Cancer Model of Tumor Progression to Lethal Disease…………………..…...132 
vi 
Figure 3.11, Cabazitaxel Impairs Advanced Prostate Cancer by Inducing MET and 
Targeting Kinesins……………………………………………………………………….…...134 
Figure 3.12, Therapeutic Dosing Regimen of Cabazitaxel Treatment in Nude Mice 
Bearing 22Rv1 CRPC Xenografts…………………………………………………………..136 
Figure 3.13, Effect of Cabazitaxel and Antiandrogen (Enzalutamide) on CRPC Xenograft 
Growth……………………………………………………………………………………….…138 
Figure 3.14, Cabazitaxel Reverses EMT and Retains Nuclear AR in Human CRPC 
Xenograft ……………………………………………………………….……………………..140 
Figure 3.15, Therapeutic Action of Cabazitaxel by Targeting AR and Mitotic Kinesins in 
CRPC…………………………………………………………….…………………………….141
 
vii 
Chapter 1.  Introduction: 
The Clinical Challenge for Treatment of Advanced Prostate Cancer 
Over seventy years ago, male steroid hormones were implicated in prostate 
cancer proliferation by Huggins and Hodges  (1941), and withdrawal of these hormones 
was shown to diminish this growth (Huggins & Hodges, 1941). Androgen deprivation 
therapy (ADT) can be achieved by a variety of surgical and/or pharmacological methods, 
but regrettably ultimately, fails to effectively cure patients with prostate cancer. 
Castration resistant prostate cancer (CRPC) occurs when prostate tumor cells begin to 
proliferate again in the absence of male steroid hormones and this represents a much 
more aggressive disease state.  Biochemical recurrence can be monitored in patients by 
sequential evaluation of serum prostate specific antigen (PSA); nearly 70,000 American 
men develop this biochemical recurrence per year (Freedland & Moul, 2007; Hu, 
Denmeade, & Luo, 2010).  PSA screening facilitates the identification of at risk patients 
experiencing biochemical recurrence to metastatic CRPC progression. Progression to 
CRPC is characterized by increased AR expression in the prostate tissues and perpetual 
AR signaling despite physiological castrate levels of androgens (C. D. Chen et al., 2004; 
B.J. Feldman & D. Feldman, 2001).   Localized prostate cancer is highly curable with 
radical prostatectomy or radiation therapy, but among men who progress to CRPC, 
median survival is less than two years and 90% of these men will endure bone 
metastases (Hotte & Saad, 2010). Until very recently, taxanes were the only 
chemotherapy class to confer additional survival and palliative benefit to CRPC patients. 
Over-expression and localization of the AR to the nucleus has been associated with 
reactivation of the androgenic signaling axis and progression to metastatic CRPC in 
patients (B. J. Feldman & D. Feldman, 2001). 
1 
Taxanes are cytotoxic chemotherapeutic agents which bind to the β tubulin 
subunit of the protofilament of the microtubule, stabilizing the structure of the cellular 
cytoskeleton. This stabilization prevents cells from dividing, inducing mitotic arrest and 
apoptosis. While the antimitotic capability of taxanes is irrefutable, prostate cancer 
tumors are not particularly fast growing. In fact, prostate tumor cells have 
characteristically slow doubling times in patients suggesting that taxanes are affecting 
more than just mitotic events. The goal of this project was to dissect the mechanisms 
and molecular events of taxane treatment beyond the antimitotic effects in tumors 
resistant to anti-androgen therapies and their exploitation towards optimal therapies for 
patients with metastatic CRPC.  
Androgen Receptor Signaling 
The role of the androgen receptor (AR) signaling axis in the progression of 
prostate cancer is a cornerstone to our current understanding of the molecular 
mechanisms behind this malignancy that has become an American epidemic.  The cross 
talk of AR with other critical signaling pathways may explain the advancement of 
prostate cancer to metastatic castration resistant prostate cancer (CRPC) (M.-L. Zhu & 
Kyprianou, 2008). Of particular interest to such crosstalk are the pathways associated 
with epithelial to mesenchymal transition (EMT). Reactivation of EMT is a hallmark of 
metastatic cancer spread, and recent evidence suggests the involvement of AR in the 
signaling pathways regulating EMT (M. Zhu & Kyprianou, 2010). Cadherin switching, 
EMT inducing transcription factors, Wnt, TGF-β, and Notch signaling can all be 
modulated by crosstalk with the AR.    The current understanding of the functional 
exchanges between the androgen signaling by AR activity and key growth factor 
signaling pathways that impact EMT towards prostate cancer progression to metastatic 
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CRPC is discussed towards appreciation of the clinical relevance in the effective 
targeting of advanced disease. 
The AR is a member of the steroid-thyroid-retinoid nuclear receptor superfamily 
found on the X chromosome  (Xq11-12) spanning approximately 180kb of DNA with 8 
exons (Gelmann, 2002).    In normal AR signaling, testosterone synthesized in the testis 
or adrenal gland is sequestered by sex hormone binding protein (SHBP) circulating in 
the blood. Testosterone dissociates from SHBP and diffuses across the plasma 
membrane, bringing testosterone into close proximity with 5 α- reductase (SRD5A1, 
SRD5A2) (cytochrome p450 enzyme) producing the cognate ligand of AR: 
dihydrotestosterone; DHT (Lonergan & Tindall, 2011; Schmidt & Tindall, 2011; Wilson, 
2001).   When AR binds its cognate ligand DHT, it facilitates the rearrangement of AR 
protein domains, facilitates conformational change within the heat shock protein 90 
(Hsp90) super complex and subsequent transcriptional activation after translocation. 
DHT bound AR undergoes homo-dimerization and phosphorylation by the Protein 
Kinase A signaling pathway resulting in activation (Brinkmann et al., 1999; Nazareth & 
Weigel, 1996).   The AR homo-dimers translocate to the cellular nucleus and may bind 
androgen responsive genes   (ARG) at specific palindromic DNA sequences known as 
androgen responsive elements   (ARE) (Feng, Zheng, Wennuan, Isaacs, & Xu, 2011). 
Upon binding to ARE, AR dimers can act as a scaffold towards the recruitment of 
accessory proteins to assemble an active transcription complex (Feng et al., 2011; 
Heinlein & Chang, 2002; Roy, Lavrosky, & Song, 1999).   AR binding to ARE forms a 
stable pre-initiation complex near the transcriptional start site facilitating the recruitment 
and initiation of RNA polymerase II (Figure. 1.2.B) (Jenster, van der Korput, Trapman, & 
Brinkmann, 1995).    
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Structurally, AR is composed of an amino-terminal activating domain (NTD), a 
carboxy-terminal ligand binding domain (LBD), a DNA binding domain in the mid-region 
that contains two zinc finger motifs to facilitate the interaction of the protein with the DNA 
double helix (DBD), and a hinge region to facilitate the change in protein folding upon 
binding to the ligand and dimerization (Figure. 1.1.A).    These four domains comprise 
the 919 amino acid protein with a mass of 110 kDa.   N-terminal Domain: The NTD 
(exon 1, amino acids 1-537) has been shown to possess multiple transcriptional 
activating units (TAU): TAU-1 and TAU-5 (Figure. 1.1.A) (Jenster et al., 1995). TAU-1 is 
associated with wild type AR transcriptional activation, and is characterized by a high 
number of acidic amino acids, three glutamine repeats, and a phosphorylation site.   
Conversely, the TAU-5 sequence is characterized by stretches of proline, alanine, and 
glycine (Jenster et al., 1995). TAU-5 is responsible for the constitutive transcriptional 
activity of the NTD and is mediated by a core sequence of 435WHTLF439  in between 
the aforementioned alanine and glycine stretches (Figure 1.1.A) (Dehm, Regan, 
Schmidt, & Tindall, 1989; Lonergan & Tindall, 2011). The cysteine rich DBD (exons 2 
and 3, amino acid: 68) contains two important motifs (Simental, Sar, Lane, French, & 
Wilson, 1991).   The P-box motif found in the first of two zinc fingers facilitates the 
interaction of the AR with gene specific nucleotide sequences inside the major groove of 
the DNA double helix (Figure. 1.1.A) (Umesono & Evans, 1989).   The D-box motif 
mediates the DBD/LBD interaction that allows for inter-domain interaction and AR homo-
dimerization after activation and facilitates the spacing of the AR over the half sites and 
binding on the ARE (Fig. 1.1.A) (Lonergan & Tindall, 2011; Umesono & Evans, 1989; 
van Royen, van Cappellen, de Vos, Houtsmuller, & Trapman, 2012; Zhou, Sar, Simental, 
Lane, & Wilson, 1994).The DBD contains one of the nuclear localization signals (NLS) 
as discussed below.  
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With only approximately 50 amino acids, the hinge region packs a big punch in a 
small space.   The flexible hinge region separates the LBD and the DBD while containing 
part of the bipartite nuclear localization signal (Figure. 1.1.A) (Haelens, Tanner, 
Denayer, Callewaert, & Claessens, 2007; Robinson-Rechavi, Escriva, & Laudet, 2003).   
The hinge region  (as well as DBD and LBD) also contains a site for interaction with 
Filamin A, an actin interacting protein and signaling scaffold required for nuclear 
translocation of the AR (Lonergan & Tindall, 2011; Ozanne et al., 2000).   The hinge 
region plays a role in nuclear localization, DNA binding inhibition, coactivator 
recruitment, and the N terminal / C terminal interaction of the AR (Haelens et al., 2007).   
A span of highly basic residues between 629 and 636  (629-RKLKKLGN-636)  is 
conserved in all AR sequences known and decreases the affinity of AR for DNA binding 
as demonstrated by deletion constructs (Haelens et al., 2007). Ligand Binding Domain: 
The LBD  (exons 4-8, ~250 amino acids) mediates the binding of the AR ligand  
(testosterone or DHT) to the AR protein and initiates the downstream cascade of the 
androgen signaling axis (Lonergan & Tindall, 2011). In addition to ligand binding, the 
LBD associates with the heat shock protein super-complex, interacts with numerous co-
regulators and participates in receptor dimerization (Figure. 1.1.A and Figure 1.1.B) 
(McKenna, Lanz, & O'Malley, 1999; Poukka et al., 2000; Pratt & Toft, 1997; Xu, Glass, & 
Rosenfeld, 1999). The AR protein is composed of two activation domains (AF-1 and AF-
2).   The AF-1 domain is localized to the NTD and is composed of TAU-1 and TAU-5 
domains contributing to the transcriptional activation program (Figure 1.1.A).   The AF-2 
domain is localized to the LBD and interacts with LxxLL-containing co-regulators such as 
the steroid receptor co-activators [SRC], and TAU domains in the NTD (Heery, 
Kalkhoven, Hoare, & Parker, 1997; Lonergan & Tindall, 2011).   
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Nuclear translocation of the AR is inhibited by its sequestration in the Hsp90 
super-complex, tethering it to the cytoskeleton. The nuclear localization signal  (NLS1) of 
AR is bipartite and spans the DBD and hinge regions of the protein with exons 3 and 4 
represented (Zhou et al., 1994).   Nuclear translocation of the full length AR is protected 
by the bipartite nature of the NLS; this feature safeguards that cooperation between the 
domains occur before nuclear transport may proceed (Zhou et al., 1994). Binding of AR 
to its cognate ligand facilitates a conformational change that brings the NLS into a 
functional orientation for signaling translocation (Zhou et al., 1994).   After nuclear 
translocation, NLS allows the binding of AR to the importin-α adaptor protein and 
importin-β carrier protein (S. C. Chan, Y. Li, & S.M. Dehm, 2012),  facilitating movement 
through the nuclear pore complex and Ran-dependent release into the nucleus (Black & 
Paschal, 2004; Brodsky & Silver, 1999; Corbett & Silver, 1997; Cutress, Whitaker, Mills, 
Stewart, & Neal, 2008; Gorlich, 1997; Nigg, 1997).   A second NLS sequence (NLS2) 
exists in the LBD and allows AR to enter the nucleus via importin-α independent 
mechanism (Picard & Yamamoto, 1987; Poukka et al., 2000; Savory et al., 1999).  In the 
cytosol, the hinge region of AR and the Hsp90 super-complex mediates interaction with 
the 280kDa cytoskeletal protein, Filamin-A  (FLNA) (C. J. Loy, Sim, & Yong, 2003; 
Ozanne et al., 2000). Filamin-A is an important regulator of the solation-gelation 
equilibrium at the cell membrane. By cross-linking F-actin fibers into orthogonal arrays, it 
is able to affect the stability of the cytoskeleton that lies beneath the cell membrane 
(Koteliansky, Shirinsky, Gneushev, & Smirnov, 1981; Ozanne et al., 2000).    Filamin-A 
contributes to mediating the translocation of the AR to the nucleus upon activation by 
facilitating interaction with the microtubule associated motor protein, dynein (Darshan, 
Loftus, Thadani-Mulero, Levy, Escuin, X.K., et al., 2011; C. J. Loy, Sim, K.S., Yong, E.L., 
2003; Ozanne et al., 2000). 
 
6 
Various co-regulatory proteins interact with AR and have been expertly reviewed 
elsewhere (Heemers & Tidall, 2007). Of particular interest are the intra-molecular 
interactions within the AR protein domains and between AR subunits in a homo-dimeric 
complex which are of utmost importance to the activation and nuclear translocation (van 
Royen et al., 2012). Upon binding DHT, the D-box of the DBD interacts with the TAU-1 
domain of the NTD, an N-terminal to C-terminal protein domain interaction that is 
initiated in the cytoplasm (Schaufele et al., 2005; van Royen et al., 2012).   The 
interaction between the D-box and the NTD of the AR is essential for the transition 
towards inter-AR molecule homo-dimerization (Schaufele et al., 2005). Homo-
dimerization occurs in the cytosol prior to reaching the nucleus. Upon binding DNA, the 
N-terminal/C-terminal intramolecular interaction is finished freeing these domains to 
interact with AR co-regulators and the homo-dimer settles into the major groove of the 
DNA double helix (Van Royen et al., 2007; van Royen et al., 2012).    
 
 
Epithelial-Mesenchymal Transition (EMT) in Prostate Cancer Progression      
The biological process of EMT was first described in the context of normal organ 
development (Greenburg & Hay, 1982). Reactivation of EMT quickly became a hallmark 
of metastatic tumors. EMT is observed extensively in non-pathological conditions such 
as mechanisms of development including gastrulation and neural crest development in 
which epithelial cells must de-differentiate to a mesenchymal form, migrate, and re-
differentiate into a new structure or organization (Yilmaz & Christophori, 2009). EMT can 
be classified into three distinct subtypes based on the biological setting hosting its 
manifestation (Kalluri & Weinberg, 2009). Type 1 EMTs are associated with embryonic 
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implantation and gastrulation facilitating the stratification of the germinal layers (Kalluri & 
Weinberg, 2009). Unlike Type 1, Type 2 EMTs are associated with wound healing, 
tissue regeneration, and organ fibrosis.  Type 2 EMTs are characteristically induced by 
inflammatory signaling, either as a response to injury-induced inflammation as seen in 
wound healing or ongoing inflammation of certain organs resulting in fibrosis. Type 3 
EMTs occur in neoplastic cells that undergo a manifold of genetic or epigenetic changes 
resulting in localized tumor cell proliferation. The Type 3 EMT is responsible for changes 
that facilitate tumor cell invasion and metastasis (Kalluri & Weinberg, 2009).     
Emerging evidence suggests that reactivation of EMT processes may facilitate 
the development of prostate cancer (Matuszak & Kyprianou, 2011b) , with increasing 
number of studies focusing on the direct involvement of androgen/AR signaling in EMT / 
MET transitions. The clinic-pathological significance of EMT in human cancers continues 
to be a topic of debate. EMT is being interrogated by proteomic analysis towards 
defining its role in prostate cancer progression to metastasis. Investigating the regulatory 
mechanisms by which EMT programs are controlled by the androgen/AR signaling, is 
fundamentally important for understanding the functional contribution of EMT to various 
stages of prostate tumor progression to metastatic CRPC disease and emergence of 
therapeutic failure.   
Mechanistically, EMT can be activated by TGF-β and receptor tyrosine kinase  
(RTK) / Ras signaling in addition to the well-known canonical Wnt-/Β-catenin, Notch, 
Hedgehog, and NFκB dependent pathways (Huber, Kraut, & Beug, 2005). “Cadherin 
switching” is an important regulatory step in EMT induction, regulated by transcriptional 
regulators including Snail and Twist (Huber et al., 2005). Recent investigations from this 
laboratory strongly implicate the androgen signaling axis as an active participant in the 
progression of the mechanistic sequelae of EMT (Matuszak & Kyprianou, 2011b; M. Zhu 
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& Kyprianou, 2010). In what is seemingly becoming a controversial topic, androgens can 
induce EMT-associated changes in prostate cancer cells, regardless of their androgen 
sensitivity, conferring enhanced invasive and motile capacity via modulating the 
transcriptional regulator, Snail (M. Zhu & Kyprianou, 2010).  Moreover, an inverse 
relationship between AR expression and extent of androgen-induced EMT induction 
suggest that very low level AR expression such as that seen immediately after beginning 
ADT may be contributing to metastatic spread of prostate cancer tumor cells (M. Zhu & 
Kyprianou, 2010). Studies by other investigators have shown that prostate cancer cells 
expressing AR in androgen-deprived conditions undergo an EMT, characterized by 
decreased E-cadherin and increased N-cadherin and Vimentin (Y. Sun et al., 2011). 
Increased N-cadherin expression and metastasis was seen in LNCaP xenografts and 
human clinical specimens (Tanaka et al., 2010). The β-catenin/ Wnt dependent signaling 
pathway is already a well-known accomplice in progression to EMT and metastasis, but 
the implication of this pathway under androgenic drive is essential to understanding 
prostate tumor specific EMT. Recent exciting insights into EMT regulation in prostate 
cancer implicates β-catenin in the androgen modulated EMT effect (M. Zhu & Kyprianou, 
2010).   
The physiological phenomenon known as “cadherin switching” has been 
accepted as a hallmark of EMT.  E-cadherin or epithelial cadherin is an important cell 
adhesion protein mediating intercellular contacts and facilitating maintenance of tissue 
architecture. This is a protein essential to formation of adherens junctions which in 
combination with tight junctions mediate intercellular adhesion (Yilmaz & Christophori, 
2009). E-cadherin is structurally characterized as a single pass transmembrane 
glycoprotein which forms calcium dependent homotypic interactions with E-cadherin on 
cell neighbors (Yilmaz & Christophori, 2009) These interactions are anchored to the 
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cytoskeleton by interactions with microfilaments composed of actin and mediated by β-
catenin and α-catenin (Yilmaz & Christophori, 2009).  E-cadherin expression can be lost, 
nonpolar, or expressed in the cytoplasm or alternatively transcriptional repression of E-
cadherin can occur by diverse mechanisms engaging AR and its transcriptional co-
regulators (Nelson & Nusse, 2004). Loss of E-cadherin expression results in loss of 
normal cell-cell interactions and facilitates progression of EMT and leads to metastasis 
(Harris & Tepass, 2010; Huber et al., 2005; Thiery, 2002; Thiery, Acloque, Huang, & 
Nieto, 2009. Upon E-cadherin loss, N-cadherin expression is enhanced to promote the 
mesenchymal cell phenotype. N-cadherin or Neural-cadherin is a mesenchymal cell 
association protein that allows transient cell-cell contacts  typically expressed in cell 
types including smooth muscle, myofibroblasts, endothelial cells, neurons, and 
neoplastic cells {Matuszak, 2011 #210; Yilmaz & Christophori, 2009).   The cell types 
usually expressing N-cadherin are also typical components of the reactive stroma 
composing the microenvironment of the prostate cancer tumor cell (Yilmaz & 
Christophori, 2009). The interactive mode employed by N-cadherin is not unlike that 
used by E-cadherin, this single span, transmembrane protein engages in homotypic 
interactions with N-cadherin on neighboring cells.  Loss of E-cadherin has been 
associated with increasing Gleason grade in prostate cancer and the concept of 
cadherin switching is traditionally considered as predictive of metastatic development 
(Gravdal, Halvorsen, Haukaas, & Akslen, 2007; Jeanes, Gottardi, & Yap, 2008).    
As illustrated in Figure 1.2.A,  E-cadherin expression is repressed by the zinc-
finger transcription factor Snail  (SNAI1) (Acloque, Adams, Fishwick, Bronner- Fraser, & 
Nieto, 2009).   Snail gained notoriety as a master regulator of EMT induction, but also 
plays an essential role in embryonic development and cell survival.   Snail employs a 
mechanism of action whereby the transcription factor binds to the E-box of the E-
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cadherin promoter and silences gene expression promoting a mesenchymal phenotype 
(Figure. 1.2.B) (Matuszak & Kyprianou, 2011b).   Interestingly enough, Snail is 
functionally capable of modulating  expression of proteins involved in tight junctions, 
including claudins, occludins, mucin-1 and cytokeratin 18 (Baritaki et al., 2009). Further 
fulfilling its infamy of “master regulator,” Snail increases expression of mesenchymal 
phenotype associated markers and proteins associated with invasive capacity: vimentin, 
fibronectin, metalloproteinase-2, -9, ZEB1, and LEF-1 (Baritaki et al., 2009).  To dissect 
the functional contribution of Snail to prostate cancer cell EMT, one must focus on its 
crosstalk with the AR signaling axis.   Indeed, AR may function in an analogous manner 
to Snail, thereby repressing the expression of E-cadherin and promoting EMT by itself 
(Figure 1.2.B) (Y. N. Liu, Liu, Lee, Hsu, & Chen, 2008).   Work from this laboratory has 
demonstrated that in an androgen-responsive, TGF-β-responsive, prostate cancer cell 
line, expression of Snail is significantly increased by exposure to DHT alone or in 
combination with TGF-β (Figure 1.2.B) (M. Zhu & Kyprianou, 2010). These observations 
support a functional involvement of the AR signaling navigated by Snail in acquisition of 
EMT characteristics of prostate tumor cells towards metastatic progression. Recent high 
throughput DNA analyses have furthered this investigation at the molecular level by 
identifying an ARE/ARG in the promoter region of Snail2 (slug), suggesting the direct 
modulation of Snail2 by AR (Bolton et al., 2007).   
Several transcription factors regulate the expression and transcriptional 
activation of genes controlling the EMT phenomenon. Identification of those which 
specifically interact with the AR signaling axis provides a unique molecular platform 
begging exploration in prostate cancer (Figure. 1.2.B).  Zeb1 (ZFHX1a gene) and Zeb2 
(ZFHX1b) are closely related transcription factors whose activity has been strongly 
implicated in EMT (Anose & Sanders, 2011).  These transcription factors are 
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characterized by separated clusters of Zinc finger domains  (7 total) which recognize the 
CAGGTA/G E-box promoter element (Brabletz & Brabletz, 2010). ZEB1 modulates 
diverse-function genes. It significantly contributes to EMT by repression of E-cadherin 
expression, genes encoding basement membrane components, and regulators of cell 
polarity. Other effects run the spectrum from tumor suppression to anti-adipose 
accumulation in vivo (Anose & Sanders, 2011; Brabletz & Brabletz, 2010; Hidaka, 
Nakahata, & Hatakeyamam, 2008; Matuszak & Kyprianou, 2011b; Saykally, Dogan, 
Cleary, & Sanders, 2009). Progression to metastasis is an event mediated by ZEB1, in 
addition to its important involvement in facilitating trans-endothelial migration (Drake, 
Strohbein, Bair, Moreland, & Henry, 2009; Spaderna et al., 2008). Clearly, ZEB1 plays 
an important role in orchestrating complex physiological processes such as, but certainly 
not limited to EMT.   Recent work has revealed a bidirectional negative feedback loop 
between AR and Zeb1 that has implicated ADT in inducing EMT signatures in prostate 
cancer cells and human tissues (Y. Sun et al., 2011). Without androgenic stimulation, 
AR expression is diminished during early ADT, but in the absence of AR, Zeb1 
expression cannot be inhibited and thereby becomes increased. With increased Zeb1 
transcription factor expression EMT promotion becomes transiently facilitated as a result 
of ADT leading to metastasis (Y. Sun et al., 2011). ZEB2 (SIP1) was originally described 
within the context of TGF-β signaling (Brabletz & Brabletz, 2010).   ZEB2 interacts with 
SMADs and promotes tumorigenic invasion and down-regulates E-cadherin expression 
(Comijn et al., 2001). Expression of ZEB transcription factor has been correlated with 
progression to malignant carcinoma in various cancer types (including prostate), and 
expression could be induced by both estrogen and progesterone (Anose & Sanders, 
2011; Chamberlain & Sanders, 1999). Identification of AREs in the promoter of the ZEB1 
gene confirms that its expression is regulated by AR signaling (Anose & Sanders, 2011).    
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Identification of Enhancer of Zeste Homolog 2  (EZH2) from seminal studies by 
Chinnaiyan’s group have enhanced our understanding regarding the role of epigenetic 
modifications in prostate, renal and breast cancer progression to EMT (Varambally et al., 
2002). EZH2 expression is associated with cancer metastases and is localized in tumors 
with poor prognosis in combination with depressed E-cadherin, both markers associated 
with poor disease free survival (Bachmann et al., 2006; Laitenen et al., 2008). EZH2 
functions as a histone lysine methyltransferase and its overexpression has been 
detected in mCRPC (Bachmann et al., 2006; M. M. Shen & Abate-Shen, 2010). Both 
EZH2 mRNA and protein levels are significantly elevated in prostate cancer compared to 
benign prostate hyperplasia (BPH) or human high grade PIN  (HGPIN) (Li, Fan, & Fan, 
2010); Functionally, EZH2 targets NKX3.1 inducing repression of the homeobox gene 
and this phenomenon is observed in up to 85% of HGPIN lesions and prostatic 
adenocarcinomas (M. M. Shen & Abate-Shen, 2010). Furthermore, EZH2 targets other 
genes undeniably linked to EMT, including E-cadherin and DAB2IP (Q. Cao et al., 2008; 
H. Chen, Tu, & Hsieh, 2005).  The fusions of TMPRSS2, an androgen regulated gene, 
and the oncogenic ETS transcription factor ERG place ERG under androgenic drive 
(Hermans et al., 2006; Nam et al., 2007; Narod, Seth, & Nam, 2008; Perner et al., 2006; 
Rajput et al., 2007; Soller et al., 2006). ERG activates EZH2 transcription allowing the 
methyltransferase to induce its repressive epigenetic agenda (Yu, Yu, & Mani, 2010). 
The neuronal chemorepellant and tumor supressor gene SLIT2 has also been linked to 
EZH2 (Yu, Cao, et al., 2010).    EZH2 targets SLIT2 and inhibits its expression under the 
drive of AR-dependent TMPRSS2-ERG fusion (Yu, Cao, et al., 2010). SLIT2 is down-
regulated in a majority of prostate cancers and low levels of SLIT2 are associated with 
aggressive disease (Yu, Cao, et al., 2010). ERG overexpression interferes with AR 
binding to ARE/ARGs, thus providing an additional layer of selective pressure for AR 
overexpression and mutation, driving progression to CRPC (Yu, Yu, et al., 2010).  
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AR Cross-Talk with Growth Factor Signaling  
The Wnt signaling pathway plays an important role in embryonic development 
and differentiation, and is a highly conserved pathway among organisms.  The 
deregulation of Wnt signaling is associated with tumorigenesis and EMT (Yardy & 
Brewster, 2005). In prostate cancer cells, this pathway can engage in direct crosstalk 
with AR, with the central protagonist being β-catenin (Figure 1.2.B) (Yardy & Brewster, 
2005). This molecule is located in distinct cellular locations: sequestered at the adherens 
junctions bonds to E-cadherin, in the cytoplasm, or in the nucleus (Yardy & Brewster, 
2005). Wnt ligand binds with the seven pass transmembrane receptors: FZD (Frizzled) 
at the plasma membrane interface with the extracellular environment (Figure. 1.2.B). 
FZD receptors transduce a signal to Disheveled (Dvl) and Dvl subsequently 
dephosphorylates an associated protein Axin. Axin functions as a signaling scaffold 
protein coordinating the interactions of Adenomatous Polyposis Coli (APC), glycogen 
synthase kinase 3β (GSK3β), β-catenin, and Conductin (Figure. 1.2.B).  The 
coordination of these proteins by Axin facilitates the phosphorylation of β-catenin and 
APC by GSK3β.  The dephosphorylation of Axin diminishes its capacity to coordinate β-
catenin in complex with GSK3β causing decreased phosphorylation of β-catenin (Figure. 
1.2.B). The phosphorylation of β-catenin mediates subsequent ubiquitination and 
degradation, but without phosphorylation by GSK3β, β-catenin accumulates in the 
cytoplasm. Accumulation of β-catenin results in nuclear translocation of the protein and 
interaction with lymphoid enhancer binding factor 1/ T-cell factor  (LEF1/TCF) 
transcription factors and transcription of β-catenin target genes, such as c-MYC, c-Jun 
and fra-1, in addition to EMT important urokinase type plasminogen activator receptor  
(uPAR), matrix metalloproteinase and cyclin D1 (Crawford et al., 1999; He et al., 1998; 
Marchenko et al., 2004; Tetsu & McCormick, 1999; Yardy & Brewster, 2005).  AR and β-
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catenin interact directly with one another (Figure. 1.2.B), impacting the EMT outcome 
(Robinson, Zylstra, & Williams, 2008).  In vitro, androgen-stimulated transcriptional 
responses are enhanced by functional involvement of Wnt signaling, consequently 
opposing the effects of antagonistic anti-androgenic treatment  (bicalutamide) (Truica, 
Byers, & Gelmann, 2000). This evidence implicates β-catenin as a co-activator of AR 
gene target transcription and potentially associated with emergence of CRPC (Yardy & 
Brewster, 2005). Furthermore, cognate ligand-induced AR signaling possesses the 
capacity to attenuate Wnt signaling and TCF/LEF1 dependent gene transcription.    
The pioneering work of Arul Chinnaiyan’s discovery of TMPRSS2: ERG gene 
fusion has been paramount in advancing our molecular understanding of prostate cancer 
pathophysiology (Clark et al., 2007; Tomlins et al., 2008). These gene fusions result in 
androgen driven expression of the transcription factor ERG.  The consequences of these 
fusions on cell fate, are diverse and intriguing, but an important observation is that ERG 
fusion-positive tumors and Frizzled4  (Fzd4: 7 pass transmembrane receptor of Wnt 
signaling pathway) co-overexpression were consistently identified in clinical prostate 
cancer (Gupta et al., 2010). Moreover, overexpression of ERG induced the EMT 
phenomenon in androgen responsive cell lines (VCaP), including repression of E-
cadherin and induction of N-cadherin. The effects of ERG overexpression could be 
abrogated by the modulation of FZD4, demonstrating that FZD4 was both necessary and 
sufficient to mediate the oncogenic effects of ERG overexpression and defining the 
impact of direct crosstalk of AR driven ERG overexpression with the Wnt signaling on 
prostate cancer EMT (Gupta et al., 2010).    
TGF-β signaling is critical in diverse cell types by impacting important features of 
cellular behavior including migration, adhesion, alterations to the extracellular 
environment, apoptosis and promoting formation of osteoblastic metastatic lesions 
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(Derynck & Zhang, 2003; Siegel & Massague, 2003; M.-L. Zhu & Kyprianou, 2008).  The 
TGF-β pathway traditionally engages signaling involving the SMAD proteins (Figure. 
1.2.B) (Coffey Jr., Shipley, & Moses, 1986; Derynck & Zhang, 2003; Pu et al., 2009; 
Siegel & Massague, 2003; M.-L. Zhu, Partin, Bruckheimer, Strup, & Kyprianou, 2008). 
TGF-β signaling is mediated by the serine / threonine kinase domains of the TGFβRI 
and TGFβRII receptors and the formation of hetero-tetrameric complexes (Figure. 1.2.B) 
(Pu et al., 2009).   Binding to TGF-β causes TβRII receptor to phosphorylate the 
regulatory GS domain of TβRI, initiating a downstream signaling cascade mediated by 
SMAD proteins (Beer et al., 2008; Derynck & Zhang, 2003).  TβRI selectively 
phosphorylates regulatory SMADs (R-SMADs) at the SSXS motif on the carboxyl 
terminus of the SMAD (Derynck & Zhang, 2003; Siegel & Massague, 2003).   The R-
SMADs, SMAD2 and SMAD3, activated by the TβRI (Siegel & Massague, 2003), are 
sequestered in the cytoplasm via their interactions with SMAD anchor for receptor 
activation (SARA) (Siegel & Massague, 2003).  Once activated by TβRI, R-SMADs lose 
affinity for SARA and become free to interact with SMAD4 (Siegel & Massague, 2003).   
SMAD4 is essential for formation of SMAD mediated transcriptional complexes, 
components of which are continuously shuttled between the cytoplasm and nucleus via 
nuclear pores (Derynck & Zhang, 2003; Siegel & Massague, 2003; B. Zhu & Kyprianou, 
2005). The SMAD complex dictates transcriptional activation, via recruitment of co-
activators such as p300, CBP, or SMIF. Conversely, for transcriptional repression, the 
SMAD complex recruits p107, SKI, SNON, TGIF, EVI1, and ZEB2 (SIP1) (Siegel & 
Massague, 2003; Ten Dijke, Goumans, Itoh, & Itoh, 2002). Expression of these co-
regulators is dependent by cell type, developmental stage, and micro-environment 
hosted crosstalk facilitating a broad cellular response repertoire (Siegel & Massague, 
2003).  
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EMT induction in response to TGFβ signaling engages oncogenic Ras or 
receptor tyrosine kinases (RTKs) to promote metastasis (Grunert, Jechlinger, & Meug, 
2003; Huber et al., 2005).   TGF-β is a ubiquitously expressed growth inhibitory cytokine 
(Siegel & Massague, 2003; B. Zhu & Kyprianou, 2005; M.-L. Zhu & Kyprianou, 2008; M.-
L. Zhu et al., 2008). TGF-β contributes to tissue and organ homeostasis by inducing a 
system of proliferative vs apoptotic balances (Siegel & Massague, 2003; B. Zhu & 
Kyprianou, 2005).  Defective / loss of TGF-β receptors and SMAD mutations are not 
directly responsible for the effects of EMT in cancer progression (M.-L. Zhu et al., 2008); 
rather, loss of apoptotic response occurs in cancer cells despite production of TGF-β 
ligand  (Akhurst & Derynck, 2001).  
Smad-independent signaling proceeds via MAPK pathways, involving activation 
of Erk, JNK, and p38 MAPK signaling pathways by TGF-β. Oncogenic Ras contributes to 
the activation of Erk/MAPK signaling, in a context dependent manner.  TGF-β activates 
TGF-β activated Kinase 1 (TAK1), a MAPK kinase kinase family member (MAPKKK), 
leading to activation of JNK and p38 MAPK.   TAK1 can also phosphorylate IκB, thereby 
activating NFκB signaling (Derynck & Zhang, 2003).  A direct mechanistic link of EMT to 
cancer progression is mediated by the effect of TGF-β signaling on activation of Rho A 
(Figure. 1.2.B).  Rho A and p160ROCK  (effector kinase) activation in conjunction with 
activation of Cdc24, p38, MAPK, and Smad signaling, correlate with stress fiber 
formation, membrane ruffling, lamellipodia formation and the physical mechanisms of 
EMT (Derynck & Zhang, 2003). Rho A is upregulated in prostate cancer cells as 
compared to the benign prostate and this elevated expression is linked to aggressive 
disease and diminished disease free survival in patients after radical prostatectomy 
(Schmidt et al., 2012). In fact, Rho A activation by TGF-β is similarly activated by action 
of AR on Serum Response Factor target genes further corroborating the cross talk 
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between TGF-β and AR (Schmidt et al., 2012), in the context of EMT  cellular 
“landscaping”.  
Significantly, elevated TGF-β correlates with increasing tumor grade in numerous 
human malignancies, including prostate cancer (Bierie & Moses, 2006; Ivanonvic, 
Melman, Davis-Joseph, Valcic, & Gelieber, 1995; Levy & Hill, 2006; Wojtowicz-Praga, 
2003). And furthermore, overexpression of TGF-β ligand is detected in advanced 
prostate cancer (Coffey Jr. et al., 1986; Derynck & Zhang, 2003; B. Zhu & Kyprianou, 
2005). TGF-β ligand binds to and induces phosphorylation of TβRI by TβRII resulting in 
SMAD signaling in prostate cancer cells. SMADs 3 and 4 serve as transcriptional co-
regulators of AR target genes and conversely, ligand bound AR transcriptionally 
modulates SMAD3 in prostate cancer (Song et al., 2010; van der Poel, 2005). SMAD4 
(alone or in conjunction with SMAD3) can co-regulate AR transactivation via binding to 
the DBD and LBD domains of the steroid receptor thereby modulating its DHT induced 
activity (M.-L. Zhu & Kyprianou, 2008; M.-L. Zhu et al., 2008). SMAD3 can bind AR as 
well, but this interaction is mediated by the NTD (Hayes et al., 2001). In a mechanistic 
twist, AR overexpression enables prostate cancer cells to overcome the growth inhibitory 
effects of TGF-β under DHT deprived conditions (van der Poel, 2005).  Moreover, 
expression of SMAD3 enhances AR mediated transactivation, whilst co- overexpression 
of SMAD3 and 4 repressed AR transactivation (Kang et al., 2002). The TGF-β/Smad 
signaling pathway elicits a downstream activation in Snail thereby repressing E-cadherin 
expression in a number of cancer cell types (Thuault, Peinado, Cano, Heldin, & 
Moustakas, 2008). In LNCaP TβRII human prostate cancer cells, DHT (alone or in 
combination with TGF-β) significantly induced Snail expression (M.-L. Zhu et al., 2008), 
pointing to a dynamic crosstalk between the AR and TGF-β pathways in control of EMT.  
Recent studies identified a role for Hexim-1 in mediating such a cross-talk between AR 
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and TGF-β in prostate cancer progression. Hexim-1 is an inhibitor of cyclin dependent 
kinase 9 (Cdk9) of transcription elongation factor (pTEFb) complex, which is upregulated 
and translocated to the cytoplasm during tumor  progression (Mascareno, Belashov, 
Siddiqui, Liu, & Dhar-Mascareno, 2012). Cdk9 interacts with AR and phosphorylates the 
AR at serine 81 (Lee & Chang, 2003), and transcriptionally programs Smads 1 and 3 via 
phosphorylation of linker region (Alcaron et al., 2009; Mascareno et al., 2012). Such 
refined mechanistic control of Hexim-1 expression, supports its role as a converging 
modifier of activity for AR and TGF-β signaling cross-talk towards EMT (Mascareno et 
al., 2012). 
Notch signaling is fundamentally significant in development and tissue 
homeostasis. Notch signaling facilitates an important mode of cell-cell communication. 
Notch proteins (1-4) are type I , single pass transmembrane receptors (Bolos, Grego-
Bessa, & de la Pompa, 2007).  The extracellular domain of the Notch protein participates 
in ligand binding and is composed of a variable number of epidermal growth factor 
(EGF) like domains (essential for ligand binding) and three cysteine rich LIN12/Notch 
repeats (LNR) (ensure signaling only transduced in presence of ligand)(Bolos et al., 
2007; Rebay et al., 1991). The intracellular domains of the Notch receptor include 
RAM23 domain, six ankyrin / cdc10 repeats, two nuclear localization signals, 
transcriptional activation domain and a PEST sequence (Bolos et al., 2007). The ligands 
recognized by the Notch receptor are Delta 1,3, and 4 as well as Jagged 1 and 2; these 
ligands are membrane bound and composed of an amino terminal domain known as 
DSL and variable number of EGF like repeats (Bettenhausen, Hrabe de Angelis, Simon, 
Guenet, & Gosler, 1995; Dunwoodie, Henrique, Harrison, & Beddington, 1997; Lindsell, 
Shawber, Boulter, & Weinmaster, 1995; Shutter et al., 2000). The Jagged ligands 
possess a cysteine rich (CR) domain and ligand-receptor initiated signaling cascade 
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results in cleavage of the Notch receptor and ultimately translocation of the Notch 
intracellular domain (NICD) to the nucleus.  As discussed above, Snail1 is a transcription 
factor responsible for repressing E-cadherin transcription, with Notch1 activation 
upstream of Snail1 (Bolos et al., 2007). This observation has been further validated in 
the immortalized porcine aortic endothelial cell line, whereby overexpression of NICD 
induced an EMT via activation of Snail1 and subsequent repression of E-cadherin 
(Timmerman et al., 2004). The correlation between expression of Notch ligand, Jagged1, 
and high grade and metastatic prostate cancer compared to localized prostate cancer 
(Santagata et al., 2004) is of major translational value as Jagged1 may serve as an 
independent prognostic indicator of prostate cancer recurrence and progression, 
potentially driven by a link with androgenic signaling (Bailey, Singh, & Hollingsworth, 
2007; Santagata et al., 2004).  Notch1 signaling is associated with osteoblast 
differentiation and Notch1 expression is markedly elevated in osteoblast skeletal derived 
prostate cancer cells (Bailey et al., 2007), evidence indirectly supporting its involvement 
in EMT driven prostate tumor metastasis to the bone. 
 
Androgen Deprivation Therapy 
 CRPC is a disease addicted to AR signaling developed through the course of 
androgen deprivation therapy (ADT). ADT is effective in patients by inducing tumor 
regression via tumor apoptosis (Kahn, Collazo, & Kyprianou, 2014). ADT induces a 
chemical castration state in the patient characterized by serum testosterone levels 
<50ng/mL (Kahn et al., 2014). AR signaling can become reactivated through a variety of 
mechanisms which have been reviewed elsewhere (B. J. Feldman & D. Feldman, 2001). 
Several mechanisms can be engaged by prostate tumors to bypass or perpetuate AR 
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signaling toward CRPC (Brinkmann et al., 1999; B. J. Feldman & D. Feldman, 2001; 
Knudsen & Penning, 2010). These mechanisms lend credence to the need for 
personalized medicine and continued research in the landscape of alternate pathways to 
CRPC (Brinkmann et al., 1999; B.J. Feldman & D. Feldman, 2001; Knudsen & Penning, 
2010). Alterations to the regulation, structure and post-translational modifications of the 
AR itself can perpetuate continued androgen signaling, and AR has been shown to be 
commonly overexpressed in CRPC (C. D. Chen et al., 2004).  However, one must 
consider the structural changes in AR as functional contributors to therapeutic 
resistance.    Point mutations increasing the affinity of the AR for ligand have been 
identified causing the pathway to become hypersensitive (Gregory, Johnson, Mohler, 
French, & Wilson, 2001). Promiscuous mutations cause binding flexibility in the LBD 
allowing the AR to become activated by adrenal androgens, androgenic metabolites, and 
even some anti-androgen therapeutics such as flutamide and bicalutamide (B. J. 
Feldman & D. Feldman, 2001; Marcelli et al., 2000; Taplin et al., 2001; Tilley, Buchanan, 
Hickey, & Bentel, 1996).   Over twenty splice variants of AR, some lacking LBD, and 
therefore constitutively active have been identified and associated with progression of 
CRPC and metastasis (Dehm, Schmidt, Heemers, Vessella, & Tindall, 2008; Z. Guo et 
al., 2009; Hu et al., 2009; Hu, Isaacs, & Luo, 2010; Jenster et al., 1995; S. Sun et al., 
2010).  AR can be activated independent of ligand interactions by aberrant signaling 
pathways causing activation of the protein and homo-dimerization by growth factors, 
receptor tyrosine kinases and the Akt pathway via loss of PTEN (Craft, Shostak, Carey, 
& Sawyers, 1999; Culig et al., 1994; B. J. Feldman & D. Feldman, 2001; J. H. Li et al., 
1997).   Growing evidence by a number of investigative teams support the abilities for 
prostate cancer cells to synthesize their own androgens “hijacking” adrenal synthesis 
enzymes (Knudsen & Penning, 2010; Locke et al., 2008; Montgomery et al., 2008; 
Stanbrough et al., 2006).    The entire AR signaling axis can even be bypassed by 
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overexpression of the apoptosis blocking protein, Bcl2, which is frequently found 
overexpressed in prostatic intraepithelial neoplasia (PIN).  
Abiraterone:  Abiraterone Acetate  (AA) is a novel anti-androgen therapy 
designed to target the adrenal androgen mediated signaling axis by blocking the 
synthesis of adrenal products which serve as precursors for testosterone and DHT 
synthesis (Figure 1.3) (Di Lorenzo, Buonerba, De Placido, & Sternberg, 2010; A. O. 
Sartor, 2011; Walcak & Carducci, 2007).   AA acts as a pregnenolone analog, inhibiting 
the rate limiting enzyme, cytochrome P450  (CYP17A1), further inhibiting androgen 
biosynthesis (Di Lorenzo et al., 2010; A. O. Sartor, 2011).   AA inhibits both the 17α-
hydroxylase and 17,20 functions of CYP17A1 (Di Lorenzo et al., 2010).     The efficacy 
of AA was demonstrated in the COU-AA-301 trial, confirming that AA imparted additional 
survival benefit compared to DR-CRPC men treated with placebo and prednisone.   In 
addition to overall survival increase, benefits were seen with regard to time to disease 
progression, biochemical recurrence and tumor burden (De Bono, Logothetis, et al., 
2010; Di Lorenzo et al., 2010; A. O. Sartor, 2011).    
Enzalutamide (MDV3100):  The importance of AR targeting in DR-CRPC is 
highlighted by the development of the direct, AR antagonist, MDV3100 (Di Lorenzo et 
al., 2010; H. C. Shen & Balk, 2009).   This drug is a diarylthiohydantoin member of the 
family of AR antagonists rationally designed from the crystal structure of the AR bound 
to its ligand (H. C. Shen & Balk, 2009).    MDV has been shown to be effective in the 
context of AR overexpression, in addition to inhibiting AR nuclear translocation, 
preventing binding of the AR to DNA, blocking recruitment of co-activators to AR target 
genes, and induces apoptosis (Figure 1.3) (Scher et al., 2010; H. C. Shen & Balk, 2009; 
Vishnu & Tan, 2010).   MDV has been shown to be efficacious in improving survival in 
therapy naïve patients, those previously treated with ADT, and in patients previously 
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treated with Docetaxel and in patients treated with both (Attard, Cooper, & de Bono, 
2009; Di Lorenzo et al., 2010; Nadal et al., 2014; Tran et al., 2009b).   MDV inhibits 
translocation of full length AR and  prevents activation of AR splice variants (ARv) 
lacking portions or all of the LBD by preventing dimerization of those ARv with full length 
AR (Watson et al., 2010). Interestingly, MDV treatment and other ADT strategies has 
been shown to induce expression of ARVs, which emphasizes the need to identify 
effective therapeutic targets to impair CRPC outside of the “classic” AR signaling 
(Watson et al., 2010).  
N terminal domain targeting EPI-002:  Anti-androgenic targeting of AR has 
primarily been focused on binding LBD and thereby preventing activation of AR, but one 
AR antagonist has emerged which takes an enlightened approach. The small molecule 
inhibitor EPI-001/002 series of anti-androgens bind the intrinsically disordered domain of 
the NTD preventing it from initiating transcription activation functions and DNA binding 
(Figure 1.3) (Andersen et al., 2010). The EPI series was originally identified from 
peptides isolated from marine sponges (Sadar, 2011). This novel anti-androgen has 
demonstrated efficacy in androgen-dependent and CRPC models of prostate cancer s 
and garnered much attention (Andersen et al., 2010). EPI small molecule inhibitors offer 
a unique feature to the AR targeting game in that they can bind and inhibit many of the 
AR variant isoforms expressed in advanced prostate cancer tumors (Martin, Banuelos, 
Sadar, & Kyprianou, 2014; Sadar, 2011).  Characteristic of AR variant structure, the C-
terminus, exons within, or the entire LBD is missing. This would prevent activity with 
most traditional anti-androgens, activity of EPI is not deterred. EPI can still effectively 
bind and inhibit activation of many AR variant isoforms as data generated in this thesis 
demonstrate (Martin et al., 2014). 
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Classical Taxane Action 
Taxanes are derived from naturally occurring molecules identified in the bark of 
yew trees (Huizing et al., 1995).   Historically, the anti-tumor action of taxanes has been 
attributed  to their inherent ability to bind and stabilize the architectural component of the 
cell: microtubules (Huizing et al., 1995).  The classic understanding of the mechanism of 
anti-tumor action of taxanes is that they bind and stabilize the interaction between two 
sub-units of β tubulin, preventing de-polymerization of the protofilament sub-structure 
within the microtubule (Figure 1.3 & Figure 1.4) (Kraus et al., 2003). This stabilization 
results in G2M arrest and apoptosis (Huizing et al., 1995; Kraus et al., 2003).   Bcl-2 
overexpression is frequently observed in prostate cancer, and taxanes are capable of 
counteracting the effects of this pro-survival protein of the apoptotic pathway 
(Bruckheimer & Kyprianou, 2001, 2002; Debes & Tindall, 2004b; Oliver et al., 2005).     
The clinical evidence for the use of taxanes in patients with CRPC emerged from 
a series of clinical trials, TAX327 and SWOG  (Southwest Oncology Group) 9916, which 
demonstrated a significant survival benefit of Docetaxel based treatment compared to 
control treated patients (Tannock et al., 2004).    Docetaxel treatment conferred palliative 
relief and overall survival benefits (Berthold et al., 2008; Petrylak et al., 2004).   Since 
FDA approval, taxane chemotherapy stood alone for nearly a decade as the only 
clinically relevant intervention for mCRPC patients.  Unfortunately, taxane treatment 
ultimately fails and, the majority of patients develop resistance. The molecular 
mechanisms driving therapeutic resistance to microtubule targeting chemotherapy in 
prostate cancer after Docetaxel treatment are not fully understood. Some of the 
mechanisms of resistance can be attributed to the adenosine triphosphate dependent 
drug efflux pump P-glycoprotein-1. Docetaxel has a high affinity for this pump and an 
increase in expression of the efflux pump itself is observed over the course of prostate 
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cancer progression (Abdulla & Kapoor, 2011; Attard, Greystroke, Kaye, & De Bono, 
2006). Biochemical recurrence is often associated with other clinical manifestations; 
bone, brain, and lymph node metastasis as well as increasing amounts of pain 
secondary to the metastatic lesions are found in CRPC patients (Abdulla & Kapoor, 
2011).  
Cabazitaxel: Cabazitaxel is a novel, next-generation semi-synthetic Taxane 
chemotherapeutic drug that has been shown to be effective in the Docetaxel resistant-
CRPC landscape (Figure 1.3) (Galsky, Dritselis, Kirkpatrick, & Oh, 2010; A. O. Sartor, 
2011). Cabazitaxel is structurally very similar to Docetaxel save that in place of hydroxyl 
groups there are methoxyl groups in those positions (Azarenko, Smiyun, Mah, Wilson, & 
Jordan, 2014; Vrignaud et al., 2013). Cabazitaxel is highly cytotoxic and has a low 
affinity for the adenosine triphosphate-dependent drug efflux pump: P-glycoprotein 1, 
known to confer chemotherapeutic resistance (Di Lorenzo et al., 2010).    Unlike 
Docetaxel, Cabazitaxel can cross the blood brain barrier and has a 95 hour terminal half-
life in humans (versus 12 hours for Docetaxel) (Bruno & Sanderink, 1993; Cisternino, 
Bourasset, & Archimbaud, 2003; Sanofi-Aventis, 2014; Schutz, Buzaid, & Sartor, 2014). 
Cabazitaxel was shown in a multicenter, randomized; phase 3 clinical trial (Treatment of 
Hormone-Refractory Metastatic Prostate Cancer (TROPIC)) to impart a statistically 
significant increase in overall survival (De Bono, Oudard, Ozguroglu, Hansen, Machiels, 
Kocak, Gravis, Bodrogi, Mackenzie, Shen, Roessner, Gupta, & Sartor, 2010; Galsky et 
al., 2010).    Tumor response, biochemical recurrence, and tumor progression all favored 
the Cabazitaxel treatment and was approved by the  US Food and Drug Administration 
for use in DR-CRPC patients (De Bono, Oudard, Ozguroglu, Hansen, Machiels, Kocak, 
Gravis, Bodrogi, Mackenzie, Shen, Roessner, Gupta, & Sartor, 2010; Galsky et al., 
2010; A. O. Sartor, 2011).  In addition to imparting overall survival benefits to 
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chemotherapeutic naïve patients, the exciting findings associated with Cabazitaxel are 
its ability to confer additional overall survival benefits in patients who have already 
experienced biochemical recurrence on ADT, Docetaxel chemotherapy, or both (Abdulla 
& Kapoor, 2011; A. O. Sartor, 2011).  
 
Beyond Microtubule Stabilization 
In addition to the intramolecular ballet required for the AR to induce 
conformational change suitable to facilitate nuclear translocation, AR must be physically 
transported from the cytoplasm to the nucleus; a feat accomplished via motorized 
translocation along microtubules (Darshan, Loftus, Thadani-Mulero, Levy, Escuin, Zhou, 
et al., 2011). Work from our lab revealed, for the first time, that in addition to stabilizing 
microtubules and inducing G2M arrest, taxanes are particularly poignant in prostate 
cancer, because they possess the ability to deter translocation of the AR to the nucleus 
and inhibit AR driven gene transcription (Figure 1.4) (M.-L. Zhu et al., 2010b).    Using 
clinical specimens from patients treated with Docetaxel versus untreated, 
immunohistochemical  analysis of tissue microarrays strikingly revealed significantly 
diminished AR nuclear localization in the Docetaxel-treated patients (M.-L. Zhu et al., 
2010b). Although, AR protein expression was not affected by the treatment, nuclear 
localization was diminished by 38%, thereby highlighting the mechanistic effect of 
Docetaxel chemotherapeutic treatment.  Further investigation into the domain of the AR 
responsible for mediating the interaction with the taxane target tubulin, revealed that the 
NTD negotiated this association (M.-L. Zhu et al., 2010b). These data were confirmed 
and extended by the finding that AR nuclear translocation is inhibited in circulating tumor 
cells from patients treated with Docetaxel (Darshan, Loftus, Thadani-Mulero, Levy, 
Escuin, Zhou, et al., 2011).  These important mechanistic insights serve as a roadmap to 
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understanding why taxane chemotherapeutics served as our only clinically relevant 
treatment for CRPC for nearly a decade and guide our pursuit for future therapeutics. 
Forkhead box protein 1 (FOXO1) has been shown to inhibit AR activity by 
binding and sequestering AR in the nucleus, and not allowing it to bind target AREs 
(Figure 1.4) (P. Liu, Li, Gan, Kao, & Huang, 2008). Taxane treatment can cause FOXO1 
nuclear translocation such that any AR reaching the nucleus may be bound by FOXO1 
and thus unable to initiate target gene activation (Gan et al., 2009b; P. Liu et al., 2008).  
Microtubules do not represent a transportation mechanism. Microtubules are 
merely a highway along which cargo is transported by ATP-dependent motor proteins: 
dynein and kinesin. Dynein motor proteins transport cargo in a “minus” end direction 
along microtubules from the cytoplasm to the nucleus. Dynein motor trafficking is 
important to efficiently transport AR from the cytoplasm to the nucleus as demonstrated 
by co-immunoprecipitation of full length AR with dynein in prostate cancer cells (Figure 
1.4) (Darshan, Loftus, Thadani-Mulero, Levy, Escuin, Zhou, et al., 2011). Furthermore, 
this association is increased following androgen ligand stimulation. In cells expressing 
full length AR, overexpression of dynein linker protein “dynamitin” prevented 
translocation of AR to the nucleus upon androgen stimulation because cargo proteins 
could not be loaded onto motor proteins (Darshan, Loftus, Thadani-Mulero, Levy, 
Escuin, Zhou, et al., 2011).  AR splice variants are expressed with high prevalence in 
CRPC and their presence has been implicated in disease progression (Sprenger & 
Plymate, 2014). Recent work has demonstrated that AR variant identity determines it’s 
ability to interact with and be transported by dynein (Thadani-Mulero, Portella, Sun, 
Sung, Matov, Vessella, Corey, Nanus, S.R., et al., 2014). ARv567es (an AR protein 
which has both N and C termini but lacks exons 5-7) associates with and is translocated 
by dynein, whereas ARv7 (lacks complete ligand binding domain) does not interact 
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directly with dynein or microtubules and  localizes to the nucleus (Thadani-Mulero, 
Portella, Sun, Sung, Matov, Vessella, Corey, Nanus, S.R., et al., 2014).  
Kinesins have been implicated as contributors to cancer progression, and their 
role has been eloquently reviewed elsewhere (Rath & Kozielski, 2012). More than 45 
kinesins are encoded in the human genome with 14 subfamilies based on phylogenetic 
analysis of the motor domain. As the counterparts to dynein, kinesins move in a “plus” 
end direction along microtubules from the nucleus to the cytoplasm and perform two 
essential functions: facilitate progression of different stages of cell division and are 
important for intracellular vesicle and organelle transport. As schematically illustrated in 
Figure 1.4, kinesin motor proteins consist of a long coiled-coil stalk with a cargo binding 
module at one end and globular motor domain (head) at the other (Wiltshire et al., 2010).  
Eg5 is a kinesin involved in bipolar spindle formation during mitosis. It forms 
homo-tetramers of two antiparallel dimers with motor domains on both ends; this allows 
Eg5 to grasp two microtubules and utilize its’ plus end directed motor activity to push 
them apart (Rath & Kozielski, 2012). Inhibition of Eg5 activates the spindle check point 
induces mitotic arrest and apoptosis, and therefore it is an attractive target for 
therapeutic targeting. Several Phase I and Phase II clinical trials have worked to bring 
Eg5 inhibitors to patients. One such inhibitor, S-Trityl-L-Cysteine (STLC) showed 
efficacy in Docetaxel-resistant prostate cancer cells and STLC was not affected by P-
Glycoprotein upregulation (Wiltshire et al., 2010).  Of clinical significance is a recent 
retrospective study that identified Eg5 nuclear expression as a predictive biomarker of 
Docetaxel response in mCRPC patients and a prognostic biomarker for hormone naïve 
prostate cancer patients (Wissing et al., 2014).  
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Mitotic centromere-associated kinesin (MCAK) is a member of the kinesin-13 
subfamily and is a non-motile, microtubule depolymerizing kinesin that targets to 
microtubule tips and utilizes its’ ATP hydrolysis power stroke to “flick” tubulin subunits off 
the end of the structure during mitotic progression (Desai, Verma, Mitchison, & Walczak, 
1999; Ogawa, Nitta, Okada, & Hirokawa, 2004; Rath & Kozielski, 2012). The mitotic 
kinase Aurora B controls that localization and activity of MCAK at the 
centromere/kinetochore while Aurora A controls the same functions at the spindle poles 
(Sanhaji et al., 2010; Sanhaji, Friel, Worderman, Louwen, & Yuan, 2011; X. Zhang, Lan, 
Ems-McClung, Stukenberg, & Walczak, 2007). Polo-like kinase 1 (Plk1) regulates MCAK 
enzymatic activity and actually controls microtubule de-polymerization in cells making it 
of particular interest in taxane resistant cells (Sanhaji et al., 2011). In normal cells, 
MCAK tracks to the plus end tips of microtubules and utilizes microtubule 
depolymerizing properties to correct improper kinetochore attachments at the 
centromere during mitosis. During interphase, MCAK localizes to the plus end of 
microtubules and actively depolymerizes them (Sanhaji et al., 2011). a variety of cancer 
types, MCAK becomes grossly overexpressed. Indeed in diverse human tumors, data 
mining has  revealed MCAK as an important protein overexpressed in CRPC data sets 
and is indicative of taxane chemotherapy resistance (Sircar et al., 2012). Early attempts 
to target MCAK via inhibitors have been described (Aoki, Ohta, Yamazaki, Sugawara, & 
Sakaguchi, 2005; Rickert, 2008). My recent studies show that while MCAK expression 
may be indicative of Docetaxel resistance, MCAK expression may actually be a target of 
Cabazitaxel (Figure 1.4). Furthermore, in castration resistant 22Rv1 and androgen 
dependent VCaP, and LNCaP cell lines MCAK expression was decreased over time in 
both the presence and absence of androgens (Figure 1.4).  
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HSET is a member of the Kinesin-14 subfamily and like the rest of this subfamily 
is a “minus” end directed motor protein unlike the rest of the kinesins. HSET promotes 
proper bi-spindle pole formation and facilitates proper cytokinesis. Furthermore, HSET 
has been shown to be overexpressed in Docetaxel resistant tumors (De, Cipriano, 
Jackson, & Stark, 2009). Chromosomal instability is common in tumor cells leading to 
missegregation, aneuploidy and cell death therefore, undergoing mitosis represents an 
additional challenge for cancer cells (Kwon et al., 2008). Centrosomal amplification and 
subsequent clustering has evolved to prevent tumor cells with aneuploidy chromosomes 
from undergoing apoptosis (Chandhok & Pellman, 2009). HSET has emerged as an 
essential regulator of centrosomal clustering and an attractive therapeutic target. Normal 
mitotic cells possess exactly two centrosomes, and thus do not require HSET to 
coordinate the clustering of their centrosomes, whilst tumor cells who cannot 
appropriately cluster their centrosomes undergo mitotic arrest and apoptosis (Chandhok 
& Pellman, 2009). HSET remains elusive as a druggable target, but recent evidence 
from our lab has shown that HSET expression is down regulated at both the mRNA and 
protein level by Cabazitaxel treatment (Martin et. al, 2015).  
 
Mechanisms of Therapeutic Resistance 
ATP binding cassette (ABC transporter) P-glycoprotein (P-gp) / Multidrug 
resistance protein (MDR) is overexpressed in the cell membranes of tumors, and its 
overexpression also has been identified in clinical specimens from CRPC patients 
(Figure 1.5.A) (Mahon, Henshall, Sutherland, & Horvath, 2011; Siegsmund, Kreukler, & 
Steidler, 1997; Theyer, Schirmbock, & Thalhammer, 1993). This protein serves as a 
membrane bound efflux pump physically pumping a wide range of substrates, including 
 
30 
Docetaxel, out of treated tumor cells compromising the effect on stabilizing microtubules. 
Variable response to P-gp can be seen in chemoresistant prostate cancer cell lines. 
Chemoresistant PC3 cells do not overexpress P-gp, whilst chemoresistant DU145 do 
overexpress P-gp and that resistance can be modulated with knockdown thereof (Mahon 
et al., 2011; Makarovskiy, Siryaporn, Hixson, & Akerley, 2002; Takeda et al., 2007). 
Another member of the MDRP family, lesser known MRP1 is up-regulated in 
chemoresistant prostate cancer cell lines which do not over-express P-gp (Zalcberg et 
al., 2000). Together the expression of ABC transporters and subsequent effects on 
chemo-resistance appear to be modulated by p53 and PIM1 kinase (Mahon et al., 2011; 
Sullivan et al., 2000; Xie et al., 2008). Hydroxyl groups on the structure of Docetaxel are 
substituted for methoxyl groups in the structure of Cabazitaxel (Vrignaud et al., 2013). 
Interestingly, in MCF7 breast cancer cells, Cabazitaxel was taken up faster than 
Docetaxel and washing did not affect intracellular concentration of the drug (unlike 
Docetaxel treated MCF7 cells which demonstrated 50% concentration of drug post 
washing). These data indicate that Cabazitaxel is better retained by cancer cells 
(Azarenko et al., 2014). Despite this improvement in intracellular retention, MDR 
resistant MCF-7 variant cells still demonstrated resistance to the effects of Cabazitaxel 
but it showed much less cross resistance than paclitaxel and Docetaxel (Duran et al., 
2014). 
Modulation of the actual microtubule and their component tubulin is another 
important mechanism of resistance to taxanes. Mutation of the taxane binding site of β-
tubulin or isotype switching may confer resistance to taxane action and also may 
modulate binding of microtubule associated proteins (MAPs) (Figure 1.5.B) 
(Giannakakou et al., 2000; Huzil, Chen, Kurgan, & Tuszynski, 2007; Madan, Pal, Sartor, 
& Dahut, 2011). There are at least seven isotypes of β-tubulin known and the 
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predominant isotype expressed in normal tissue is isotype I (Luadena, 1998; Mahon et 
al., 2011).  Increased expression of isotype β III tubulin has been clinically demonstrated 
for lung, breast and ovarian cancers; in addition, overexpression of the β III tubulin 
isoform has been associated with progression to mCRPC is predictive of Docetaxel 
efficacy, and may further serve as a theranostic biomarker (Ploussard et al., 2010; Terry 
et al., 2009). Cabazitaxel is also subject to therapeutic resistance induced by expression 
of β III tubulin isotype (Duran et al., 2014).  
Furthermore, alterations of microtubule binding dynamics also contribute to 
taxane resistance. The binding site of taxane only exists on microtubules when tubulin is 
polymerized and not on tubulin dimers (Orr, Verdier-Pinard, McDaid, & Band Horwitz, 
2003). Therefore, a shift toward preference of the dimerized form of tubulin and away 
from polymerized tubulin would represent a survival advantage for cells exposed to 
taxanes (Figure 1.5.C). Certain taxane resistant cell lines have developed a requirement 
for exposure to taxane suggesting that the microtubules have become “hypostable” and 
must be exposed to taxane to stabilize their microtubules adequately for normal function 
(Orr et al., 2003). For example, A549 cells continually exposed to taxane were selected 
for resistance and were developed to be between nine and 17 fold more resistant than 
parental cells. These cells were dependent on exposure to taxanes for growth, were 
blocked at G2/M phase of the cell cycle in its absence, and exhibited increased dynamic 
instability towards dimerized tubulin (Goncalves et al., 2001; Orr et al., 2003). Recently, 
ERG was implicated in affecting the shift of microtubules toward instability (Galletti et al., 
2014). ERG rearrangements are the most frequently recurring genetic alteration in 
human prostate tumors and are known to undergo gene fusion with the 5’ promoters of 
TMPRSS2, SLC45A3 and NDRG1 (Tomlins et al., 2005). In addition to playing a 
causative role in transformation of normal prostate epithelium, ERG has now been 
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shown to bind soluble tubulin in the cytoplasm and shift tubulin binding dynamics toward 
catastrophe contributing to taxane resistance (Galletti et al., 2014). 
Earlier studies by Giannakakou et al. identified two taxane resistant human 
ovarian carcinoma cell lines that are 24 fold more resistant to taxanes but hypersensitive 
to the microtubule depolymerizing agent Vinblastine (Giannakakou et al., 1997; Orr et 
al., 2003). The primary β-tubulin isotype βI was identified to have a Phe270 to valine 
substitution in one cell line and an Ala364 to threonine substitution in the other 
(Giannakakou et al., 1997). These substitutions exist close to the region of the tubulin 
domain responsible for interacting with the taxane ring system, and are thus are capable 
of disrupting taxane binding (Orr et al., 2003).  
Altered expression of Microtubule Associated Proteins (MAPs) is associated with 
progression to chemotherapeutic resistance in prostate cancer (Figure 1.5.E). Stathmin 
is a microtubule-destabilizing protein that plays an important role in mitotic spindle 
formation and disassembly (Belmont & Mitchison, 1996; Marklund, Larsson, Gradin, 
Brattsand, & Gullberg, 1996; Mistry & Atweh, 2006). Stathmin is expressed at very high 
levels in a variety of human cancers including prostate cancer and its expression has 
been shown to correlate with malignant phenotype of the cancer. Stathmin may serve as 
a prognostic marker of progression in prostate cancer (Friedrich, Grongberg, Landstrom, 
Gullberg, & Bergh, 1995).  Inhibition of stathmin expression has been associated with 
shift towards EMT in prostate cancer and the extent of its expression is stage specific 
(Williams et al., 2012).  Overexpression of stathmin may contribute to taxane resistance 
by shifting the equilibrium between soluble and polymerized tubulin dimers towards un-
polymerized tubulin counteracting the action of tubulin polymer stabilizing taxanes. 
Treatment of prostate cancer cells (LNCaP) with stathmin interference plus taxane 
induces a synergistic effect on decreasing viability compared to either treatment alone 
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(Mistry & Atweh, 2006). Conversely, MAP4 is a microtubule stabilizing protein and 
phosphorylation of MAP4 causes it to dissociate from microtubules resulting in the loss 
of stabilizing function (Chang et al., 2001; Chien & Moasser, 2008). Increased 
phosphorylation of MAP4 has been associated with a decrease in taxane sensitivity in 
ovarian cancer cell lines (Poruchynsky et al., 2001). Furthermore, MAP4 expression is 
suppressed in the presence of wild-type p53 (Murphy, Hinman, & Levine, 1996; C. C. 
Zhang et al., 1998).  
Among MAPs whose activity becomes altered through the course of 
development of taxane resistance, ATP-driven motor protein kinesins have emerged as 
key players (Figure 1.5.F). In breast cancer, KIFC3, KIFC1, and KIF5A can confer or 
enhance docetaxel resistance (X. Liu, Gong, & Huang, 2013). In prostate cancer and 
others, KIF2A (MCAK) overexpression has also been shown to confer or enhance 
Docetaxel resistance (Ganguly, Yang, & Cabral, 2011; Sircar et al., 2012). Others: 
KIF2B, CENPE, and HSET have also been implicated in resistance to microtubule 
targeting (Schmizzi, Currie, & Rogers, 2010; Yang, Liu, Ikui, & Horwitz, 2010). In all 
cases, the ATP-binding domain of the kinesin is required to enhance taxane resistance 
(Tan et al., 2012). With regard to MCAK, this kinesin is a plus end tracking, microtubule 
depolymerizing kinesin, which induces an unnatural bend conformation to the 
microtubule structure inducing the removal of tubulin subunits from the end of the 
structure. These kinesins therefore work to counteract the effect of taxanes by 
depolymerizing the ends of microtubules which have been stabilized. Overexpression of 
these kinesins allows tumor cells to “out run” the effects of taxanes (De et al., 2009; X. 
Liu et al., 2013; Tan et al., 2012). 
EMT as a mechanism of resistance: Recent evidence has implicated that 
resistance to Cabazitaxel chemotherapy can be induced by EMT  (Figure 1.5.G) (Duran 
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et al., 2014). The significance of EMT in cancer emerges as tumor cells must physically 
detach from their immediate primary tumor, invade into the surrounding 
microenvironment, intravasate into the vasculature, endure the turbulence of circulation 
in the blood stream or lymphatics, and extravasate from the circulatory system at a 
secondary site (Kalluri & Weinberg, 2009; Yilmaz & Christofori, 2009).   Each step 
required for execution of EMT requires a vast number of molecular events (Kalluri & 
Weinberg, 2009; Matuszak & Kyprianou, 2011a; Yilmaz & Christofori, 2009).   Epithelial 
cells must begin their transition to a mesenchymal phenotype by disrupting their 
intercellular adhesive contacts (Acloque et al., 2009).   This initial modification occurs by 
formation of apical constrictions and disorganization of the basal cytoskeleton resulting 
in detachment and loss of apical-basal organization (Acloque et al., 2009; Barrallo- 
Gimeno & Nieto, 2005; Moreno-Bueno, Portillo, & Cano, 2008; Peindao, Olmeda, & 
Cano, 2007).   The phenotype of the detached cell becomes spindle-like and exhibits a 
front-rear polarity conferring enhanced motility and invasive shape (Kalluri, 2009; 
Matuszak & Kyprianou, 2011a; Thiery et al., 2009; J. Yang & R. Weinberg, 2008).     
Furthermore, breakdown of the basal membrane and extracellular matrix must occur for 
migration to ensue and this is accomplished via secretion of proteases and acquisition of 
migratory/invasive properties (Acloque et al., 2009; Haraguchi et al., 2008).    Using 
gene expression profiling techniques, Cabazitaxel resistant tumor cells were shown to 
possess alterations in the expression of EMT marker profiles. Specifically, they exhibited 
increased expression of the mesenchymal marker, vimentin, and decreased expression 
of the epithelial marker, E-cadherin, compared to parental controls (Duran et al., 2014).  
Overcoming Taxane Resistance in Clinical Setting: Intermittent Chemotherapy. 
Administering cytotoxic taxane chemotherapies is associated with significant toxicity in 
patients. One tactic that has been successfully employed is the use of intermittent 
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chemotherapy. Patients enjoy “drug holidays” or breaks in therapy during which they 
may be able to recover from cumulative toxicity of prolonged treatment (Madan et al., 
2011). In fact, allowing time for patients to resolve drug side effects may allow taxane 
therapy to be extended longer than otherwise would be tolerated by the patient (Beer et 
al., 2008; Bellmunt, Albiol, & Albanell, 2007). Furthermore, it is attractive to hypothesize 
that intermittent chemotherapy prevents selection for “taxane-resistant” cell population 
and potentially circumvents development of resistance (Madan et al., 2011). This 
intermittent approach was directly evaluated in the ASCENT trial in which 250 patients 
were administered 36mg/m2 Docetaxel weekly with high dose calcitriol or placebo. The 
parameters of the study established guidelines regarding eligibility for drug holiday. In 
order to qualify for such a treatment break, patients must exhibit a PSA decline of >50% 
to a level less than 2.0 ng/mL.  After Docetaxel intervention, 45 of the 250 enrolled 
patients (18%) were eligible for intermittent chemotherapy based on the rigorous 
parameters described. The treatment holidays lasted until there was evidence of disease 
progression or increase of PSA by 50% to a value of greater than 2.0 ng/mL. The 
median holiday lasted greater than or equal to 20 weeks for these patients. Of those 
patients given treatment holiday, 90.9% responded to treatment after resumption of 
chemotherapy. Responsiveness to chemotherapy was measured as either a second 
decline in PSA of 50% or stabilization of PSA level (stop increasing PSA) (Beer et al., 
2008). Since then, further investigation has lent credence to the concept of intermittent 
chemotherapy (Kelly et al., 2012; Lin, Ryan, & Small, 2007; Ning et al., 2010). 
Specifically, a phase II study from the National Cancer Institute investigating the 
combination of Docetaxel with anti-angiogenesis therapeutics reported a median overall 
survival of more than 28 months with employment of intermittent Docetaxel 
administration, representing a huge survival advantage (Ning et al., 2010).  
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Combination Strategies 
Platinum Based Therapy. An attractive combination therapy is combining the 
microtubule stabilizing action of taxanes with the cytotoxic, DNA-alkylating properties of 
platinum based chemotherapies, such as carboplatin. Two small format studies have 
investigated the combination of carboplatin + Docetaxel versus Docetaxel alone with 
modest but seemingly optimistic results. Twenty percent of Carboplatin + Docetaxel 
treated patients experienced delayed disease progression with associated PSA decline 
(Dayyani, Gallick, Logothetis, & Corn, 2011; Nakabayashi et al., 2008; Regan et al., 
2010). Disappointingly, after Phase III trials demonstrated no overall survival advantage 
of satraplatin (oral platinum therapy) in patients who progressed on taxane 
chemotherapy. Thus, scientific efforts have been redirected towards other evolving 
therapy options (Sternberg et al., 2009).  
Abiraterone Acetate. The COU-AA-301 randomized, double blinded, placebo 
controlled Phase III clinical trial investigated the effect of Abiraterone acetate in mCRPC 
patients who had previously received Docetaxel treatment and found an improvement in 
overall survival of 4.6 months compared to control-treated patients (De Bono et al., 
2011; Fizazi et al., 2012). In a retrospective study mCRPC patients who had been 
treated with Enzalutamide alone or in combination with Docetaxel, Abiraterone acetate 
yielded only modest anti-tumor effects (Loriot et al., 2013; Noonan et al., 2013) 
Enzalutamide. The AFFIRM Phase III, double blinded, placebo controlled clinical 
trial demonstrated that metastatic castration-resistant prostate cancer patients, 
previously treated with taxanes, were definitively responsive to enzalutamide (Hoffman-
Censits & Kelly, 2013; Scher, Fizazi, Saad, Taplin, Sternberg, Miller, De Wit, Mulders, 
Chi, et al., 2012). Patients treated with enzalutamide had an overall survival of 18.4 
37 
months versus 13.6 months for the placebo control treated patients. Furthermore, 
enzalutamide-treated patients who had reduction in PSA level by 50% or greater had 
improved quality of life, longer radio-graphic progression free survival, and increased 
time to first skeletal related event (Scher, Fizazi, Saad, Taplin, Sternberg, Miller, De Wit, 
Mulders, Chi, et al., 2012).  In a direct comparison trial, the efficacy of enzalutamide was 
shown to be greater when administered to Docetaxel naïve patients as opposed to those 
pre-treated with taxane (Nadal et al., 2014). In contrast, the use of enzalutamide in 
patients with metastatic CRPC pre-treated with Docetaxel and Abiraterone, was not 
overtly effective. Specifically, in 39 patients with metastatic CRPC, selected for a 
retrospective analysis, 41% of patients had a PSA decline of 30% or greater, but overall 
activity of enzalutamide in this population was fairly limited (Bianchini et al., 2014). 
Despite the small sample size, this study implicates that mechanisms of cross resistance 
are at play between these three agents when they are sequentially administered. 
Another recent study confirmed these results by showing that enzalutamide exhibited 
limited activity in mCRPC patients previously treated with Docetaxel and Abiraterone, 
but for those patients which exhibited PSA decline of greater than 30% overall survival 
was significantly improved (Brasso et al., 2014).  
Radio-pharmaceuticals such as 153Sm-
ethylenediaminetetramethylenephosphonate (153Sm –EDTMP) may offer a unique 
combination with Docetaxel. This therapy is intravenously administered and delivers β-
emitting radiation to newly remodeled bone such as osteoblastic bone metastases 
(Goeckeler et al., 1987; Madan et al., 2011) .  This therapy has been shown to confer 
palliation of bone pain in mCRPC patients and has been approved by the FDA for such 
use (O. Sartor et al., 2004; Serafini et al., 1998). Promising Phase I trial results indicated 
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that the combination therapy of  153SmEDTMP and Docetaxel was well tolerated and 
induced decline in PSA level (Serafini et al., 1998).  
Clusterin targeting (OGX-011). Clusterin is also known as testosterone-repressed 
prostate message 2 and sulfated glycoprotein-2 (Gleave & Miyake, 2005; Zellweger et 
al., 2002). Functionally, clusterin is involved in tissue remodeling, reproduction, lipid 
transportation, apoptosis, and more (Dayyani et al., 2011). Its association with apoptosis 
has been controversial because it is highly overexpressed in dying tissues, but 
contradictorily it is also highly overexpressed in prostate, lung, breast tumors, 
lymphoma, and renal cell carcinoma (Gleave & Miyake, 2005). Clusterin becomes highly 
expressed in castration and chemo- resistant prostate tumors rendering it a potential 
candidate for targeting. In fact, induced overexpression of clusterin can confer resistance 
to hormone deprivation and taxane chemotherapy in LNCaP xenografts tumors (Gleave 
et al., 2001). In order to target clusterin, employment of an antisense oligonucleotide to 
the clusterin gene was developed and optimized to become Custirsen/ OGX-011 
(Gleave et al., 2001). A randomized phase II trial investigated the effect of Docetaxel + 
Prednisone with or without OGX-011 in 82 metastatic CRPC patients (Chi et al., 2010). 
Although, there was no difference in PSA decline between the two arms, this trial 
provided encouraging results in that OGX-011 was well tolerated in patients and 
demonstrated improved overall survival compared to those treated with Docetaxel + 
Prednisone alone (23.8 versus 19.6 months) (Chi et al., 2010). Another randomized 
phase III trial concluded that tested Docetaxel + prednisone versus Docetaxel + 
prednisone with OGX-011 in nearly 1,000 patients with overall survival as the primary 
endpoint (Dayyani et al., 2011).  
Other combinations. Extensive efforts have been invested in identifying potential 
efficacious for combination therapy with taxane chemotherapy, but disappointment has 
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been rampant (Antonarakis & Eisenberger, 2013). Antiangiogenic agents including 
Bevacizumab and Aflibercept in combination with Docetaxel did not confer any 
improvement in overall survival (Fizazi et al., 2013; Tannock et al., 2013) . Other agents 
targeting the bone microenvironment have been tested in phase II trials; Atrasentan, 
Zibotentan, and Dasatinib among them did not garner overall survival benefit when 
combined with Docetaxel compared to Docetaxel alone (Araujo et al., 2013; Kelly et al., 
2012; Quinn et al., 2012). Furthermore, immune modulators, GVAX and Lenalidomide 
actually produced inferior overall survival results compared to Docetaxel alone (Petrylak 
et al., 2012; Small et al., 2009).     
Docetaxel to Cabazitaxel. The TROPIC phase III clinical trial led to FDA approval 
of Cabazitaxel (Jevtana, Sanofi-Aventis) for use in mCRPC patients who progressed on 
Docetaxel chemotherapy (De Bono, Oudard, Ozguroglu, Hansen, Machiels, Kocak, 
Gravis, Bodrogi, Mackenzie, Shen, Roessner, Gupta, Sartor, et al., 2010). The trial 
demonstrated a significant overall survival benefit for patients treated with Cabazitaxel 
versus mitoxantrone of 2.4 months. Cabazitaxel-treated patients had a 30% relative 
reduction in risk of death, doubled rate of progression-free survival, and demonstrated 
both PSA and tumor response compared to mitoxantrone treated patients (De Bono, 
Oudard, Ozguroglu, Hansen, Machiels, Kocak, Gravis, Bodrogi, Mackenzie, Shen, 
Roessner, Gupta, Sartor, et al., 2010). One must critically consider the recently 
demonstrated therapeutic impact of Cabazitaxel in patients progressing on Docetaxel 
followed by Abiraterone acetate as well as Docetaxel followed by enzalutamide. This 
clinical evidence supports an action by Cabazitaxel not directly targeting the AR 
signaling axis, as established for Docetaxel (Nakouzi et al., 2014; Pezaro et al., 2014; 
M.-L. Zhu et al., 2010a), thereby challenging its place in limitations of overcoming cross-
resistance with anti-androgen treatment regimes in CRPC (Figure 1.6).  
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Conclusions 
The AR acts as a cornerstone of the aberrant signaling mechanisms associated 
with prostate cancer.  Intense pursuit of the anomalous pathways via which androgen 
signaling is perpetuated in CRPC has identified “diverting” mechanisms that still impact 
tumor progression and therapeutic response in patients. The androgenic signaling axis 
can become altered in a number of ways:  point mutations, truncations, variant 
expression of the AR itself, post translational modifications deviating from the normal 
signaling by RTKs and downstream of growth factor signaling pathways, and the ability 
of prostate cancer cells to commandeer androgen synthesis in the face of ADT.  In close 
exchanges directed by AR, EMT can be reactivated in prostate cancer epithelial cells by 
the key signaling controllers of prostate growth and their functional interactions (TGF-β 
and androgen axis/AR), towards metastatic behavior. Thus, unfolding the key players in 
EMT-activating signaling pathways engaged in crosstalk with AR signaling is paramount 
to recognizing potential therapeutic targets for CRPC. Loss of E-cadherin expression 
and induction of N-cadherin are regulated by key transcription factors, Snail and Slug, 
which transcriptionally repress E-cadherin via the androgenic signaling axis. In a more 
prominent role, Zeb1, directly recruited by the AR signaling, engages in a bidirectional 
negative feedback loop, highlighted in ADT. In the absence/repression of AR (as in early 
ADT), Zeb1 is overexpressed facilitating the mechanistic events leading to EMT. Also 
impacted by the androgenic status, β-catenin, accumulates in the cytoplasm and 
translocates to the nucleus, to induce transcription of LEF1/TCF genes and others which 
mediate EMT processes. Interestingly, β- catenin can also interact with AR directly and 
act as a transcriptional coactivator of AR driving not only EMT, but progression to CRPC.  
In a less direct crosstalk event, AR drives over-expression of TMPRSS2: ERG 
genes fusion products resulting in highly overexpressed transcription factor ERG (ETS 
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family of transcription factors). In the clinical setting, overexpression of ERG and FZD is 
associated with prostate tumor progression. At the cellular level, elevated ERG induces 
EMT, an effect that can be abrogated by silencing of FZD, thus implicating the Wnt 
signaling pathway in driving the effects of ERG gene fusions (Gupta et al., 2010). In view 
of the documented significant association between elevated TGF-β ligand and 
increasing prostate tumor grade, a dynamic cross-talk of TGF-β signaling with AR, in 
controlling EMT during progression to metastasis, becomes central to the cellular 
landscape of CRPC development. Moreover, Smads3 and 4 interact directly with AR to 
reciprocally modulate both target gene transcriptional activation and expression. 
Androgen treatment of human prostate cancer cells significantly upregulates Snail and 
promotes the TGF-β and AR interaction in controlling EMT (M. Zhu & Kyprianou, 2010). 
Notch signaling is essential to intercellular communication, and expression of Jagged1 
(main effector) emerges as a potential independent prognostic indicator of prostate 
cancer recurrence and progression, since expression of Jagged1 correlates with high 
grade and metastatic prostate cancer compared to benign disease or localized tumors. 
Moreover Jagged1 bypasses AR in prostate cancer metastasis, and Notch1 signaling is 
functionally involved with osteoblast differentiation in skeletal derived prostate cancer 
cells. As our understanding of the role of AR signaling in navigating EMT towards 
prostate cancer metastasis and CRPC expands, so do the opportunities to exploit the 
interactions of AR with lead partners, in pursuit of novel therapeutic targets and 
prognostic indicators of disease progression.  
Rapidly growing evidence supports additional actions of taxanes beyond 
microtubule stabilization. Docetaxel exerts many effects on prostate tumor cells including 
increasing expression of FOXO1, inhibiting translocation of the AR from the cytoplasm to 
the nucleus, and overcoming overexpression of Bcl2 (Haldar, Basu, & Croce, 1997) . 
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While Cabazitaxel treatment exerts a similar mechanism of “classic” microtubule 
targeting action, additional mechanisms also emerge that may drive a new therapeutic 
response to this 2nd line chemotherapy.  It regulates the expression of AR and mitotic 
kinesins MCAK and HSET towards promoting apoptosis. The major challenge of 
prostate cancer chemotherapy is overcoming inevitable resistance to taxanes caused by 
alterations in microtubule dynamics, isotype expression, and microtubule associated 
protein expression. Intermittent taxane chemotherapy and combination therapy with anti-
androgens, Enzalutamide and Abiraterone Acetate, have provided additional survival 
benefit to patients but we are still far from a cure. Emergence of Cabazitaxel as a taxane 
effective in the post-Docetaxel landscape represented a huge step forward to treatment 
of CRPC conferring a significant improvement in survival for patients.  Both of these 
concepts are pursued in the two subsequent chapters of this thesis. 
  
 
43 
Figure 1.1 The Androgen Receptor (AR) 
A, AR Structure: Schematic diagram of protein domains and functions. The N-terminal 
domain possesses the Tau-1 and Tau-5 transcriptional activation domains which 
together comprise the AF1 (activation function 1 domain). The DNA binding domain 
confers AR dimerization and binding to ARE via two zinc finger domains (P-Box and D-
Box), which facilitate interaction with the DNA double helix. The Hinge region contains 
the nuclear localization sequence (NLS), which confers nuclear import and regulates 
spacing between the NTD and ligand binding domain. The LBD interacts with DHT, 
associates with chaperones and co-regulatory proteins and interacts with the N terminal 
domain to achieve AR dimerization. The LBD comprises the second activation function 
domain (AF2).  
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Figure 1.1 continued, The Androgen Receptor (AR) 
B, Targeting AR translocation to the nucleus in prostate cancer. A. After binding of 
cognate ligand, molecular handling by super-chaperone complexes, dimerization, 
phosphorylation and association with dynein motor proteins onto microtubules (MT), AR 
translocates to the nucleus to mediate transcription of Androgen Responsive Elements 
(ARE). B. Taxane chemotherapeutics stabilize the interaction of β-tubulin subunits within 
the proto-filaments of the microtubule preventing the de-polymerization of the structure 
resulting in G2M arrest, apoptosis, and increased accumulation of AR in the cytoplasm. 
C. With regard to Docetaxel (Taxane) resistant – CRPC, differential signaling is 
potentially inclined to facilitate translocation of AR to the nucleus despite microtubule 
stabilization.  
B. 
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Figure 1.2. Role of AR in prostate cancer and EMT Panel A. Cadherin switching, 
Zeb1 feedback loop, and expression of Snail2 are modulated by the crosstalk with the 
Androgen Receptor (AR).  
A.
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Figure 1.2 continued, Role of AR in prostate cancer and EMT Panel B. TGFβ 
signaling induces EMT-associated changes in prostate cancer cells via Smad-dependent 
and -independent signaling and their signaling crosstalk with the AR. C. Wnt/ β-catenin 
signaling engages in direct crosstalk with AR. AR and TCF-LEF1 transcription factors 
compete for β-catenin acting as a coactivator of transcription promoting EMT. 
B. 
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Figure 1.3 Therapeutic Targeting of Hormonally Dependent Prostate Cancer. 
Therapies employed to treat prostate cancer include inhibiting signaling through the 
hypothalamic pituitary axis via LHRH Analogues, inhibition of adrenal androgen 
synthesis with Abiraterone, direct inhibition of AR activity by treatment with AR 
antagonist ,Enzalutamide, targeting of the NTD of AR with EPI-001 to prevent 
transcriptional activation, microtubule stabilization by Docetaxel leading to inhibition of 
dynein mediate AR nuclear translocation and Cabazitaxel mediated microtubule (MT) 
stabilization leading to AR stranded in the nucleus and decreased expression of MT de-
polymerizing kinesins. 
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Figure 1.4 Taxane Mechanism of Action. Taxanes (Docetaxel and Paclitaxel) directly 
stabilize the interaction between tubulin subunits to prevent de-polymerization of 
microtubules (MT), leading to G2M arrest and apoptosis. In addition, taxanes can inhibit 
AR nuclear translocation along the MT, induce overexpression of FOXO1, and thus 
causing sequestration of AR away from ARE. Taxanes also inhibit the association of 
dynein with microtubules (MT) leading to diffuse AR localization. Moreover, Cabazitaxel 
therapy decreases expression of pro-mitotic kinesins in prostate cancer cells. 
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52 
Figure 1.5 Mechanisms of Taxane Resistance in CRPC 
Overexpression of MDR1/P-gp ATP dependent drug efflux pumps can promote 
resistance by increasing the efficiency with which cells may pump out taxanes Panel (A), 
Alterations in the tubulin subunit and its structural/spatial dynamics leads to taxane 
resistance via isotype switching from βI to βIII tubulin. Panel (B); expression of tubulin 
with a hypostable binding site leads to a shift in microtubule (MT) binding dynamics 
towards dimerized tubulin and away from polymerized tubulin; Panel (C), mutational 
alterations in the tubulin subunit lead to decreased binding of Docetaxel to microtubule 
structure, consequently conferring resistance to taxane. MT interaction with other 
microtubule associated proteins (MAP) such as MAP4 and Stathmin affect stability of MT 
structure (E). Overexpression of MT depolymerizing kinesins (HSET, MCAK, Eg5) can 
lead to taxane resistance by circumventing effects of stabilized MT (F). Induction of EMT 
also causes resistance to taxane therapy (G). 
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Figure 1.6 Differential Effect of Docetaxel (DOC) and Cabazitaxel (CBZ) on ATP-
dependent Motor Proteins Driving Therapeutic Response. Docetaxel decreases the 
association between AR and dynein thereby inhibiting the translocation of AR from 
cytoplasm to nucleus. Cabazitaxel therapy decreases expression of microtubule de-
polymerizing kinesins (MCAK and HSET), causing multi-nucleation and centrosomal 
amplification stranding AR in the nucleus. 
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Chapter 2. N-Terminal Targeting of AR Variant Enhances Response of Castration 
Resistant Prostate Cancer to Taxane Chemotherapy   
Background and Significance 
Development of metastatic castration-resistant prostate cancer (mCRPC) is a 
consequence of lack of an apoptotic response to androgen deprivation (B. J. Feldman & 
D. Feldman, 2001).  The treatment landscape for mCRPC has been transformed by the 
recent FDA approval of the androgen/AR signaling axis inhibitors, built on clinical 
evidence that AR signaling drives both the therapeutic response and resistance in 
mCRPC (C. D. Chen et al., 2004; Visakorpi et al., 1995). Overexpression of AR, 
detected in CRPC, (B. J. Feldman & D. Feldman, 2001; Visakorpi et al., 1995) is able to 
mediate resistance to anti-androgens (C. D. Chen et al., 2004), while point mutations 
increasing the ligand-binding affinity of AR cause signaling hypersensitivity (Gregory et 
al., 2001). Promiscuous mutations cause binding flexibility in the ligand-binding domain 
(LBD) allowing the AR to become activated by adrenal androgens, androgenic 
metabolites, and anti-androgen therapeutics including enzalutamide and ARN-509 
(Dehm et al., 2008; Scher, Fizazi, Saad, Taplin, Sternberg, Miller, De Wit, Mulders, 
Hirmand, et al., 2012; Tanner et al., 2010; Yilmaz & Christophori, 2009). Moreover, over 
twenty splice variants of AR, some lacking LBD, and therefore constitutively active have 
been identified and associated with progression of CRPC and metastasis (Dehm et al., 
2008; Z. Guo et al., 2009; Hu et al., 2009; Hu, Isaacs, et al., 2010; Jenster et al., 1995; 
S. Sun et al., 2010). AR signaling mediated by truncated AR splice variants (AR-Vs) 
lacking LBD, may potentially drive the emerging resistance to anti-androgen therapies 
and CYP17 inhibitors (B. Cao et al., 2014; Mostaghel et al., 2011; X. Zhang et al., 2011). 
In support of this, selective loss of AR V7 variant in prostate cancer cells restored 
sensitivity to enzalutamide (Y. Li et al., 2013). Furthermore, expression of an androgen 
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receptor variant can predict therapeutic response to anti-androgens such as 
enzalutamide (Antonarakis et al., 2014).    
 Taxane-based chemotherapy is a clinically effective treatment for CRPC, by 
disruption of microtubule dynamics via stabilization of β-tubulin subunits within the 
microtubule structure, resulting in deregulation of the mitotic spindle assembly. As 
discussed in the introduction, taxanes bind the β-subunit of tubulin, stimulating 
polymerization into stabilized microtubules that inhibit cell cycle progression leading to 
G2M arrest and apoptosis (Harrington & Jones, 2011; Vrignaud et al., 2013).  Evidence 
from this laboratory and others established that taxane stabilization of microtubules 
inhibits AR translocation into the nucleus thus, preventing the transcriptional activity of 
AR (Darshan, Loftus, Thadani-Mulero, Levy, Escuin, Zhou, et al., 2011; M.-L. Zhu et al., 
2010a).  Additionally, taxanes lead to an increase in Forkhead box 01 (FOXO1), a 
transcriptional repressor of AR, consequently resulting in inhibition of ligand-dependent 
and ligand-independent transcription (Gan et al., 2009a). The therapeutic impact of 
Docetaxel in prohibiting prostate cancer progression and improving survival in patients 
with advanced disease, has been attributed to utilization of mechanisms previously 
targeted by androgen deprivation therapy (ADT) (Fitzpatrick & de Wit, 2014; Mistry & 
Oh, 2013).  Despite a proven survival advantage, resistance to Docetaxel develops, 
leading to disease progression in approximately 7.5 months (Loriot & Fizazi, 2013). 
Mechanisms implicated in the development of Docetaxel resistance include 
overexpression of P-glycoprotein drug efflux pump, mutational alterations in tubulin 
expression and induction of EMT (Fitzpatrick & de Wit, 2014; Loriot & Fizazi, 2013; Puhr 
et al., 2012).  
The N-terminal domain (NTD) of AR is effectively targeted by the novel small 
molecule, EPI-001/002 (EPI), which interacts with the disordered domain of the AF-1 
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region and blocks AR transcriptional activity (Andersen et al., 2010; Myung et al., 2013).  
The functional contribution of the microtubule network and the cytoskeleton to androgen-
mediated signaling via navigating AR cellular localization, as well as the consequences 
of their inhibition by taxanes on AR activity in human prostate cancer  have been 
established (Darshan, Loftus, Thadani-Mulero, Levy, Escuin, Zhou, et al., 2011; M.-L. 
Zhu et al., 2010a).   Considering the compelling evidence that AR variant expression and 
EMT have both been implicated as mechanisms of resistance to anti-androgens and 
taxane-based chemotherapy and poor survival (Hornberg et al., 2011; Y. Li et al., 2013; 
Mostaghel et al., 2011; Puhr et al., 2012; X. Zhang et al., 2011) and since the 
association of AR with tubulin occurred via the AR NTD (M.-L. Zhu et al., 2010a), this 
study investigated the effect of the novel AR NTD antagonist EPI on the sensitivity to 
taxane treatment in vitro and in vivo of CRPC harboring the full length AR and the AR 
splice variants. My work identified that such a combination strategy effectively 
suppressed CRPC via navigating cycles of EMT and changes in the cytoskeleton 
integrity.  
 
Approach 
Cell Lines.  The human prostate cancer cell lines, the castration-resistant cell line 
22Rv1 and androgen-sensitive LNCaP cells were obtained from American Type Culture 
Collection (ATCC, Manassas, VA). Cells were maintained in RPMI 1640 (Invitrogen, 
Grand Island, NY) and 10% fetal bovine serum (FBS), 100units/ml penicillin and 
100µg/ml streptomycin in a 5% CO2 incubator at 37C. The androgen-independent 
LNCaP95 cell line (derivative cells from LNCaP) was a generous gift from Dr. Stephen 
Plymate (University of Washington, Seattle, WA). For experiments examining responses 
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to androgen, cells were seeded in 10% charcoal-stripped serum and were stimulated for 
24hrs by growth medium containing 1nM dihydrotestosterone (DHT) (Sigma-Aldrich, St. 
Louis, MO) or R1881.  
Antibodies.  The following antibodies were used for the various experiments. 
Antibodies against E-cadherin, β-tubulin, Androgen Receptor (N-20), Dynein IC1/2 
proteins were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The 
antibodies against N-cadherin and CD31 were obtained from AbCam Cell Signaling 
(Cambridge, UK); antibodies against PARP-1, Vimentin, GAPDH, Snail, cofilin and β-
catenin proteins were obtained from Cell Signaling Technology (Danvers, MA).   
Cell Viability Assay. The effect of the various treatments on prostate cancer cell 
viability was evaluated using the Thiazolyl Blue Tetrazolium bromide (MTT) assay). Cells 
were seeded into 24-well plates, grown to 60-75% confluence, treated with vehicle 
control (DMSO, Sigma-Aldrich, St. Louis, MO), Docetaxel (DOC, 1µM), EPI-002 (25µm), 
or the combination (1µM DOC + 25µM EPI-002) in RPMI 1640 with 10% CSS (Charcoal 
Stripped Serum) for 24hrs. Following treatment, media was aspirated and cells rinsed 
with PBS then treated with 250µl/well MTT (1mg/ml) for 30mins at 37°C. After 
incubation, MTT was aspirated and formazan crystal was solubilized with DMSO. 
Absorbance was measured at 570nm using μQuant Spectrophotometer (Biotech 
Instruments Inc., Winooski, VT).  
Cell Proliferation.  Cells were seeded into 96-well plates and pretreated for 1hr 
with vehicle or EPI-002 (25µM).  After 16hrs, cells were treated with Docetaxel (0.5µM) 
(alone or combination with EPI-002) before addition of R1881 (synthetic androgen, 
0.1nM) or vehicle under serum-free and phenol red-free conditions, and subsequently 
incubated for 23hrs. After pulse-labeling with 10 µM BrdU (for 2hrs), BrdU-labeled cells 
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were identified with the anti-BrdU-POD (Roche). BrdU incorporation was measured at 
570nm using a VersaMax ELISA Microplate Reader (Molecular Devices). The results 
from three independent experiments performed triplicate were analyzed. 
Western Blot Analysis. Total cellular protein was extracted from cell pellets by 
homogenization with RIPA buffer (Cell Signaling Technology, Danvers, MA). Protein 
samples were loaded into 4% to 12% SDS-polyacrylamide gels (Bio-rad, Hercules, CA) 
and subjected to electrophoretic analysis and blotting.  The following antibodies were 
used against these specific proteins: E-cadherin, N-cadherin, β-tubulin, the AR (N-20), 
Snail, Vimentin, PARP-1, β-catenin and GAPDH proteins. Membranes were incubated 
with the specific primary antibody (overnight at 4°C) and were subsequently exposed to 
the relevant secondary antibody (90mins, room temperature). For signal detection, 
membranes were incubated with the Amersham ECL Plus Western Blotting Detection 
System (Amersham, GE Healthcare, Buckinghamshire, UK) for 5mins and auto-
radiographed using X-ray film (Denville Scientific, South Plainfield, NJ). All protein 
expression bands were normalized to GAPDH expression (used as loading control).  
Quantitative RT-PCR Analysis.  In vitro samples: RNA was extracted with 
the Trizol© reagent (Life Technologies, Grand Island, NY) and RNA samples (1μg) were 
subjected to reverse transcription using the Reverse Transcription System (Promega, 
Madison, WI). TaqMan real time reverse transcriptase-PCR (Life Technologies, Grand 
Island, NY) analysis of the cDNA samples was conducted in an ABI7700 Sequence 
Detection System (Applied Biosystems, Inc, Branchburg, NJ), using the following 
specific primers: for Prostate Specific Antigen (KLK3; Hs02576345_m1), E-cadherin 
(CDH1; Hs01023894_m1), N-cadherin (CDH2; Hs00983056_m1), Vimentin (VIM; 
Hs00185584_m1), Snail (SNAI1; Hs00195591_m1), Twist (TWIST1; Hs01675818_s1), 
UGT2B17 (Hs00854486_sH),  and 18S rRNA (4319413E) (Applied Biosystems, Life 
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Technologies, Grand Island, NY). For the qRT-PCR experiments, each sample was 
analyzed in duplicate and data represent average values from three independent 
experiments. Numerical data for transcript levels were normalized to 18s rRNA in 
controls and expressed relative to untreated controls. 
Luciferase Reporter Gene Assays.  LNCaP95 cells (1.5x105) and 22Rv1 cells 
(9.5x105 in 10% FBS phenol red free RPMI) were transfected with the AR responsive 
PSA(6.1kb)-luciferase, probasin (PB)-luciferase and ARR3-luciferase reporters in serum-
free media.  At 5hrs post- transfection, cells were pretreated with vehicle or EPI-002 
(EPI) (25µM) for 16hrs, and were subsequently exposed to Docetaxel (DOC) (0.5µM), or 
EPI and Docetaxel (EPI + DOC). Cells were incubated with R1881 (1nM) for 23hrs.  
After 24hrs of treatment, cells were lysed and subjected to luciferase reporter activity 
analyses that were normalized to protein concentrations using the Glomax luminometer 
(Promega Corporation; Madison, WI). All transfection assays were performed in at least 
three independent experiments in triplicate wells. 
Immunofluorescent Confocal Microscopy. Cells were plated (1x105) in chamber 
slides coated with fibronectin (Invitrogen). After 24-48hrs, cells were exposed to medium 
(RPMI 1640 with 10% CSS) in the presence of DHT (1nM), Docetaxel (DOC: 1µM), EPI-
002 (EPI: 25µM) or in combination of the two agents. Following treatment, cells were 
fixed in 4% (v/v) paraformaldehyde and permeabilized with 0.1% Triton X-100 in sterile 
phosphate buffer saline (PBS). Fixed cells were incubated overnight with primary 
antibody specific for AR (N-20), Dynein IC1/2 and Tubulin, (at 4°C) with gentle rocking 
and the appropriate Alexa-Fluor (Life Technologies, Grand Island, NY) fluorescent 
secondary (1.5 hrs, room temperature). Slides were mounted using Vectashield 
mounting medium with DAPI and were visualized using a FV1000 Confocal Microscope 
(Markey Cancer Center Core, University of Kentucky). 
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In Vivo Tumor Targeting Studies. All animal experiments were performed in 
accordance with the guidelines approved by the Animal Care and Use Committee of the 
University of British Columbia.   NOD-SCID mice (6-8wks old) were castrated before any 
drug treatments. At 7 days post-castration, mice were subcutaneously injected with 
22Rv1 cells (3x106cells plus Matrigel™ media). Mice were subsequently divided into two 
groups of 10 mice each: the control group receiving 1% medium /0.1% Tween-20 daily 
via oral gavage; the other 10 mice in the treatment group received EPI-001 (100 mg/kg 
twice daily) via oral gavage.  EPI-001 had no effect as a monotherapy so when tumors 
reached approximately 140mm3, 5 mice in each group was intraperitoneal injected (I.P.) 
with Docetaxel (15mg/kg) on day 1 and day 5; and the combination treatment of EPI-001 
(100 mg/kg twice daily) and Docetaxel (15mg/kg) for 11 days; Tumors were measured 
twice a week and the volume calculated by using the formula, length x height x width x 
0.5236.  Prostate tumor xenografts were harvested two days after the last treatment and 
tissue specimens were subjected to histopathological analysis. Immunostaining was 
conducted for the expression and cellular localization of AR, cytoskeleton organization, 
EMT, vascularity (CD31), and apoptosis (TUNEL, EMD Millipore, Billerica, MA). TUNEL 
analysis for detection of apoptotic cells was performed as previously (Pu et al., 2009).  
Immunohistochemical Analysis. Tissue specimens from human prostate tumor 
22Rv1 xenografts were formalin fixed and paraffin-embedded; serial sections (5µ) were 
subjected to immunohistochemical analysis using antibodies against E-cadherin, N-
cadherin, β-tubulin, AR (N-20), cofilin, and CD31. After blocking nonspecific binding 
(1.5%NGS/TBS-Triton), sections were incubated with primary antibody (overnight, 4°C).  
and subsequently incubated with biotinylated goat anti-rabbit IgG (2hrs, room 
temperature) and horseradish peroxidase-streptavidin (EMD Millipore, Billerica, MA). 
Color detection was achieved with SigmaFast 3,3’-Diaminobenzidine tablets (Sigma-
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Aldrich, St. Louis, MO) and counterstained with haematoxylin. Images were captured via 
light microscopy (40x and 100x) using an Olympus BX51 microscope (Olympus 
America, Center Valley, PA). Content and intensity of immunoreactivity were recorded 
by two independent observers (S.K.M. and N.K.).   
Statistical Analysis.  Student’s t test or one-way ANOVA were performed using 
Graph Pad Prism 6 software to determine the statistical significance of difference 
between means. All numerical data are presented as Mean ± Standard error of the mean 
(SEM). Statistical significance was set at P value < 0.05. ImageJ software was used for 
calculation of densitometry.  
 
Results 
Combination of Docetaxel and EPI Maximizes Blockade of AR Activity and 
Impairs Human Castration Resistant Prostate Cancer Growth In Vitro and In Vivo 
Considering that constitutively active AR splice variants V7 and V567es 
(Hornberg et al., 2011) regulate the expression of both canonical and a unique subset of 
gene targets that are enriched for M-phase cell cycle genes (B. Cao et al., 2014; S. Sun 
et al., 2010), I used two different human prostate cancer cell lines as models. They 
express full length functional AR and AR variants to examine the anti-tumor effect of 
combined targeting of microtubules and AR NTD. The 22Rv1 human prostate cancer 
cells express both functional full-length AR with duplication of exon 3 and substantial 
levels of constitutively active AR-V7, although they do not exhibit a proliferative response 
to androgens (Dehm et al., 2008; Z. Guo et al., 2009; Marcia et al., 2010). Docetaxel 
treatment (1µM) of 22Rv1 cells for 24 hrs resulted in significant loss of cell viability 
(Figure 2.1.A). Combination of EPI with Docetaxel increased loss of cell viability beyond 
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DOC alone (P<0.05), while EPI as a single agent exerted no significant effect on 22Rv1 
cell viability at 24 hours.   
To examine the anti-tumor effect of EPI alone or in combination with the 
microtubule-targeting chemotherapy in vivo, I used 22Rv1 xenografts in mice (castrated 
for 2 -weeks prior to inoculation).  As shown in Figure 2.1.B, daily treatment with the AR 
N-terminal inhibitor EPI (200mg/kg), did not result in a significant growth inhibition of the 
22Rv1 xenografts compared to vehicle control. The combination treatment of Docetaxel 
and EPI led to a significant suppression of CRPC tumor growth compared to either 
single treatment modality or untreated controls (Figure 2.1.B) (**, P<0.05). This dramatic 
reduction in prostate cancer xenograft growth was associated with a significant increase 
in the number of apoptotic cells in the combination treated tumor xenografts compared to 
untreated control or single treatment arms, as evaluated with the TUNEL assay (Figure 
2.2.A & Figure 2.2.C). Assessment of the tumor vascularity based on the CD31 immuno-
reactivity in xenograft tumors demonstrated a significant decrease in tumor vascularity in 
response to EPI and Docetaxel combination compared to untreated controls (Figure 
2.2.B; Figure 2.2.D). 
In response to Docetaxel, there was an apparent decrease in the AR immuno-
reactivity in the 22Rv1 CRPC xenografts (Figure 2.3.A). Quantitative evaluation of AR 
positivity and cellular localization however, did not reveal any significant changes after 
any of the treatments relative to untreated control (Figure 2.3.B). Treatment of mice with 
Docetaxel led to reduction in tubulin expression in the prostate tumor xenografts that 
was further enhanced by the combination treatment of Docetaxel and EPI.  Quantitative 
analysis of cofilin immuno-reactivity revealed a significant decrease of this critical 
cytoskeleton protein in response to Docetaxel and the combination treatment, compared 
to untreated control (Figure 2.3.C). To further interrogate these protein changes elicited 
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by the combination treatment of Docetaxel and the NTD AR targeting, we use confocal 
microscopy in 22Rv1 cells in vitro. As shown on Figure 2.3.D, treatment with Docetaxel 
alone (for 4hrs), led to a marked reduction in tubulin expression and mitotic arrest 
(merged image) in CRPC. Prostate cancer cells exhibiting microtubule stabilization 
appear to have some cytoplasmic AR localization in 22Rv1 cells (Figure 2.3.D and E). 
Consistent with the in vivo xenograft data (Figure 2.3.A), there were no significant 
changes in the expression of AR after Docetaxel treatment (as single agent or in 
combination with EPI) compared to untreated control cells (Figure 2.3.D and E). 
Docetaxel caused a significant loss in body weight compared to animals treated 
with vehicle control (86% +/- 3.0% vs 102% +/- 1.3%, p=0.0011), while EPI had no 
significant effect (98% +/- 1.3%, p=0.6088). The body weight of mice treated with EPI in 
combination with Docetaxel was also significantly lower than that obtained for the vehicle 
control (86% +/- 5.4%, p=0.0156), but not significantly different than the weight 
measurements from mice treated with Docetaxel monotherapy (p=0.9529). Thus the 
combination treatment of EPI and Docetaxel does not appear to induce toxicity beyond 
that obtained from Docetaxel alone. 
Impact of AR Variants on Taxane-mediated AR Trafficking 
The existence of AR variants capable of androgen-independent signaling may be 
critical in dictating the therapeutic response to taxanes. The AR variant core consisting 
of the AR NTD and DNA-binding domain is sufficient for nuclear localization and 
androgen-independent transcriptional activation of AR target genes (S.C. Chan, Y. Li, & 
S.M. Dehm, 2012). I examined the effect of EPI and Docetaxel on the expression and 
cellular localization of the AR, as well as tubulin, in the 22Rv1 cells in the presence of 
DHT. An apparent stabilization of microtubule structures and a decrease in tubulin levels 
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were detected in response to the combination treatment of Docetaxel and EPI (Figure 
2.3.D and E). Figure 2.3 reveals fluorescent images of the 22Rv1 prostate cancer cells 
in response to Docetaxel or EPI (as single agents), or the combination of the two agents. 
A modest effect of Docetaxel on androgen-induced nuclear AR translocation was 
observed after 4hrs of treatment. This was confirmed by subcellular fractionation 
analysis revealing that Docetaxel treatment reduced the nuclear presence of full length 
AR, without causing marked changes in AR variants (nuclear vs cytosolic levels) (Figure 
2.4.A).  This is in contrast to the ability of Docetaxel and also EPI (given as single agents 
or in combination) to promote the cytoplasmic sequestration of AR from the nuclei in the 
androgen-sensitive LNCaP cells, harboring a full length AR (Figure 2.5.A). This impact 
on AR nuclear translocation by taxane and EPI-Docetaxel combination in LNCaP cells 
was translated into a significant inhibitory effect against cell viability (Figure 2.5.B). 
Western blot analysis revealed that within 6hrs of treatment with EPI there was an 
increase in protein levels of both full-length and variant AR compared to untreated 
22Rv1 cells that was suppressed by the combination treatment of EPI with Docetaxel 
(Figure 2.6.B).    
Dynein is a microtubule-traversing motor protein capable of efficiently facilitating 
nuclear transport of cytoplasmic proteins, that was previously shown to navigate AR 
trafficking along the microtubules and its nuclear translocation, towards induced 
transcriptional activity (Darshan, Loftus, Thadani-Mulero, Levy, Escuin, Zhou, et al., 
2011). I thus examined the expression and cellular localization of dynein in 22Rv1 cells 
in response to the various treatments and its co-localization with AR. Androgens (DHT) 
increase expression of dynein and this correlates with increased AR nuclear 
translocation (Figure 2.6.A; Merge + DAPI). In response to Docetaxel, there was a 
marked alteration in dynein localization as detected by confocal microscopy (appearing 
 
65 
as punctate sequestration (Figure. 2.6.A). In marked contrast, in the androgen-sensitive 
LNCaP cells (full length AR), treatment with Docetaxel alone or in combination with EPI, 
in the presence of DHT, resulted in diffuse cellular localization of dynein (Figure 2.5.A).  
Differential Effect of Taxane and EPI Treatment on AR vs AR-V7 Target Genes 
To determine the impact of treatment on the functional activity of AR, the 
temporal induction of AR regulated genes was evaluated in 22Rv1 cells in response to 
Docetaxel, EPI or the combination treatment.  Prostate-specific antigen (PSA/KLK3) is a 
gene target for the full length AR and UGT2B17 is a gene target for AR V7 variant. 
There was a significant increase in KLK3 mRNA expression in response to treatment 
(within an hour) with Docetaxel monotherapy and combination therapy (Figure 2.6.C) 
(P<0.05). There was no significant effect on KLK3 expression, in response to either EPI 
or Docetaxel given as single agents, or in combination (after 24 and 48hrs), relative to 
untreated levels. A transient increase in UGT2B17 mRNA levels was detected within 1-
6hrs of treatment with EPI (Figure 2.6.D). After longer treatment periods (12-48hrs), 
upregulation of UGT2B17 in response to either EPI or combination with Docetaxel, was 
not sustained.  
Next I examined the combination treatment of Docetaxel and EPI on AR 
transcriptional activity to find it exerts an enhanced inhibitory effect therein, using three 
AR-driven reporter gene constructs in the 22Rv1 cells. The probasin (PB, -286/+28) 
reporter gene construct is the natural promoter that contains two functional androgen 
response elements (AREs), that comprise the androgen response region (ARR). The 
PSA (6.1 kb) reporter gene construct is also a natural reporter with several AREs in both 
the enhancer and promoter regions. The ARR3 is an artificial reporter with 3 repeats of 
the PB ARR in front of a minimal thymidine kinase promoter. The data shown on Figure 
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2.6, demonstrate that treatment with EPI led to significant inhibition of the androgen-
induced PB-luciferase and PSA-luciferase reporters (panels E and F respectively), while 
unexpectedly increased the activity of the synthetic ARR3 reporter (Figure. 2.6.G) 
(P<0.05); this finding resonates with the increase in AR protein levels by EPI (Figure 
2.6.B). The combination of Docetaxel and EPI consistently achieved a significant 
inhibitory effect for all three AR-driven reporters in 22Rv1 cells (Figure 2.6, panels E-G).  
To validate the enhanced anti-tumor potency of the combination approach of 
taxanes and EPI against another androgen-insensitive prostate cancer cell line, the 
proliferative response of LNCaP95 human prostate cancer cells that express functional 
full-length AR and the AR-V7 variant was investigated (Hu et al., 2012). We found that 
EPI treatment alone or in combination with Docetaxel significantly inhibited cell 
proliferation in LNCaP95 cells (Figure. 2.7.A).  Furthermore analysis of the AR 
transcriptional activity, demonstrated that treatment of LNCaP95 cells with either EPI or 
Docetaxel given as single agents significantly inhibited the androgen-induced activity for 
all three reporters (Figure 2.7, panels B, C and D), prior to manifestation of cell death 
(Figure 2.8.E). Consistent with the findings in 22Rv1 cells, the combination of Docetaxel 
and EPI resulted in maximal blockade of AR transcriptional activity in LNCaP95 cells.  
Role of EMT in Therapeutic Response of CRPC to Combined Targeting of AR 
NTD and Microtubules 
The recently reported association of AR variants with clinical prostate cancer 
progression and therapeutic resistance to taxanes and anti-androgens (B. Cao et al., 
2014; Y. Li et al., 2013; Mostaghel et al., 2011; X. Zhang et al., 2011) may be driven by 
induced EMT. To assess the impact of AR NTD targeting on the EMT phenotype of 
prostate tumor epithelial cells after Docetaxel treatment, we subsequently conducted an 
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expression profile of key EMT effectors in 22Rv1 cells following single agent or 
combination treatment. Treatment with EPI led to a marked increase of N-cadherin 
protein levels compared to the untreated control cells (Figure 2.8.A); N-cadherin up 
regulation was attenuated by combination with Docetaxel.  By 24hrs-post treatment, the 
key phenotypic change of elevated N-cadherin associated with EMT induction was 
restored to control levels (Figure 2.8.A). No significant changes in levels of Twist, E-
cadherin or N-cadherin temporal expression were detected. A modest decrease in the 
cytoskeleton protein, cofilin was evident after 24hrs of DOC or EPI monotherapy.  
The EMT landscape was interrogated in the in vivo setting of 22Rv1 prostate 
tumor xenografts (from Figure 2.1.B).  E-cadherin expression was increased in response 
to both Docetaxel and EPI given as single agents, while N-cadherin levels were 
decreased compared to the untreated controls (Figure 2.8.B) consistent with the 
phenotypic reversion of EMT to MET in prostate tumor epithelial cells.  Interestingly, the 
combination treatment led to an apparent decrease in E-cadherin and upregulation of N-
cadherin protein levels pointing to EMT induction. Tissue levels of vimentin were 
increased after treatment with EPI or Docetaxel given as single agents, an effect that 
was blocked by the combination treatment (Figure. 2.8.B). 
The temporal changes in gene expression for EMT regulators were interrogated 
by analysis of mRNA expression levels by qRT-PCR. The results summarized in Figure 
2.8 indicate that consistent with EPI increasing levels of N-cadherin protein at 6hrs, 
levels of N-cadherin mRNA were also elevated within the same period of exposure to 
EPI, compared to levels observed for CSS control (Figure 2.8.C). Upregulation of mRNA 
for vimentin and E-cadherin was also detected within 6hrs of treatment with EPI.  After 
longer treatment periods (12, 24 and 24hrs), the levels for both proteins were restored to 
levels comparable to the controls. A significant increase in N-cadherin mRNA was 
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detected in response to Docetaxel (as single agent) at 1 and 3hrs, but with no effect on 
vimentin mRNA (Figure 2.8.C). The combination treatment of EPI and Docetaxel for 
24hrs resulted in a significant increase in the levels of mRNA for both N-cadherin and 
vimentin. A significant induction of Snail mRNA was observed in response to both 
monotherapies and this was further enhanced in response to the combination of 
Docetaxel with EPI (Figure 2.8.C). Within the first hour of combination treatment, there 
was a significant induction in Twist gene expression (Figure 2.8.C). Elevated expression 
of N-cadherin occurs in response to attenuated AR transcriptional activity or reduced 
levels of expression of AR (Jennbacken et al., 2010; Tanaka et al., 2010). Thus, these 
findings support the “programming” of EMT by the AR N-terminal inhibitor, to potentially 
drive the sensitivity/resistance of CRPC 22Rv1 cells to microtubule-targeting taxane-
based chemotherapy (Figure 2.8.D). 
 
Conclusions 
Taxane-based chemotherapy is an effective treatment for castration-resistant-
prostate cancer (CRPC) via stabilization of microtubules. Previous studies identified that 
the inhibitory effect of microtubule targeting chemotherapy on androgen receptor (AR) 
activity was conferred by interfering with AR intracellular trafficking. The N-terminal 
domain (NTD) of AR was identified as a tubulin-interacting domain that can be effectively 
targeted by the novel small molecule inhibitor, EPI. Taken together this evidence 
provided the rationale that targeting AR nuclear translocation and activity via a 
combination of an antagonist of the AR NTD and taxane-based chemotherapy may 
enhance the therapeutic response in CRPC. The present study investigated the anti-
tumor efficacy of a combination of EPI with Docetaxel chemotherapy, in cell models of 
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CRPC, harboring the AR splice variants in addition to the full length AR. My studies 
demonstrate that there was no significant effect on the androgen-mediated nuclear 
transport of AR variants and AR transcriptional activity by Docetaxel. The therapeutic 
response to Docetaxel was enhanced by inhibition of the NTD of AR (by EPI) through 
cycling of EMT to MET among prostate cancer epithelial cells.  These results support 
that transient “programming” of EMT by the AR NTD inhibitor, potentially drives the 
sensitivity of prostate tumors with differential distribution of AR variants to microtubule-
targeting chemotherapy.  
 Therapeutic response durations to androgen-depletion in advanced metastatic 
prostate cancer are variable and prostate tumors nearly always become resistant and 
ultimately lethal. Diverse mechanisms have been implicated in driving aberrant AR 
function, including intra-tumoral synthesis of androgens from inactive precursors, 
increased AR expression, truncated AR with constitutive activity, ligand-independent  
activation of AR signaling and alterations in nuclear receptor co-activators (Debes & 
Tindall, 2004a; Knudsen & Penning, 2010). Novel pharmacologic targeting of these 
mechanisms has provided some validation in the clinical setting in the treatment of 
CRPC, such as those that require the AR ligand-binding domain (Lunardi et al., 2013). A 
new paradigm has emerged in therapeutic targeting of microtubule-mediated androgen 
signaling in prostate cancer, as growing evidence indicates that taxane–induced 
stabilization of microtubules inhibits the nuclear translocation of the androgen-AR 
complex and impairs AR transcriptional activation (Darshan, Loftus, Thadani-Mulero, 
Levy, Escuin, Zhou, et al., 2011; Gan et al., 2009a; M.-L. Zhu et al., 2010a). My findings, 
as presented in this chapter, indicate that Docetaxel treatment causes only a modest 
inhibition of the AR nuclear localization, although there was a significant suppression of 
AR-transcriptionally activated gene expression, in the 22Rv1 CRPC prostate cancer 
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cells. Considering that these cells express a mixture of the full-length AR as well as the 
AR variants, this was not entirely unexpected. These results gain mechanistic support 
from recent evidence by Chan and colleagues demonstrating that AR splice variants 
activate AR target genes and promote prostate cancer growth independent of canonical 
AR nuclear localization signal (S.C. Chan et al., 2012). More recently it was reported that 
the nuclear accumulation and transcriptional activity of AR V7 variant was not affected 
by microtubule-targeting chemotherapy (Thadani-Mulero, Portella, Sun, Sung, Matov, 
Vessella, Corey, Nanus, Plymate, et al., 2014), in full support of this work. Thus one may 
argue that while nuclear AR localization is functionally critical for controlling AR (full 
length) transcriptional activation of target genes in androgen-dependent prostate cancer, 
other distinct pathways may exist to regulate the AR variants nuclear translocation in 
CRPC, thus driving therapeutic resistance to microtubule-targeting chemotherapy and/or 
anti-androgens. Interestingly enough, the AR V7 lacks the hinge region which facilitates 
microtubule targeting and navigates AR nuclear trafficking (Tanner et al., 2010; Thadani-
Mulero, Portella, Sun, Sung, Matov, Vessella, Corey, Nanus, Plymate, et al., 2014). Our 
findings on the modest effect of microtubule-targeting treatment on AR V7 transcriptional 
activity are in accord with the above mechanistic evidence.  
 My observations indicate that the microtubule motor protein, dynein can 
efficiently facilitate the cytoplasmic AR trafficking along the microtubules and its nuclear 
translocation in the presence of androgens, resonates with previous reports (Darshan et 
al., 2011).  In addition, I found that the status of the AR dictates the cellular response to 
Docetaxel treatment (alone or in combination with EPI) in terms of changes in dynein 
localization causing punctate sequestration in nuclear and cytoplasmic fractions in 
CRPC 22RV1 cells (variant AR), while in the androgen-sensitive LNCaP cells (full length 
AR), treatment leads to massive distribution of dynein throughout the cytosol, promoting 
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the nuclear export of AR (Figure. 2.8.D). Mechanistically, a differential association with 
microtubules and the dynein motor protein has been shown for the clinically significant 
splice variants ARv567es and AR V7, with the AR V7 unable to interact with dynein and 
ultimately not having an effect on AR nuclear transport and transcriptional activity 
(Thadani-Mulero et al., 2014).   This evidence together with our present results, suggest 
that dynein may be engaging additional cytoplasmic partners such as HSP90, as well as 
cytoskeleton modulators to generate a new dynamic of interactions with full length AR 
versus AR variants,  effective targeting of which can potentially bypass cross-resistance 
to Docetaxel and anti-androgens in advanced prostate cancer (Figure 1.6). 
 My studies have shown for the first time that combination of the microtubule-
targeting agent, Docetaxel with targeting the AR NTD with EPI leads to enhanced anti-
tumor action possibly via changes in the EMT landscape and the cytoskeleton of 
prostate cancer cells harboring AR variants. A functional significance of the EMT 
process in therapeutic response to microtubule-targeting is supported by the recently 
reported association between reduced E-cadherin expression and Docetaxel-resistance 
in prostate cancer cells (Puhr et al., 2012). Reduced E-cadherin expression promotes 
loss of cell adhesion, cell polarization, and gain of cell migration, which leads to invasion 
and metastases (J. Yang & R. A. Weinberg, 2008; Yilmaz & Christophori, 2009).  
Moreover there is growing clinical evidence implicating EMT as a cellular mechanism 
conferring therapeutic resistance, development of metastases, and contributing to 
patient mortality (Puhr et al., 2012).  Considering that functional disruption of the 
androgen/AR signaling axis is associated with EMT induction (Matuszak & Kyprianou, 
2011b; Y. Sun et al., 2011; M. Zhu & Kyprianou, 2010), Docetaxel administration prior to 
androgen deprivation may result in improved therapeutic outcomes via navigating the 
EMT-MET cycling, towards cytoskeleton remodeling and sensitizing prostate tumor cells 
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to androgen- depletion mediated apoptosis.  An alternative mechanistic scenario is that 
mutations in tubulin may affect the binding sites of taxanes leading to therapeutic 
resistance. One may argue that when taxanes are structurally unable to effectively bind 
tubulin, the microtubules can no longer become stabilized, an effect that fails to elicit 
disruption of cell cycle progression, and consequentially the AR is free for a nuclear 
translocation (schematically illustrated on Figure. 2.8.D). Treatment of CRPC with EPI, 
an AR NTD inhibitor, leads to decreased transcriptional activity of both full-length AR 
and constitutively active truncated variants  (Andersen et al., 2010; Myung et al., 2013) 
and is thereby an attractive target for prohibiting AR from the nucleus to remain in the 
cytoplasm using taxanes as a combination therapy.  
 In summary, the present pre-clinical studies demonstrate that the combination 
strategy of targeting tubulin (by taxane chemotherapy) -and the NTD of AR variants 
association (by EPI) and cellular localization can impair CRPC by reversing EMT and 
navigating EMT-MET cycling. These findings provide a new insight into a potential 
mechanism for overcoming cross-resistance driven by differential status, and activity of 
AR, depending on its nuclear/cytosolic localization.  
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Figure 2.1: Combination of an AR NTD Inhibitor and Docetaxel Impairs Growth of 
Castration Resistant Prostate Cancer in vitro and in vivo.  Panel A, the human 
prostate cancer cells 22Rv1 were treated with EPI (25µM), or Docetaxel (DOC) (1µM), 
as single agents or in combination (DOC+EPI), for 24hrs and cell death was assessed 
on the basis of MTT assay after exposure the drugs. Values represent the average of 
three experiments (in triplicates) ±SEM. Statistical significance was set at p<0.05 (* 
compared to CSS, ** compared to DOC).  
A. 
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Figure 2.1 continued, Combination of an AR NTD Inhibitor and Docetaxel Impairs 
Growth of Castration Resistant Prostate Cancer in vitro and in vivo. Panel B, In 
vivo anti-tumor action of Docetaxel (microtubule-targeting chemotherapy) and EPI 
(targeting of the N-terminal domain of AR) in 22Rv1 human prostate cancer xenografts. 
Palpable tumor-bearing mice were treated with CMC (control), EPI alone (200mg/kg),  
Docetaxel alone (DOC) (15mg/kg), or the combination of the two agents (EPI +DOC) 
and tumor measurements were conducted as described in “Approach” (n=5/treatment 
group). Tumor xenografts were surgically excised 2 days after the last treatment (11 
days). Error bars represent SEM. ** shows statistically significant difference at p<0.05.   
B. 
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Figure 2.2:  Effect of DOC and EPI Combination on Apoptosis and Vascularity of 
CRPC Xenografts. Panel A, Immunohistochemical quantitation of apoptosis via TUNEL 
assay using serial sections of prostate tumor 22Rv1 xenografts. Number of TUNEL 
positive cells per high powered field counted in three separate, non-continuous fields by 
two independent reviewers (N.K., S.K.M.) Panel B reveals the numerical quantification of 
CD31 positivity in sections of prostate tumor 22Rv1 xenografts to assess the 
consequences of various treatments on tumor vascularity. Number of CD31 positive 
vessels per high powered field counted in three separate, non-continuous fields by two 
independent reviewers (N.K., S.K.M.). Panel C, Detection of apoptosis by TUNEL assay 
in 22Rv1 human prostate cancer xenograft sections from untreated control (CMC) and 
treated tumor-bearing mice (DOC, EPI or the combination treatment). Serial sections 
were subjected to CD31 immunoreactivity to assess tumor vascularity. Magnification 
200X.  
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Figure 2.3:  Effect of Microtubule and NTD AR Targeting on AR and Cytoskeleton 
in CRPC.  Panel A, To determine the effect of treatment on the expression and cellular 
localization of the specific proteins, immno-histochemical profile of AR (N-20), β-tubulin 
(microtubules) and cofilin (actin cytoskeleton) as evaluated in paraffin-embedded serial 
sections from 22Rv1 prostate tumor xenografts. Magnification 40X and 100X as 
indicated.  Panel B, numerical quantification of total AR expression in 22Rv1 xenograft 
sections before and after the various treatments (based on H-scoring). H-score 
calculation: on a scale of 1-10, value for intensity of staining and value for percentage of 
cells in field positive for staining assigned and averaged based on observation of three 
separate, non-continuous fields of specimen. Panel C, quantitative results of cofilin 
immunoreactivity in 22Rv1 xenograft sections (representative images shown on panel 
A). Docetaxel alone, or in combination with EPI led to a significant decrease in cofilin 
(P<0.05). Quantification represents the average (mean) of three fields, evaluated by two 
independent reviewers ± SEM. Statistical significance determined by one-way ANOVA; * 
indicates P<0.05. Panel D, reveals the confocal, immunofluorescent images of tubulin 
(green) and AR (N-20) (red) localization and expression in 22Rv1 cells before (CSS) and 
after treatment with DOC, EPI, or combination (4hrs). 
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Figure 2.3 continued, Effect of Microtubule and NTD AR Targeting on AR and 
Cytoskeleton in CRPC. Panel E, confocal immunofluorescent microscopy analysis of 
22Rv1 cells treated with EPI, DOC, as single agents or a combination of EPI+DOC for 
6hrs, in the presence of DHT (1nM).  
E.  
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Figure 2.4.  Impact of Androgens on the Effect of Taxane Monotherapy on AR 
Localization.  Panel A. 22Rv1 cells treated with 500nM DOC for 24 and 48hrs in 
presence and absence of 1nM DHT. Subcellular fractionation analysis indicating that 
DOC decreases full length nuclear AR and ARv7, but does not effect on AR or V7 
variant in in cytoplasm of 22Rv1 cells.   
A. 
80 
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Figure 2.5: Cell Death in Response to Microtubule Targeting (Taxane), N-terminal 
Targeting of AR or the Combination in the Androgen-Sensitive Human Prostate 
Cancer Cells, LNCaP. Panel A. Reveals the characteristic images of confocal 
microscopy analysis of dynein cellular distribution and AR nuclear 
expression/localization in LNCaP cells after the various treatments. LNCaP were treated 
with DOC, EPI as single agents or in combination (6hrs) in the presence of DHT.  40X 
Oil Objective, 400X magnification. Panel B. Cell viability was assessed using the MTT 
assay in LNCaP cells (and expressed as a percentage relative to CSS control medium). 
Cells treated with Docetaxel and EPI combination in the presence or absence of 
androgens (DHT). Values are the mean of three independent experiments performed in 
triplicate +/- SEM. Statistical significance at **P<0.05 (Two-tailed, unpaired, Student’s t-
test) compared to CSS treated controls. 
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Figure 2.6. Effect of Targeting Microtubules and N-terminal AR on Cytosolic 
Protein Association and Nuclear Localization /Activity in 22Rv1 Prostate Cancer 
Cells. Panel A, Confocal microscopy of dynein IC ½ and AR (N-20) expression and 
localization in 22Rv1 prostate cancer cells (+DAPI).  22Rv1 cells were exposed to DOC, 
EPI (as single agents), or in combination (4hrs) and were then treated with DHT (1nM) 
for 1hr. Representative images shown, 40X oil objective, 400X magnification. Panel B, 
Western blot analysis of AR protein expression profile in 22Rv1 cells after treatment with 
DOC, EPI or combination for 6 and 24hrs.  Expression normalized to GAPDH as loading 
control.  MW of the full length AR and the variants are shown to left and densitometry of 
full length AR indicated below blot and densitometry of protein bands on Western blot for 
expression of AR. Panels C and D, RT-PCR analysis of PSA/KLK3 mRNA expression 
(FL-AR target gene) and UGT2B17 mRNA expression (AR V7 target gene) respectively 
in 22Rv1 human prostate cancer cells in response to indicated treatments. Numerical 
values represent the mean of three independent experiments measured in duplicate +/- 
SEM; (* indicated P<0.05). Panels E, F and G represent transcriptional reporter assays 
in 22Rv1 cells. Cells were transiently transfected with PB-luciferase (E), PSA (6.1kb)-
luciferase (F), or ARR3-Luc reporters (G) and pre-treated with EPI, DOC, or combination 
(EPI+DOC) prior to incubation with R1881. Luciferase activity is represented as 
percentage of vehicle control activity in response to androgen. Bars represent SEM of 
three independent experiments. Luciferase reporter assays performed by lab of 
Marianne Sadar (Vancouver Genome Center).  
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Figure 2.7: Effect of Combined Targeting of Microtubules and AR NTD in 
Androgen-Sensitive LNCaP95 Cell Growth and AR Activity. Panel A, Cell 
proliferation assay in LNCaP95 prostate cancer cells, that harbor the FL AR as well as 
the AR V7, pre-treated with EPI, DOC or combination for 24hrs prior to measurement of 
BrdU incorporation.  Bars represent the mean ± SEM of three independent experiments. 
Panels B, C and D represent analysis of transcriptional activity assays in LNCaP95 cells. 
Cells were transiently transfected with PB-luciferase (B), PSA (6.1kb)-luciferase (C), or 
ARR3-Luc reporters (D) and pre-treated with EPI, DOC, or combination prior to 
incubation with R1881. Luciferase activity is represented as percentage of vehicle 
control activity in response to androgen. Bars represent the mean ± SEM of at least 
three independent experiments. *P<0.005 (Two-tailed, unpaired, Student’s t-test). Panel 
E, morphological appearance of the LNCaP95 cells (as detected by light microscopy), 
after the various treatments.  
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Figure 2.8: Impact of AR Variant on EMT in CRPC 22Rv1 Cells in Response to 
Combination Targeting of the AR NTD and Microtubules.  Panel A. Western blot 
analysis of critical EMT regulator proteins after 6 and 24hrs of treatment of 22Rv1 cells 
with DOC, EPI or combination. Expression levels for E-cadherin, N-cadherin, β-catenin, 
Twist and cofilin are shown. GAPDH was used as a loading control. The MW of 
individual proteins is shown (kDa).  
A. 
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Figure 2.8 continued: Impact of AR Variant on EMT in CRPC 22Rv1 Cells in 
Response to Combination Targeting of the AR NTD and Microtubules.  Panel A 
continued. EMT and Cytoskeleton Effector Profiling in Response to Treatment. 
Densitometric analysis of the protein expression bands from Western blot analysis of 
EMT and cytoskeleton regulator proteins.  E-Cadherin, N-Cadherin, β-catenin, Twist, 
Cofilin. 
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Figure 2.8 continued, Impact of AR Variant on EMT in CRPC 22Rv1 Cells in 
Response to Combination Targeting of the AR NTD and Microtubules.  Panel B, 
Serial sections of 22Rv1 prostate tumor xenografts from untreated control (CMC) and 
treated tumor-bearing mice (DOC, EPI, or combination, obtained as in Fig.2.1 B), were 
subjected to immunohistochemical analysis for the EMT markers E-cadherin, N-cadherin 
and vimentin. Magnification 100X.  
B. 
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Figure 2.8 continued, Impact of AR Variant on EMT in CRPC 22Rv1 Cells in 
Response to Combination Targeting of the AR NTD and Microtubules. Panel C. 
Reveals the temporal analysis of gene expression of EMT regulators. 22Rv1 prostate 
cancer cells were treated with DOC, EPI or the combination (1, 3, 6, 12, 24 and 48hrs) 
and mRNA expression was analyzed by RT-PCR. The gene expression profile of mRNA 
for the EMT effectors, E-cadherin (CDH1), N-cadherin (CDH2), and vimentin (VIM), as 
well as for the transcriptional regulators SNAIL1 and Twist, in response to treatments is 
shown. Values represent the mean +/- SEM of duplicate measurements from three 
independent experiments; (*) denotes statistical significance at p<0.05.   
C. 
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Figure 2.8 continued, Impact of AR Variant on EMT in CRPC 22Rv1 Cells in 
Response to Combination Targeting of the AR NTD and Microtubules. Panel D, 
Schematic Diagram projecting the potential interactions of AR with cytoplasmic proteins 
(dynein, tubulin, cofilin) that may control its nuclear translocation and transcriptional 
activity of target genes, mediating EMT and apoptosis in CRCP cells.  
D. 
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Chapter 3.  Cabazitaxel Induces Mesenchymal Epithelial Transition (MET) and 
Overcomes Phenotypic Resistance in Advanced Prostate Cancer       
Background and Significance 
As described in Chapter I, combination of taxane-microtubule targeting 
chemotherapy and anti-androgen therapies have demonstrated additional survival 
benefits in late stage CRPC patients. Previous studies from our lab and others 
demonstrated that Docetaxel chemotherapy inhibits AR activity by blocking its nuclear 
translocation (Darshan, Loftus, Thadani-Mulero, Levy, Escuin, Zhou, et al., 2011; M. Zhu 
& Kyprianou, 2010). The present study pursued the anti-tumor efficacy of a combination 
strategy of the AR antagonist Enzalutamide, MDV3100 (MDV), with second line taxane 
chemotherapy, Cabazitaxel (CBZ) in vitro and in vivo models of advanced CRPC.    
Progression to metastatic castration resistant prostate cancer (mCRPC) is 
characterized by aberrant over expression of androgen receptor (AR), de novo intra-
prostatic androgen production, and cross talk between androgen signaling with other 
oncogenic pathways (Kahn et al., 2014; Mohler, 2008). Anti-androgen therapies 
Abiraterone Acetate and Enzalutamide (next generation anti-androgens) effectively 
target the androgen signaling axis (Acloque et al., 2009; Beer et al., 2014; Ryan et al., 
2013) however, due to the addiction of CRPC cells to AR signaling and its splice variants 
resistance develops driving CRPC progression (Antonarakis & Eisenberger, 2013; C. D. 
Chen et al., 2004). Taxanes are the mainstay of chemotherapy for patients who 
developed resistance to anti-androgen strategies and progressed to metastatic CRPC. 
First generation taxane chemotherapies, Docetaxel (Taxotere©) effectively target the 
cytoskeleton by stabilizing the interaction between β-tubulin subunits of microtubules 
preventing de-polymerization, inducing G2M arrest and apoptosis (Huizing et al., 1995). 
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Un-liganded AR is sequestered in the cytoplasm by the HSP90 super-complex until it 
encounters its’ cognate ligand, dihydrotestosterone (DHT), dimerizes and translocates 
via microtubules into the nucleus (B.J. Feldman & D. Feldman, 2001; Thadani-Mulero, 
Nanus, & Giannakakou, 2012).  Nuclear AR binds androgen responsive elements of 
DNA and activates transcription of androgen responsive genes promoting prostate cell 
growth (B.J. Feldman & D. Feldman, 2001).   
Evidence from this laboratory, confirmed by others, established that stabilization 
of microtubules by Docetaxel chemotherapy inhibits the AR translocation into the 
nucleus, thus preventing its transcriptional activity (Darshan, Loftus, Thadani-Mulero, 
Levy, Escuin, Zhou, et al., 2011; M.-L. Zhu et al., 2010a; M. Zhu & Kyprianou, 2010). 
Additionally, taxanes lead to an increase in Forkhead box 01 (FOXO1), a transcriptional 
repressor of AR, consequently resulting in inhibition of ligand-dependent and ligand-
independent transcription (Gan et al., 2009b), as well as down-regulation of AR resulting 
in decreased PSA expression (Mistry & Oh, 2013).  The therapeutic impact of taxanes in 
impairing metastatic CRPC and improving overall survival in patients with advanced 
disease, has been attributed to microtubule stabilization and AR targeting ADT 
(Fitzpatrick & de Wit, 2014; Mistry & Oh, 2013). Despite showing initial efficacy and a 
proven survival advantage in patients with mCRPC, resistance to Taxane treatment 
invariably develops leading to disease progression in approximately 7.5 months (Loriot 
et al., 2013).  Mechanisms implicated in the development of Docetaxel resistance, 
include high affinity of the drug for the P-glycoprotein drug efflux pump, mutational 
alterations in tubulin expression, overexpression of microtubule associated proteins, and 
induction of EMT (Fitzpatrick & de Wit, 2014; Loriot et al., 2013; Puhr et al., 2012).  
A veritable boom of FDA approvals have brought us such promising agents 
Jevtana© (Cabazitaxel, CBZ), Xtandi© (Enzalutamide, MDV3100, MDV), and Provenge© 
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(Sipleucel-T) providing additional survival benefits to patients with advanced 
therapeutically resistant disease (Bianchini et al., 2014; Fizazi et al., 2012). Cabazitaxel 
is a second-line taxane chemotherapy, a drug developed by addition of two methyl 
groups to the structure of Docetaxel to significantly decrease its’ affinity for the multi-
drug resistance protein and P-Glycoprotein pump and increase cellular retention of the 
drug (Vrignaud et al., 2013). The novel non-steroidal, anti-androgen enzalutamide 
(MDV) was rationally designed from the crystal structure of the AR (Acloque et al., 2009; 
Brasso et al., 2014; Fizazi et al., 2012). As discussed in Chapter 1, MDV blocks 
androgen signaling with a three-headed mechanism. MDV has been shown to prevent 
binding of AR with DHT, prevent translocation of AR into the nucleus, and inhibit AR 
from binding to androgen responsive elements on DNA thus driving its therapeutic 
impact (Fizazi et al., 2012; Thadani-Mulero et al., 2012). However, recently emerging 
clinical evidence indicates that the AR splice variant V7 confers therapeutic resistance to 
MDV in select populations of patients with CRPC (Antonarakis et al., 2014; Y. Li et al., 
2013).  
In this chapter, I describe the results of my recent efforts to pursue the 
mechanism of anti-tumor action of Cabazitaxel against prostate cancer cell models 
harboring AR mutations, splice variants and full length AR. Similar to Docetaxel, 
Cabazitaxel induces apoptosis and G2M arrest. In contrast to Docetaxel, Cabazitaxel it 
sustains AR nuclear presence, while it reduces its’ expression regardless of androgen 
presence. In CRPC cell models harboring AR splice variants including the V7 variant, 
combination treatment of Cabazitaxel as a single agent with anti-androgen resulted in a 
growth response. My findings established for the first the ability of Cabazitaxel to 
overcome phenotypic resistance in CRPC and promote glandular formation, by reversing 
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EMT to MET of prostate tumor cell populations in in vivo models of prostate cancer 
progression.   
 
Approach 
Cell Lines and Transfections.  Human prostate cancer cell lines, the androgen 
independent cell lines PC3 and DU145, the CRPC cancer cell line 22Rv1, and the 
androgen sensitive human prostate cancer cell lies LNCaP and VCaP were obtained 
from American Type Culture Collection (ATCC, Manassas, VA). PC3 AR variant 
transfectants PC3v7, PCv12 and PC3v567es were generated in this lab using plasmids 
generously provided by Drs. Plymate (University of Washington) and Luo (Johns 
Hopkins). TGF-β responsive LNCaP TβRII were generated in this lab and have been 
previously described (Y. Guo & Kyprianou, 1998, 1999) All cell lines, but the VCaP cells, 
were maintained in RPMI 1640 (Invitrogen, Grand Island, NY) and 10% fetal bovine 
serum (FBS), 100units/ml penicillin and 100µg/ml streptomycin in a 5% CO2 incubator at 
37° C. The VCaP cells were cultured in growth medium with DMEM instead of 
RPMI1640 (ATCC, Manassas, VA). For experiments on androgen responses cells were 
seeded in 10% charcoal-stripped serum (CSS) and stimulated for 3hrs by 
dihydrotestosterone (DHT) (Sigma-Aldrich, St. Louis, MO) or R1881 (1nM).  
Drugs: Cabazitaxel (Jevtana©) was generously provided by Sanofi Aventis. For 
the in vivo administration, Cabazitaxel was prepared by mixing 1 volume of ethanol stock 
solution, 1 volume of polysorbate 80, and 18 volumes of 5% glucose in sterile water. 
Solutions were administered intravenously as a slow bolus. Drug doses were adjusted 
on the basis of body weight at the beginning of treatment. CBZ stock (500 µM) was 
prepared in 100% ethanol and stored at -20° C in amber bottles.  MDV3100 was 
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purchased from Selleck Chemicals (Houston, TX). For in vivo administration in mice, 
MDV3100 was prepared in dimethyl-sulphoxide (DMSO), diluted with sterile PBS (75% 
PBS: 25% CBZ DMSO Solution) and injected intraperitoneally.   
Antibodies.  The antibody against the AR (N-20) protein was purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against tubulin, N-cadherin, 
MCAK (KIF2C), HSET, CD31, and phospho-Histone H3 were obtained from AbCam Cell 
Signaling (Cambridge, UK); antibodies against cleaved Caspase-3, GAPDH, and E-
Cadherin proteins were obtained from Cell Signaling Technology (Danvers, MA). The 
ZEB1 antibody was obtained from Bethyl Laboratories (Montgomery, TX).  
Western Blot Analysis. Total cellular protein was extracted from cell lysates by 
homogenization with RIPA buffer (Cell Signaling Technology, Danvers, MA); subcellular 
fractionation was performed using NE-PER nuclear-cytoplasmic fraction kit (Thermo 
Scientific.). Protein samples were loaded into 4%-15% SDS-polyacrylamide gels (Bio-
Rad, Hercules, CA), and subjected to electrophoretic analysis and blotting. Membranes 
were incubated with the specific primary antibody (overnight at 4°C) and were 
subsequently exposed to relevant secondary antibody. For signal detection, membranes 
were incubated with the Amersham ECL Plus Western Blotting Detection System 
(Amersham, GE Healthcare, Buckinghamshire, UK) and auto-radiographed using X-ray 
film (Denville Scientific, South Plainfield, NJ). Protein expression bands were normalized 
to GAPDH expression (loading control).  
Cell Viability Assay. The effect of the various treatments on prostate cancer cell 
viability was evaluated using the Thiazolyl Blue Tetrazolium bromide (MTT) assay. Cells 
were seeded into 24-well plates, grown to 60-75% confluence, and treated with vehicle 
control (DMSO, Sigma-Aldrich, St. Louis, MO), Cabazitaxel, MDV3100, and combination 
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in RPMI 1640 with 10% CSS (Charcoal Stripped Serum) for 24hrs (or DMEM for VCaP). 
Following drug treatment, media was aspirated and cells rinsed with PBS then treated 
with 250µl/well MTT (1mg/ml) for 30mins at 37°C. After incubation, MTT was aspirated 
and formazan crystals were solubilized with DMSO. Absorbance was measured at 
570nm using μQuant Spectrophotometer (Biotech Instruments Inc., Winooski, VT).  
Migration Assays. Cells were seeded in 6-well plates and at 65% to 70% density 
the cell monolayers were wounded. After 24hrs the number of migrating cells towards 
center of the wound is counted in three different fields. 
Quantitative RT-PCR Analysis. In vitro samples: RNA was extracted with the 
Trizol© reagent (Life Technologies, Grand Island, NY) and RNA samples (1μg) were 
subjected to reverse transcription using the Reverse Transcription System (Promega, 
Madison, WI). TaqMan real time reverse transcriptase-PCR (Life Technologies, Grand 
Island, NY) analysis of the cDNA samples was conducted in an ABI7700 Sequence 
Detection System (Applied Biosystems, Inc, Branchburg, NJ), using the following 
specific primers: for Prostate Specific Antigen (KLK3; Hs02576345_m1), AR 
(Hs00171172_m1), KIF2C (Hs00901710_m1), FOXO1 (Hs01054576_m1), KIFC1 
(Hs00954801_m1), E-Cadherin (CDH1; Hs01023894_m1), N-Cadherin (CDH2; 
Hs00983056_m1), Twist (TWIST1; Hs01675818_s1), Vimentin (VIM; Hs00185584_m1) 
and 18S rRNA (4319413E) (Applied Biosystems, Life Technologies, Grand Island, NY). 
For the qRT-PCR experiments, data represent mean values from three independent 
experiments and each sample were analyzed in duplicate. Numerical data for transcript 
levels were normalized to 18s rRNA in controls and expressed relative to controls. 
Immunofluorescent Confocal Microscopy. Cells were plated (1x105) on cover 
glass in 6 well plates. After 24-48hrs, cells were exposed to medium (RPMI 1640 with 
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10% CSS) in the presence of DHT (1nM), CBZ (35-100nM), MDV3100 (1µM) or in 
combination of the two agents. Following treatment, cells were fixed in 100% methanol 
and permeabilized with 0.1% Triton X-100 in sterile phosphate buffer saline (PBS). Fixed 
cells were incubated overnight with primary antibody specific for AR (N-20), and Tubulin 
(AbCam Cell Signaling, Cambridge, UK), (at 4°C) with gentle rocking and the 
appropriate Alexa-Fluor (Life Technologies, Grand Island, NY) fluorescent secondary 
(1.5hrs, room temperature). Slides were mounted using Vectashield mounting medium 
with DAPI and were visualized using a FV1000 Confocal Microscope (Markey Cancer 
Center Core, University of Kentucky).  
Flow Cytometric Analysis. The human prostate cancer cells harboring the AR 
variants PC3v567es and 22Rv1 cells were exposed to various treatments (MDV, CBZ, 
or combination for 24-96hrs), and subjected to washing with PBS in 0.1% bovine serum 
albumin. Cells were subsequently fixed with 100% ethanol (-20°C). For cell cycle 
measurement, the cells were incubated with propidium iodide staining solution with 
RNase A (10ug/mL) overnight, at 4°C. Samples were analyzed for cell cycle progression 
using Becton-Dickinson FACSCalibur by the flow cytometry core facility at the University 
of Kentucky. 
In Vivo Tumor Targeting Studies. All animal experiments were performed in 
accordance with the guidelines approved by the Animal Care and Use Committee of the 
University of Kentucky.  Male nude mice (5-6 weeks old) mice were subcutaneously 
injected with 22Rv1 cells (2x106 cells) and after tumors were palpable (approximately 3 
weeks post-inoculation), mice were divided into four groups, 5 mice/group: (a) Control 
group receiving 1% medium /0.1% Tween-20 daily via oral gavage; (b) CBZ treatment 
group, mice received CBZ (Day 1 and 4: 5 mg/kg, Day 8 and 14: 2.5 mg/kg) via tail vein 
injection for two weeks (c)  Enzalutamide group, mice receiving 30 mg/kg MDV3100 via 
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intraperitoneal injection for 2-weeks; (d) CBZ and MDV3100 combination group, mice 
receiving both Cabazitaxel and Enzalutamide for 2wks.  Tumors were measured twice a 
week and the volume was calculated (length x width x 0.5236).  Prostate tumor 
xenografts were harvested at 4 days after the last treatment (2wks of drug exposure) 
and tissue specimens were subjected to histopathological analysis. Formalin-fixed 
paraffin embedded sections were subjected to immuno-staining for assessing the 
expression and cellular localization of AR, mitotic kinesins, EMT, vascularity (CD31), and 
apoptosis (TUNEL, EMD Millipore, Billerica, MA). TUNEL analysis for detection of 
apoptotic cells in situ was performed as previously described (Pu et al., 2009).  
Transgenic Mouse Model of Prostate Cancer Progression. Mice were maintained 
under environmentally controlled conditions and subject to a 12-h light/dark cycle with 
food and water ad libitum. Animals TRAMP+/DNTGFβRII+ (Pu et al., 2009) (age 16-18 
weeks) were matched with littermates and were treated with either vehicle control (VHC) 
or highest non-toxic dose (HNTD) of CBZ (Day 0 and 3: 10mg/kg; Day 7 and 11: 
5mg/kg) dosed intraperitoneally and harvested on Day 14. TRAMP+/DNTGFβRII+ male 
mice were castrated and followed by treatment with CBZ (Day 3 and 7: 10mg/kg; Day 11 
and 15: 5mg/kg) and harvested on Day 18.  
Immunohistochemical Analysis. Tissue specimens from human prostate tumor 
22Rv1 xenografts and transgenic mouse prostate tumors were formalin fixed and 
paraffin-embedded; serial sections (5µ), were subjected to immunohistochemical 
analysis using antibodies against E-cadherin, N-cadherin, Androgen Receptor (N-20), 
MCAK, HSET, pH3, ZEB1 and CD31. After blocking nonspecific binding (1.5% NGS in 
TBS-Triton), sections were incubated with primary antibody (overnight, 4°C) and were 
subsequently exposed to biotinylated goat anti-rabbit IgG (2hrs, room temperature) and 
horseradish peroxidase-streptavidin (EMD Millipore, Billerica, MA). Signal/Color 
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detection was achieved with SigmaFast 3, 3’-Diaminobenzidine tablets (Sigma-Aldrich, 
St. Louis, MO) and counterstained with haematoxylin. TUNEL analysis for detection of 
apoptotic cells was performed as previously described (Pu et al., 2009). Images were 
captured via light microscopy (40x and 100x) using an Olympus BX51 microscope 
(Olympus America, Center Valley, PA). The intensity and level of immunoreactivity was 
recorded by two independent observers counting three different fields per section (N.K. 
and S.K.M.).   
Statistical Analysis.  Student’s t test, one-way, or two-way ANOVA were 
performed using GraphPad Prism 6 software to determine the statistical significance of 
difference between means / treatments. All numerical data are presented as mean ± 
standard error of the mean (SEM). Statistical significance was set at P value < 0.05.  
 
Results 
Significance of AR Status in Prostate Cancer Cell Response to Cabazitaxel   
The pre-clinical efficacy of Cabazitaxel chemotherapy against prostate cancer 
was originally demonstrated using the androgen-independent human cancer cell line, 
DU145 (lacking AR) as a model (Vrignaud et al., 2013). To establish the cellular 
response of androgen sensitive and CRPC cancer cells to CBZ treatment, a panel of 
human prostate cancer cell lines with varying AR expression status was used. A dose 
response analysis of prostate cancer cell  viability to increasing concentrations of CBZ 
(10-500 nM) for 96hrs, demonstrated that  DU145 cells were highly sensitive to CBZ 
treatment consistent with earlier reports (Vrignaud et al., 2013) (Figure 3.1, panel A). A 
time course analysis of the temporal response to increasing treatment periods to CBZ 
(100nM) was also conducted (Figure 3.1, panel B).  The androgen-independent PC3 
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cells exhibited a similar sensitivity to CBZ as the DU145 cells (Figure 3.1, panels A and 
B). In contrast, PC3 cells with forced overexpression of the AR splice variant v567es 
(PC3v567es) were resistant to CBZ even at very high doses of the drug, compared to 
parental PC3 cells (Figure 3.1, panel A). The CRPC cell line 22Rv1 harboring a mixture 
of the clinically relevant AR variants as well as the full length AR, exhibited relative 
resistance to low doses of CBZ and early treatment periods (24-48hrs), but in response 
to high doses and for longer treatment periods (over 72hrs), there was significant loss of 
cell viability (Figure 3.1, panels A and B). The androgen sensitive cells VCaP (full length 
AR) demonstrated resistance to CBZ even at high concentrations (500nM) and after 
longer treatment (120hrs) compared to other androgen sensitive cell lines, LNCaP and 
LNCaPTβRII (Figure 3.1, panels A and B).  
To examine the effect of AR targeting inhibition by the antiandrogen (MDV3100, 
MDV) to sensitize prostate cancer cells to CBZ, human prostate cancer cell lines were 
treated with CBZ alone (100nM) or in combination with MDV (1-10µM). The PC3v567es 
cells did not exhibit additional loss of cell viability as a result of MDV treatment compared 
to CBZ alone (except at supra-physiological concentration of the antiandrogen) (Figure 
3.1, panel C). For the androgen-sensitive and CBZ resistant VCaP cells (Figure 3.1, 
panel A), exposure to increasing concentrations of MDV in combination with CBZ 
resulted in a significant loss of viability (P<0.05) (Figure 3.1, panel C). The CRPC 22Rv1 
cells (harboring a mixture of full length AR and AR splice variants) exhibit loss of viability 
in response to CBZ alone; however combination of the taxane with MDV at high 
concentrations (10µM) led to an increase in cell viability compared to single CBZ 
treatment (Figure 3.1, panel C), and compared to untreated control cells. Cell cycle 
analysis revealed that for the PC3v567es cells CBZ treatment promotes G2 and S phase 
arrest (Figure 3.1, panels D and E). For CRPC 22Rv1 cells, exposure to CBZ alone for 
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96hrs resulted in a significant G2 arrest that was further increased by the antiandrogen 
(MDV) treatment (Figure 3.1, panels F and G). Accumulation in S phase was also 
induced in 22Rv1 cells at 96hr when treated with CBZ alone or in combination with MDV.  
Treatment of PC3v567es and 22Rv1 cells with CBZ in presence or absence of 
androgens increases the total cell population in the S and G2 phase.  
Recent work from this laboratory demonstrated that combination therapy of 
taxanes (Docetaxel)  and N-terminal targeting of AR with novel anti-androgens 
enhanced the therapeutic efficacy of taxane against CRPC tumor growth (Martin et al., 
2014). Thus, we comparatively analyzed the dose response of prostate cancer cells to 
Docetaxel (microtubule targeting), MDV (AR targeting), given as single agents or in 
combination (Figure 3.2, Panel A, B, C). The PC3, PC3v567es, 22Rv1 and LNCaP cells 
exhibited resistance to MDV but all the cell lines showed partial sensitivity to Docetaxel 
(Figure 3.2, panels A and B, respectively). Combination of Docetaxel and MDV led to a 
significant loss of cell viability for all of the prostate cancer cell lines (Figure 3.2, panel 
C). Transfection-mediated overexpression of clinically relevant AR variants in PC3 cells 
resulted in stable clones PC3567es, PC3v7 and PCv12 that all exhibited a significant 
increase in their migration potential compared to parental control cells (Figure 3.2, panel 
D).  
Effect of Cabazitaxel on AR Expression, Localization and Activity    
Docetaxel chemotherapy has been shown to impair prostate cancer growth by 
preventing the physical translocation of cytoplasmic AR into the nucleus ultimately 
inhibiting the activity of AR-regulated target genes (PSA) (Darshan, Loftus, Thadani-
Mulero, Levy, Escuin, Zhou, et al., 2011; M.-L. Zhu et al., 2010a; M. Zhu & Kyprianou, 
2010). LNCaP and VCaP cells were grown in CSS supplemented media to simulate an 
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androgen-deprived environment. Confocal microscopy analysis identified that LNCaP 
control cells had a diffused distribution of AR between cytoplasm and nucleus (Figure 
3.3, panel A).  As expected, treatment with DHT (1nM for 2hrs) (Figure 3.3, panel A) 
resulted in AR translocation to the nucleus, without marked effect on microtubule 
structure. Treatment with the MDV (1µM; 24 hrs) increased cytoplasmic AR with no 
apparent effect on microtubule structural network (Tran et al., 2009a) (Figure 3.3, panel 
A). CBZ reduced overall AR immunoreactivity, while it sustained nuclear localization of 
AR regardless of the presence of synthetic androgens (R1881) or MDV. Treatment of 
VCaP cells for 24hrs with MDV, followed by pulsing with DHT (2hrs) was visualized by 
confocal microscopy (Figure 3.4, panel A). AR localization was primarily confined to the 
nucleus, indicating that MDV was unable to completely block the androgen-mediated AR 
nuclear translocation (Figure 3.4, panel A).  Treatment of VCaP with CBZ for 96hrs leads 
to AR nuclear localization independently of androgens (Figure 3.3, panel A; Figure 3.4, 
panel A).  There was a significant impact by CBZ treatment on the microtubule structure 
with clear tubule bundling on the periphery of the cell and complete loss of fibrous 
microtubule network appearance (Figure 3.3, panel A; green fluorescence). The effects 
on the microtubule appearance were consistently detected in response to CBZ, 
associated with remarkable multi-nucleation in both cell lines (Zoom images) (Figure 3.3, 
panel A; Figure 3.4, panel A). The PC3v567es cells expressing the AR variant v567es 
(resistant to CBZ) (Figure 3.1, panels A and B) were treated with CBZ and subjected to 
confocal microscopy. For the PC3567es AR variant cells, CBZ exerts the bundling effect 
on microtubule structures (Figure 3.5, panel A); the taxane also reduced AR levels but it 
fails to sustain nuclear localization of AR variant v567es. Extensive multi-nucleation can 
be observed for PC3v567es cells treated with CBZ alone or in combination with 
androgens.  
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To determine the effect of CBZ treatment on AR expression, LNCaP and VCaP 
prostate cancer cells were treated for 24, 48, or 72hrs with CBZ alone or pulsed with 
DHT for 3hrs prior to cell lysis and Western blot analysis. CBZ treatment for 72hrs 
markedly reduced AR protein levels in the androgen sensitive prostate cancer cell lines, 
LNCaP and VCaP (Figure 3.3, panel B and Figure 3.4, panel B), respectively. 
Expression of β-tubulin was not affected. CBZ treatment (48hrs) led to caspase-3 
cleavage indicative of apoptosis induction in LNCaP cells (Figure 3.3, panel B). To 
confirm the effect of CBZ on AR localization in vitro, we next performed subcellular 
fractionation analysis in LNCaP cells after exposure to CBZ (24, 48, or 72hrs), alone or 
pulsed with R1881 (1nM for 2hrs). Androgens predictably increased nuclear AR 
expression compared to controls (Figure 3.3, panel C). CBZ treatment for 24-48hrs 
decreased AR levels in LNCaP cells, while there was nuclear retention of AR (Figure 
3.3, panel C); by 72hrs AR levels were diminished in both cytosolic and nuclear fractions 
(Figure 3.3, panel C). 
We subsequently analyzed the effect of CBZ on the expression of AR regulated 
genes in androgen responsive prostate cancer cells as well as in CRPC cells. To 
establish that the effect of CBZ on AR expression was a consequence of transcriptional 
inhibition, the AR mRNA levels were evaluated. LNCaP cells were treated with CBZ (24, 
48 or 72hrs) alone or pulsed with DHT for 2hrs prior to mRNA extraction. CBZ treatment 
(24hrs) led to downregulation of AR mRNA (Figure 3.3, panel D). Moreover CBZ 
significantly inhibited expression of the AR-regulated gene PSA and AR interactor 
FOXO1, (Figure 3.3, panels E and F), respectively indicating targeting of AR 
transcriptional activity by CBZ. A similar effect of Cabazitaxel on AR regulated gene 
expression was also found for the VCaP cells (Figure 3.4, panels C, D and E). 
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Cabazitaxel Causes Multi-nucleation in Prostate Cancer Cells by Targeting 
Kinesins  
As chemotherapeutic agents, taxanes can effectively target the microtubules and 
the mitotic spindle apparatus thus blocking cellular division by inducing G2M arrest and 
apoptosis (Rath & Kozielski, 2012). To determine whether exposure of prostate cancer 
cells to Cabazitaxel results in the characteristic G2M arrest consequential to microtubule 
stabilization, we performed confocal microscopy analysis. As shown on Figure 3.6 (panel 
A), three human prostate cancer cell lines with different AR status, DU145 cells (AR 
negative), PC3v7 AR variant, LNCaP (mutant AR) and VCaP (full length AR) cells, 
exhibit increased incidence of multi-nucleation in response to CBZ treatment. In the 
LNCaP cells, there was a disruption of the mitotic spindle and mono-astral spindle 
formation (Figure 3.6, panel A.) Overexpression of certain mitosis promoting kinesins 
can facilitate taxane resistance due to their microtubule depolymerizing action. To 
establish the targeting of “pro-mitotic” kinesins by CBZ, we next profiled the expression 
of a subset of mitotic kinesins in human prostate cancer cell lines (Figure 3.6, panel B).  
MCAK kinesin plays an important role in facilitating spindle pole capture and also acts as 
a microtubule de-polymerizing factor.  HSET functionally mediates cytokinesis. LNCaP 
cells express relatively low kinesin levels, while VCaP cells exhibit high expression of 
both proteins (Figure 3.6, panel B). DU145 and PC3v567es have high expression of 
MCAK but completely lack HSET protein expression (Figure 3.6, panel B).  In response 
to CBZ (24, 48 or 72hrs) alone or under androgenic pulse, there was a transient 
increase in expression of MCAK and HSET kinesins within the first 24hrs in the VCaP 
cells; by 72hrs of treatment kinesin levels were significantly down regulated (Figure 3.6, 
panel C and Figure 3.7, panel A). In addition there was a significant decrease in MCAK 
(KIF2C) mRNA expression in LNCaP and VCaP cells (Figure 3.6, panel D and Figure 
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3.7, panel C), and in HSET (KIFC1) mRNA levels for VCaP cells (Figure 3.7, panel B) in 
response to CBZ. To determine the potential link between action of CBZ on mitotic 
spindle formation and resistance, we subsequently examined pericentrin (marker of 
centrosomes) expression in the Cabazitaxel-resistant prostate cancer PC3v567es and 
VCaP cells and the CBZ sensitive CRPC 22Rv1 cells. As shown on Figure 3.6 (panel E), 
PC3v567es cells in response to CBZ (48 and 72hrs) exhibited centrosome clustering 
and amplification accompanied with severe multi-nucleation, independent of androgenic 
presence. The VCaP cells (tetraploid) also exhibited prominent multi-nucleation and 
centrosome clustering and amplification (detected by pericentrin) in response to CBZ; 
these effects on the mitotic dynamics were not influenced by the status of androgen axis 
(presence of androgens or antiandrogen, MDV) (Figure 3.6, panel F). In the CRPC 
22Rv1 cells, CBZ treatment led to multi-nucleation but not centrosomal amplification 
(Figure 3.8, panel A).  
In Vivo Novel Action of Cabazitaxel in Models of Advanced Prostate Cancer via 
Induction of Mesenchymal-Epithelial Transition (MET) and Glandular Differentiation    
To define the physiological significance of our in vitro findings we investigated the 
cellular phenomena driving the anti-tumor action of Cabazitaxel in an in vivo model of 
advanced prostate cancer. Previous work in our laboratory established a double 
transgenic mouse model of TRAMP crossed with mice expressing a conditional 
dominant negative TGFβRII (Pu et al., 2009). This TRAMP/DNTGFβRII model is 
characterized by aggressive tumor progression to metastasis driven by EMT. The 
consequences of Cabazitaxel treatment on the phenotypic landscape and growth 
dynamics of advanced prostate cancer were evaluated in prostate tumors from (N=10) 
16-18-wks male mice (castrate versus non-castrate groups) receiving treatment for 14 
days with pharmacological dose of CBZ (described in Figure 3.9; panels A and B). CBZ 
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treatment led to a significant decrease in the body weight but not prostate weight 
(P<0.005) (Figure 3.9, panels C and D respectively; P<0.005). At 18-20wks, 
TRAMP+DNTGFBRII+ mice progressed to aggressive poorly differentiated prostate 
cancer (Pu et al., 2009); Histopathological evaluation (H&E staining) revealed that 
treatment with CBZ alone or in combination with androgen depletion restored the 
glandular structures and luminal secretions of the prostate epithelium compared to 
controls (VHC) (Figure 3.10, panel A).  
To determine the impact of CBZ treatment on the tumor growth kinetics, 
apoptosis and cell proliferation were evaluated in the transgenic mouse model of 
androgen-sensitive prostate cancer, in the presence of an intact or depleted androgen 
axis. Evaluation of prostate tumor cell proliferative capacity based on Ki-67 and 
phospho-Histone 3 (pH3) immunoreactivity revealed an increased proliferative activity in 
response to CBZ alone, while castration-induced-androgen deprivation resulted in a 
significant decrease in the proliferative index (Figure 3.10, panels A and D). To correlate 
the effect by CBZ on the mitotic spindle with resulting multi-nucleation (observed in vitro; 
Figure 3.6), expression of the nuclear protein phospho-H3 histone, was examined in 
prostate tumors. As shown on Figure 3.10 (panel B), CBZ resulted in distinct multi-
nucleation among prostate tumor glands from CBZ-treated mice, compared to VHC 
controls (Figure 3.10, panel B, arrows). The incidence of apoptosis as reflected by an 
increased number of TUNEL positive cells in prostate tumors was induced after 
castration-induced androgen withdrawal; at 48hrs-post castration-induced apoptosis 
reaches a peak compared to controls (P<0.005) (Figure 3.10, panels A and C). 
Treatment of either intact or castrate mice (androgen-depleted), with CBZ (2wks) failed 
to induce significant apoptosis compared to VHC control mice (Figure 3.10, panels A 
and C). The incidence of proliferation as reflected by an increased number of Ki67 
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positive cells in prostate tumors was decreased after castration-induced androgen 
withdrawal alone or in combination with CBZ treatment (P<0.005) (Figure 3.10, panels A 
and D).  
The potential contribution of EMT-MET cycling to the glandular formation and 
phenotypic reversion to differentiated prostate epithelium in response to the taxane 
treatment was interrogated by profiling the expression of EMT markers, E-cadherin and 
N-cadherin in serial sections of prostate tumors from treated and untreated mice. Figure 
3.11, panel A indicates representative images of immunoreactivity analysis of the EMT 
landscape. Certain populations of tumor epithelial cells exhibited strong E-cadherin 
immunoreactivity paralleled by decreased N-cadherin expression in response to CBZ,  
supporting an effect by the drug on reversing EMT (Figure 3.11, panel A). Our previous 
work established that prostate tumors from TRAMP+DNTGFβRII mice exhibit marked 
acceleration of progression to metastatic lethal disease via changes in the tumor 
microenvironment driven by increased inflammation and enhanced EMT (Pu et al., 
2009). The present study demonstrates that Cabazitaxel alone or in combination with 
androgen-depletion reversed EMT to MET as reflected by elevated E-Cadherin and 
decreased N-Cadherin immunoreactivity (Figure 3.11, panel A). Intense nuclear 
immunoreactivity for AR was detected in the prostate tumors from control (VHC) male 
mice; upon castration-induced androgen ablation there was a marked reduction in AR 
nuclear presence associated with a diffused localization to the cytoplasm (Figure 3.11, 
panels B and C). Treatment of intact mice with CBZ resulted in a significant nuclear AR 
localization, compared to androgen-depletion mediated cytoplasmic translocation (Figure 
3.11, panels B and C).  Prostate tumor epithelial cells in castrate mice treated with CBZ 
(for 2wks) exhibited a reduced AR expression with a significant inhibition of AR nuclear 
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localization compared to VHC controls or CBZ-alone treated mice (Figure 3.11, panels B 
and C).  
The kinesin immunoreactivity profile in prostate tumors from the transgenic 
mouse model revealed decreased MCAK expression in response to CBZ (given as a 
single agent), compared to VHC controls, castration-androgen depletion or combination 
of CBZ with castration (Figure 3.11, panel B). Impairing the androgen axis (castration) 
alone or in combination with CBZ led to increased kinesin expression (Figure 3.11, panel 
B). We subsequently examined the effect of CBZ on the gene expression profile of 
critical EMT regulators in the two androgen-sensitive human prostate cancer cell lines, 
VCaP and LNCaP RT-PCR analysis of mRNA expression for E-cadherin, Vimentin and 
Twist1 (Figure 3.11, panels D, E and F) in VCaP cells after CBZ treatment, 
demonstrated a significant downregulation in all three genes within 24hrs of treatment, 
that was not affected by the presence of DHT. A similar profile of decrease in mRNA 
expression for EMT effectors in response to CBZ was observed in LNCaP cells (Figure 
3.11, panels G, H and I).    
The in vivo anti-tumor effect of CBZ alone or in combination with anti-androgen 
(MDV) against the human CRPC 22Rv1 xenografts is shown on Figure 3.13 (Dosing 
regimen described in Figure 3.12).  CBZ alone decreased tumor mass in tumor-bearing 
mice (when compared initiation vs termination of treatment per individual mouse), 
although this failed to reach statistical significance (Figure 3.13, panels A and B). CBZ 
alone or in combination with MDV3100 led to a significant reduction in body weight 
(Figure 3.12, panel C).  Tumor specimens from control (VHC) and treated mice were 
subjected to immunohistochemical analysis for the tumor growth kinetics, apoptosis and 
cell proliferation, vascularity, AR expression and localization, and kinesin expression. 
Our data indicate that treatment with CBZ alone or in combination with MDV results in 
 
109 
significant induction of apoptosis (Figure 3.13, panels C and D). The antiandrogen given 
as a single agent failed to induce apoptosis in the CRPC 22Rv1 tumors. We also 
observed a significant reduction in tumor vascularity in response to CBZ alone that was 
reversed by the combination treatment with the anti-androgen (Figure 3.13, panels C 
and E). There was a significant increase in Ki-67 immunoreactivity in response to CBZ 
treatment alone, while CBZ in combination with MDV3100 suppressed prostate tumor 
proliferation (Figure 3.13, panels C and F). Treatment of CRPC 22Rv1 cells with CBZ 
downregulates MCAK protein levels in a temporal correlation with loss of E-cadherin 
expression driven by CBZ, in the presence or absence of androgens (R1881) (Figure 
3.13, panel G). We observed a pattern of transient changes in AR expression levels in 
CRPC 22Rv1 cells in response to CBZ; As shown on Figure 3.13 (panel G) there was 
temporal reduction in full length AR levels within 24 hrs of treatment followed by a 
significant increase at 48hrs post-treatment, compared to untreated control cells (Figure 
3.13, panel G). No marked changes were detected for the AR variant V7 in response to 
CBZ. 
The impact of Cabazitaxel on EMT landscape in the CRPC xenografts was 
profiled with three marker proteins, E-cadherin, N-cadherin and ZEB-1. As shown on 
Figure 3.14 (panel A), CBZ treatment resulted in increased E-cadherin, while it 
decreased N-cadherin and ZEB1 immunoreactivity indicating abrogation of EMT 
programming in response to the taxane. These in vivo phenotypic findings in the CRPC 
xenograft model are consistent with the effect of the drug in the transgenic model of 
EMT-driven prostate tumor progression (Figure 3.11).  Also shown on Figure 3.14 is the 
effect of CBZ on reducing kinesin immunoreactivity, for both MCAK and HSET in serial 
sections of CRPC xenograft tumors (Figure 3.14, panel B).  MDV3100 treatment had no 
significant effect on HSET kinesin levels, while it reduced MCAK expression. CBZ 
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treatment reduced AR expression but it maintained a strong AR nuclear localization in 
the CRPC 22Rv1 tumors compared to VHC control (Figure 3.15, panel A). In contrast, 
the antiandrogen, MDV3100 induced a marked cytoplasmic distribution of AR (Figure 
3.15, panel A). Quantitative analysis of the cellular distribution of AR in response to 
treatment revealed a significant increase in high intensity nuclear AR in the CBZ-treated 
CRPC tumors compared to MDV3100 or combination of CBZ and the antiandrogen ( 
Figure 3.15, panel B). 
 
Conclusions 
Microtubule-stabilizing chemotherapeutic agents such as Docetaxel and 
Paclitaxel have been shown to inhibit AR nuclear localization and activity in human 
prostate cancer, an action that correlates with the therapeutic response in patients as 
discussed in Chapters 1 and 2 (Darshan, Loftus, Thadani-Mulero, Levy, Escuin, Zhou, et 
al., 2011; M.-L. Zhu et al., 2010a). Our lab and others have reported the effect of 
Docetaxel on preventing nuclear translocation of the AR from the cytoplasm in prostate 
cancer, (Darshan, Loftus, Thadani-Mulero, Levy, Escuin, Zhou, et al., 2011; M.-L. Zhu et 
al., 2010a). In sharp contrast, the present results demonstrate that in in vitro and in vivo 
models of androgen sensitive and CRPC advanced prostate tumors Cabazitaxel 
chemotherapy maintains AR nuclear localization, while it inhibits AR expression.  
Moreover, my data demonstrate that the sensitivity of human prostate cancer cells to 
Cabazitaxel was not associated with AR variant status. Thus PC3v567es (androgen 
independent with AR variant) and VCaP (androgen responsive with AR full length) cells 
exhibited comparable resistance to Cabazitaxel treatment. These findings are in accord 
with recent evidence indicating that the therapeutic antitumor effect of Cabazitaxel 
 
111 
proceeded via an AR-independent mechanism (van Soest et al., 2014). The 
mechanisms driving therapeutic cross-resistance to taxanes and antiandrogens in CRPC 
involve microtubule stabilization and inhibition of AR activity and nuclear localization by 
interfering with tubulin-AR association (Darshan, Loftus, Thadani-Mulero, Levy, Escuin, 
Zhou, et al., 2011; Mistry & Oh, 2013; M.-L. Zhu et al., 2010a). Recent studies identified 
new signaling effectors conferring mechanistic resistance to taxane chemotherapy in 
CRPC, including overexpression of  ERG (Galletti et al., 2014) and activation of the 
GATA2-IGF2 signaling axis (Vidal et al., 2015).  
Centrosome amplification promotes transient spindle multipolarity during mitosis 
and correlates with tumor aggressiveness and chemotherapeutic resistance (Ogden et 
al., 2014; Ogden, Rida, & Aneja, 2012, 2013). The phenomenon of multi-nucleation that 
predominated the Cabazitaxel- treated prostate cancer cells regardless of their AR 
variant status, as well as the ability of the drug to induce centrosome amplification in the 
resistant cancer cell lines, provides a shift in our understanding of therapeutic resistance 
to taxane chemotherapy.  Indeed, my work identified the mitotic centromere-associated 
kinesin (MCAK) is a direct target of Cabazitaxel in both androgen-sensitive and CRPC 
tumors. The kinesin spindle protein (KSP) is a molecular motor that crawls along the 
microtubules to assist cell division (also known Eg5) and different mitotic kinesins serve 
specific functions during cell division. Although a specific KSP inhibitor has been 
evaluated in Phase II clinical trials for relapsed multiple myeloma, the clinical data 
indicate that such KSP inhibitors (Ispinesip) might be used in combination with 
proteasomal inhibitors or immuno-modulators as frontline therapy for myeloma patients. 
In prostate cancer, early-phase clinical trials in CRPC patients using the first generation 
Eg5 inhibitor, Ispinesip, have met limited success (Blagden et al, 2008; Beer et al; 2008).  
The kinesin spindle protein KIF11 (Eg5) has been shown to be functionally involved in 
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prostate cancer cell growth in vitro and in vivo models (Hayashi et al, 2008; Davis et al; 
2006). In accordance with my present findings, MCAK was identified as a potential 
mitosis phase target in prostate cancer that was overexpressed in CRPC gene 
expression datasets (Sircar et al., 2012).   
 My results demonstrate that Cabazitaxel can effectively stabilize microtubule 
structures in androgen-sensitive and castration-resistant prostate cancer cells in 
accordance with the current evidence on the action of this taxane chemotherapeutic 
agent (Azarenko et al., 2014; Vrignaud et al., 2013). With the knowledge that 
Cabazitaxel was designed to bind with β-tubulin subunits and stabilize their interaction 
preventing depolymerization of the structure, once assembled, the microtubules cannot 
disassemble leading to mitotic blockade. In contrast to Docetaxel that induced 
microtubule stabilization leading to classic G2M arrest and apoptosis as well as AR 
cytoplasmic localization, I report that Cabazitaxel treatment induces severe multi-
nucleation and centrosome clustering that led to the development of mono-astral spindle 
formations in the androgen-sensitive prostate cancer cells. These aberrations of mitosis 
lent insight that in addition to microtubule stabilization, Cabazitaxel treatment targets 
expression of the mitotic kinesins which facilitate this process  (Nakouzi et al., 2014). 
The inhibitory effect of Cabazitaxel on protein and mRNA expression of MCAK and 
HSET kinesins provides an initial mechanistic insight into the ability of a microtubule 
targeting chemotherapy to effectively target a mitotic kinesin and consequently 
interfering with AR transport across the microtubules, leading to tumor suppression 
(illustrated on Figure 3.15, panel C).  The concept that kinesins determine the 
therapeutic targeting and response to Cabazitaxel in advanced prostate cancer gains 
strong support from clinical evidence documenting a  correlation between 
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overexpression of MCAK with tumor progression to advanced disease in CRPC patients 
(Sircar et al., 2012);   
Utilizing a transgenic mouse model of androgen-responsive prostate cancer that 
is driven by EMT to advanced disease, we analyzed the consequences of Cabazitaxel 
on EMT in prostate tumor progression in vivo. At 18-20wks of age, the transgenic mouse 
model is characterized by aggressive and poorly differentiated prostate tumors (Pu et al 
2009). I made the intriguing observation that prostate tumors from mice treated with 
Cabazitaxel alone or in combination with androgen deprivation, exhibited a 
phenotypically re-differentiated prostate epithelium with intact luminal secretions. One 
could argue that the plasticity afforded to a fully differentiated epithelium by Cabazitaxel 
treatment, allows individual cells to de-differentiate into mesenchymal-like derivatives in 
reversible phenotypic transformative process. Thus, during several rounds of EMT and 
the reverse process, MET allow for the formation of differentiated glandular epithelial 
structures in response to Cabazitaxel. This gains indirect support by the observation that 
the incidence of apoptosis in prostate tumors in response to Cabazitaxel, or the 
combination treatment of Cabazitaxel and androgen-depletion was lower compared to 
significant apoptosis induced by androgen deprivation. In an interesting twist of growth 
kinetics, Cabazitaxel increased the proliferative activity of prostate tumor cell populations 
similar to the intact control mice. Considering that a dynamic EMT-MET cycling has been 
functionally implicated in the formation of complex epithelial tissues (Moreno-Bueno et 
al., 2008), my data strongly support the ability of Cabazitaxel to induce epithelial 
glandular differentiation of aggressive advanced prostate tumors via reversal of EMT to 
MET, possibly driving phenotypic response to taxane chemotherapy.  
This work provides a molecular basis for the emerging role of AR variants in 
predicting therapeutic resistance of advanced CRPC to MDV (Antonarakis et al., 2014) 
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and  taxanes in experimental models of CRPC  (Thadani-Mulero, Portella, Sun, Sung, 
Matov, Vessella, Corey, Nanus, Plymate, et al., 2014). Overexpression of AR splice 
variants may preclude patients from undergoing Cabazitaxel and antiandrogen (MDV) 
combination therapy due to therapeutic resistance potentially driven by centrosome 
clustering.  An insight into this cross-resistance is provided by our observations that 
combination of Cabazitaxel and MDV (at high doses) leads to a significant growth 
stimulatory response in the CRPC 22Rv1 cells (harboring AR variants), while in the 
androgen-sensitive VCaP cells (full length AR), MDV treatment was able to overcome 
Cabazitaxel resistance.  A molecular explanation for this effect is provided by a recent 
study reporting that MDV treatment of CRPC 22Rv1 cells has no effect on AR V7 variant 
expression, while it upregulated V7 in the VCaP cells (Schweizer et al., 2015).  
In summary, the present study provides the first evidence that Cabazitaxel 
chemotherapy impairs prostate tumor progression by reversing EMT to MET towards 
phenotypically differentiated prostate glandular/luminal architecture, via disrupting the 
kinesin network. Cellular re-differentiation via MET conversions may account for the 
similarities in the phenotypic landscape between primary tumors and bone distant 
metastatic lesions that can dictate their therapeutic resistance to taxane-based 
chemotherapy and antiandrogens.  My findings indicate that resistance to Cabazitaxel 
can be overcome by concurrently targeting the androgen/AR axis in the androgen-
responsive prostate tumors, while in CRPC antiandrogens may further enhance 
centrosome amplification-driven resistance to Cabazitaxel, provide a new molecular 
basis for understanding therapeutic cross-resistance in prostate cancer patients failing 
treatment with Cabazitaxel chemotherapy and antiandrogens.  
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Figure 3.1:  Human Prostate Cancer Cell Response to Cabazitaxel and AR 
Targeting. Panel A, Dose response analysis of human prostate cancer cells, DU-145, 
PC3, PC3v567es, 22Rv1, LNCaP, LNCaPTβRII and VCaP to increasing concentrations 
of Cabazitaxel (10-500nM) for 96hrs. Cell viability was evaluated by the MTT assay.  
Panel B, Time course of loss of cell viability in response to Cabazitaxel (100nM, 24-
120hrs). 
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Figure 3.1 continued, Human Prostate Cancer Cell Response to Cabazitaxel and 
AR Targeting. Panel C, Effect of Cabazitaxel (100nM) treatment alone or in combination 
with antiandrogen MDV3100 (MDV, 1-10µM) on prostate cancer cell viability. Panels D 
and E, Results of cell cycle analysis of PC3v567es cells indicating that CBZ alone 
induces G2 and S phase arrest. Panels F and G, Cell cycle analysis of CRPC 22Rv1 
cells after treatment with CBZ, synthetic androgen (R1881) and MDV as single agents or 
in combination. CBZ induces G2 and S phase arrest alone or in combination with MDV. 
Data represent the mean of three independent experiments analyzed in duplicate ± 
SEM; * indicates P<0.05 as determined by one way ANOVA. 
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Figure 3.2. Dose Response Analysis of Human Prostate Cancer Cells to 
Antiandrogen Enzalutamide (MDV3100) and Docetaxel. Prostate cancer cell lines 
were treated for 24hrs with increasing concentrations of MDV/DTX/Combination and cell 
viability was assessed using MTT assay. Data represent the mean of three independent 
experiments analyzed in duplicate ± SEM; * indicates P<0.05 as determined by one way 
ANOVA. Panel A, reveals the dose response to MDV treatment (0.1nM, 10nM, 1µM, 
10µM). Panel B, reveals the dose response to Docetaxel (DTX) treatment (0.1, 0.5, 1, 
2.5, 5 µM). 
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Figure 3.2 continued, Dose Response Analysis of Human Prostate Cancer Cells to 
Antiandrogen Enzalutamide (MDV3100) and Docetaxel. Panel C reveals the dose 
response of combination of MDV (1, 5, 10 µM) with DTX (1µM). Panel D reveals the 
consequences of forced overexpression of AR variants on PC3 prostate cancer cell 
migration using wound healing assay. The migration potential of PC3 parental, 
PCv3567, PC3v7 and PCv12 cells was analyzed. Data represent the mean of 
quantitated distribution of AR (N-20) in response to various treatments ± SEM; * 
indicates P<0.05 as determined by one way ANOVA. 
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Figure 3.3: Effect of Cabazitaxel on AR Localization and Gene Expression in 
Prostate Cancer Cells.  Panel A, Representative confocal images of AR expression in 
androgen sensitive human prostate cancer cells, LNCaP. Cells were treated with either 
DHT (1nM for 3hrs), MDV3100 (1µM for 24 hrs), and CBZ (25nM for 96hrs) as single 
treatments, or in combination and subjected to fluorescent labeling for tubulin, AR (N-20) 
and DAPI (nucleus). Images were visualized under 40x oil immersion confocal 
microscopy, scale bars for Tubulin and AR (N-20) are 100 µM and scale bars for Zoom 
Merge (10 µM) . Panel B reveals, Expression profile of AR(N-20), β-tubulin, and cleaved 
caspase-3 in  LNCaP cells treated with CBZ (25nM) in the presence or absence of 
R1881 (1nM) for 24-72hrs. GAPDH expression was used as a loading protein control. 
There was a significant decrease in AR within 24hrs of CBZ treatment, paralleled by 
increased caspase-3 cleavage. Panel C, subcellular fractionation of LNCaP prostate 
cancer cells, after treatment with CBZ (25nM), in the presence or absence of R1881 
(1nM). Western blots were probed for AR (N-20), Histone H3 and GAPDH. Panels D, E 
and F, Effect of CBZ (25nM) on AR mRNA expression, its target gene PSA, and FOXO1 
in LNCaP prostate cancer cells (in presence / absence of androgens). RT-PCR analysis 
shows a significant decrease in mRNA expression for the three genes, AR, PSA, and 
FOXO1 by CBZ treatment. Data represent the mean of three independent experiments 
analyzed in duplicate ± SEM; * indicates P<0.05 as determined by multiple comparisons 
of two way ANOVA.   
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Figure 3.4. Combined Effect of Cabazitaxel and Enzalutamide on AR Expression 
and Localization in VCaP Cells.  Panel A, Representative confocal images of AR 
expression and localization in VCaP cells, control (CSS), and in response to MDV (1 
µM), in the presence of DHT (1nM for 3hrs), or CBZ (100nM for 96hrs) as single 
treatments or in combination; Cells were subjected to immunofluorescence staining for 
tubulin, AR (N-20) and DAPI (nuclear presence). Images were captured under 40x (oil-
immersion) objective; scale bars are 100µM for Tubulin and AR (N-20) and for Zoom 
Merge (+DAPI) scale bars are 10µM. Panel B reveals Western blot analysis of AR (N-
20), VCaP prostate cancer cells treated with CBZ (100nM) with or without androgens 
(R1881, 1nM). GAPDH expression was used as loading control. Panels C, D and E 
represent RT-PCR analysis of mRNA expression for AR, PSA and FOXO1 genes in 
response to CBZ (100nM), in the presence or absence of R1881.  Data represent the 
mean of three independent experiments analyzed in duplicate ± SEM; * indicates P<0.05 
as determined by multiple comparisons of two way ANOVA. 
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Figure 3.5: AR variant Localization and Tubulin Expression in CBZ Resistant 
PC3v567es Cells.  Confocal microscopy was conducted in PC3v567es cells treated with 
either R1881 (1nM for 3hrs), MDV (1µM, 24hrs), and CBZ (100nM, 96hrs) as single 
treatments or in combination (CBZ and MDV).  Cells were subjected to 
immunofluorescence staining for tubulin, AR (N-20) and DAPI (nucleus). Images were 
captured under 40x oil immersion objective; for Tubulin, AR (N-20) and Merge scale bars 
are 100 µM. For Zoom Merge, scale bars are 10 µM. CBZ leads to diffused cytosolic 
distribution of AR variant v567es.   
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Figure 3.6: Cabazitaxel Results in Multi-nucleation and Centrosome Clustering in 
Prostate Cancer Cells by Targeting Kinesins. Panel A, From left to right: Human 
CRPC prostate cancer cells, DU145 treated with CBZ (35nM) for 96hrs exhibit multipolar 
spindle and microtubule bundling; LNCaP prostate cancer cells treated with CBZ (35nM; 
48hrs) exhibit mono-astral spindle formation; LNCaP, prostate cancer cells exhibit 
multipolar spindle, after treatment with CBZ (72hrs); PC3 cells transfected with AR 
variant V7 and treated with CBZ exhibit extensive multi-nucleation; VCaP treated with 
100 µM CBZ for 96hrs exhibit multipolar spindle and multi-nucleation. Scale bars are 10 
µM. Panel B reveals the expression profile of kinesins, KIF2C (MCAK) and KIFC1 
(HSET) protein in human prostate cancer cell lines. Panel C, Western blot analysis of 
HSET, MCAK, and β-tubulin in LNCaP cells treated with CBZ (25nM) alone, or in the 
presence of androgens (1nM R1881) for 24-72hrs. GAPDH used as loading control. 
Panel D, RT-PCR analysis of mRNA expression of KIF2C in LNCaP cells in response 
CBZ for 24, 48 and 72hrs. Panel E, Detection of pericentrin (green), actin (phalloidin-red) 
and DAPI (blue) by confocal microscopy in PC3v56es cells in response to CBZ for 48 
and 72hrs in the presence or absence of androgens. Visualized under 40x oil immersion 
objective, scale bars are 10 µM. Panel F, Confocal images of VCaP cells treated with 
CBZ revealing multi-nucleation and centrosome amplification in response to treatment; 
scale bars are 10 µM.  Panel E, Detection of pericentrin (red), tubulin (green) and DAPI 
(blue) by confocal microscopy in VCaP cells in response to CBZ for 72 and 96hrs in the 
presence or absence of androgens (1nM) or MDV (1uM) induced multi-nucleation and 
centrosome amplification in response to treatment. Visualized under 40x oil immersion 
objective, scale bars are 10 µM. 
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 Figure 3.7. Effect of Cabazitaxel on Kinesin Expression in VCaP Cells. Panel A, 
Western blot analysis of HSET, MCAK, and GAPDH in VCaP cells treated with CBZ 
(100nM) alone or in the presence of DHT for 24, 48 and 72 hrs. Panels B and C, RT-
PCR analysis of mRNA expression for KIFC1 and KIFC2 (MCAK) genes respectively in 
VCaP cells. Data represent the mean of three independent experiments analyzed in 
duplicate ± SEM; * indicates P<0.05 as determined by multiple comparisons of two way 
ANOVA. 
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Figure 3.8: Effect of Cabazitaxel on Centrosomal Amplification in CRPC 22Rv1 
cells. Detection of pericentrin, tubulin and DAPI by confocal microscopy with 
immunofluorescence in 22Rv1 cells in response to CBZ (72 and 96hrs) in the presence 
or absence of androgens (R1881) or anti-androgens (MDV). Images captured under 40x 
oil immersion objective; scale bars are 10 µM. 
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Figure 3.9. In Vivo Therapeutic Regimen of Cabazitaxel in a Transgenic Mouse 
Model of Aggressive Prostate Tumor Progression. Panel A, Schematic depiction of 
CBZ/VHC treatment administration to TRAMP+DNTGFβRII transgenic mice utilizing 
highest non-toxic therapeutic dose over a course of 14 days. Panel B, Scheduling of 
castration and CBZ/VHC treatment regime in TRAMP+DNTGFβRII transgenic mice 
utilizing highest non-toxic therapeutic dose.  
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Figure 3.9 continued, In Vivo Therapeutic Regimen of Cabazitaxel in a Transgenic 
Mouse Model of Aggressive Prostate Tumor Progression. Panel C, The relative % 
change in mouse body weight on day-14 of CBZ treatment vs. VHC controls compared 
to body weight at experiment start. Data represent the mean of percent body weight 
change of all animals ± SEM; * indicates P<0.05 as determined Student’s t-test. Panel D, 
Effect of CBZ, CSTR, and CSTR+CBZ on prostate gland weight in transgenic mice. 
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Figure 3.10. In Vivo Effect of Cabazitaxel on an Androgen-Responsive Prostate 
Cancer Model of Tumor Progression to Lethal Disease. Panel A, Histopathological 
appearance of prostate tumors from transgenic mouse model of prostate tumor 
progression TRAMP/DNTGFβRII (400x magnification, scale bars are 50 µM). Tumors 
from control mice (VHC), castrated for 14 days (CSTR), or treated with CBZ for 14 days 
alone (CBZ) or in combination with castration induced androgen depletion (CSTR+CBZ) 
were subjected to immunostaining analysis. Serial sections were used for apoptosis 
detection (TUNEL) and cell proliferation (Ki-67 and phospo-H3 nuclear staining). Panel 
B, immunostaining for phospho-histone H3 expression identifying endoreduplication of 
nuclei in prostate tumor cells from the transgenic model of TRAMP/DNTβRII of 
advanced prostate cancer after 2wks of CBZ treatment; visualized under 100x oil 
immersion objective, scale bars are 50 µM.  Panel C, Quantitation of apoptosis analysis 
of TUNEL-positive cells. Panel D, Quantitative analysis of cell proliferation in prostate 
tumors from vehicle control and treated mice. The number of positive cells per high 
power field was counted and data represent the mean of three non-continuous fields 
counted by two independent reviewers (N.K. and S.K.M.)  ± SEM; * indicates P<0.05 as 
determined by one way ANOVA. 
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Figure 3.11: Cabazitaxel Impairs Advanced Prostate Cancer by Inducing MET and 
Targeting Kinesins. Panel A & B, Immunoreactivity profile of E-cadherin, N-cadherin, 
AR and MCAK expression in prostate tumor sections from control (VHC), castrated 
(CSTR), Cabazitaxel-treated (CBZ) or castration and Cabazitaxel (CSTR+CBZ) treated 
TRAMP/DNTGFβRII transgenic mice. CBZ induces EMT phenotypic changes and 
reduces AR (without affecting nuclear localization) and kinesin expression. Magnification 
400x; scale bars are 50 µM. Panel C Quantification of AR nuclear staining (3+) in 
respective sections as indicated; numerical data (expressed as % nuclear AR) represent 
the mean of three non-continuous fields ± SEM; * indicates P<0.05 as determined by 
one way ANOVA. Panels D, E and F, RT-PCR analysis of mRNA expression for EMT 
effectors, E-cadherin (CDH1), Vimentin (VIM) and Twist1 (TWIST1) in VCaP cells after 
CBZ treatment in the presence or absence of androgens (24, 72 and 96hrs). Panels G, 
H and I, results of RT-PCR mRNA profiling of EMT genes in LNCaP cells in response to 
CBZ. Data represent the mean of three independent experiments analyzed in duplicate ± 
SEM; *indicates P<0.05 as determined by multiple comparisons of two way ANOVA.   
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Figure 3.12.  Therapeutic Dosing Regimen of Cabazitaxel Treatment in Nude Mice 
Bearing 22Rv1 CRPC Xenografts.  Panel A, Schematic depiction of dosing schedule in 
nude mice bearing subcutaneous tumors of 22Rv1 treated with MDV alone (30mg/kg), 
CBZ or the combination. Panel B shows the distribution of the tumor surface area in 
individual mice (n=5) at the initiation and termination of treatment (from Panel A). Panel 
C, Effect of treatment on mouse body weight. Data represent the mean of percent body 
weight change of all animals within respective treatment groups ± SEM; * indicates 
P<0.05 as determined Student’s t-test. Panel D, The relative % change in mouse body 
weight on day-14 of CBZ treatment vs. VHC controls compared to body weight at 
experiment start.  
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Figure 3.13. Effect of Cabazitaxel and Antiandrogen (Enzalutamide) on CRPC 
Xenograft Growth. Male nude mice were inoculated with CRPC 22Rv1 cells and when 
prostate tumors were palpable mice were exposed to vehicle (VHC), Cabazitaxel alone 
(CBZ), Enzalutamide (MDV) or combination (CBZ+MDV) for 2wks. Three days after the 
last treatment tumors were surgically excised and subjected to immunostaining analysis. 
Panel A, Characteristic images indicating gross appearance of prostate tumors after 
various treatments. Panel B, indicates the quantitative numerical data of tumor mass (g) 
of the 22Rv1 xenograft tumors in response to various treatments. Panel C, reveals 
immunohistochemical assessment of serial sections of 22Rv1 tumor xenografts, for 
apoptosis (TUNEL), CD31 (vascularity) and cell proliferation (Ki-67); scale bars are 50 
µM. Panels D, E and F, Quantitative analysis of the numerical data for the TUNEL-based 
detection of apoptosis incidence, CD31-detected vascularity and Ki-67–based 
proliferative index, respectively. The number of positive cells per high power field was 
counted and data represent the mean of three non-continuous fields counted by two 
independent reviewers ± SEM; * indicates P<0.05 as determined by one way ANOVA. 
Panel G, Western blot analysis of AR (N-20), kinesin MCAK and E-cadherin (EMT) in 
22Rv1 cells treated with CBZ (35nM) alone, or in the presence of androgens (1nM 
R1881) for 24-96hrs. GAPDH was used as loading control. Numerical data indicate the 
relative expression based on densitometric analysis.   
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Figure 3.14.  Cabazitaxel Reverses EMT and Retains Nuclear AR in Human CRPC 
Xenograft.  Panel A, Profiling of the EMT landscape in 22Rv1 prostate xenografts in 
response to CBZ and antiandrogen (MDV) treatment as single agents or as combination 
regime. Serial sections from control (VHC) and treated tumor-bearing mice were 
subjected to immunostaining for protein markers, E-cadherin, N-cadherin and Zeb-1; 
Magnification 400x, scale bars are 50 µM. Panel B, Effect of CBZ treatment on kinesin 
immunoreactivity, for MCAK and HSET proteins.  Lower panel indicates H&E staining of 
serial sections of CRPC tumors.  
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Figure 3.15:  Therapeutic Action of Cabazitaxel by Targeting AR and Mitotic 
Kinesins in CRPC.  Panel A, CRPC prostate 22Rv1 tumors from VHC control and after 
treatment with MDV3100, Cabazitaxel as single agents or in combination were subjected 
to AR (N-20) immunostaining. Magnification 400x; scale bars are 50 µM.  Cabazitaxel 
reduces AR expression but retains AR nuclear localization compared to VHC.  Panel B, 
Data represent the mean of quantitated distribution of AR (N-20) in response to various 
treatments ± SEM; * indicates P<0.05 as determined by one way ANOVA. Panel C, 
Schematic illustration of targeting actions of CBZ against AR (independent of status) and 
Kinesins leading to EMT reversal and apoptosis. CBZ inhibits kinesin expression (at 
protein and mRNA level) and reduces AR expression and activity (full length and 
variants). The inhibitory effect by Cabazitaxel on mitotic kinesins across the microtubules 
however compromises export of AR from the nucleus into the cytosol, retaining nuclear 
AR localization and thus conferring therapeutic resistance. Combination of Cabazitaxel 
with androgen deprivation therapy (ADT) causes cytosolic distribution of AR (full length 
variants) towards overcoming cross-resistance. Therapeutic response to Cabazitaxel in 
advanced prostate cancer proceeds via novel action in causing phenotypic reversal of 
EMT to MET and multi-nucleation, (in addition to G2M + S phase arrest and apoptosis 
induction). 
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Chapter 4. Discussion 
Taxane-based chemotherapy is an effective treatment for CRPC via stabilization 
of microtubules. Previous studies have demonstrated that microtubule-stabilizing 
chemotherapeutic agents such as Docetaxel and Paclitaxel inhibit AR nuclear 
localization and activity in human prostate cancer, an action that correlates with the 
therapeutic response (Darshan, Loftus, Thadani-Mulero, Levy, Escuin, Zhou, et al., 
2011; M.-L. Zhu et al., 2010a).  Moreover, the interaction between AR and tubulin occurs 
via binding in the N-terminal domain of AR (M.-L. Zhu et al., 2010a). My initial studies 
investigated the anti-tumor efficacy of a combination of AR N-terminal targeting EPI with 
Docetaxel chemotherapy in models of prostate cancer (Chapter 2). I found that there 
was no significant effect on the androgen-mediated nuclear transport of AR variants and 
AR transcriptional activity by Docetaxel. Given that 22Rv1 cells the full-length AR as well 
as the AR splice variants, this result was not entirely unexpected. These results gain 
mechanistic support from recent evidence by Chan and colleagues demonstrating that 
AR splice variants activate AR target genes and promote prostate cancer growth 
independent of canonical AR nuclear localization signal (S.C. Chan et al., 2012). More 
recently, it was reported that nuclear translocation and transcriptional activity of AR V7 
variant was not affected by microtubule-targeting chemotherapy while ARv567es could 
associate significantly with microtubules and be modulated as such by taxanes 
(Thadani-Mulero, Portella, Sun, Sung, Matov, Vessella, Corey, Nanus, Plymate, et al., 
2014).  Treatment of CRPC with EPI leads to decreased transcriptional activity of both 
full-length AR and constitutively active truncated variants (Andersen et al., 2010; Myung 
et al., 2013).  Further understanding of the mechanisms of aberrant activation of AR and 
the distinct transcriptome of AR variants compared to full length wild-type AR, is central 
to the optimization of therapeutic targeting of CRPC and of major significance in patients 
who failed Docetaxel therapy.   
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The therapeutic response to Docetaxel was greatly enhanced by inhibition of the 
NTD of AR (by EPI) through cycling of EMT to MET among prostate cancer epithelial 
cells.  These results support that transient “programming” of EMT by the AR NTD 
inhibitor, potentially drives the sensitivity of prostate tumors with differential distribution 
of AR variants to microtubule-targeting chemotherapy.  My work provided the first 
evidence that combination of the microtubule-targeting agent, Docetaxel with targeting 
the AR NTD with EPI leads to enhanced anti-tumor action possibly via changes in the 
EMT landscape and the cytoskeleton of prostate cancer cells harboring AR variants. A 
functional significance of the EMT process in therapeutic response to microtubule-
targeting is supported by the recently reported association between reduced E-cadherin 
expression and Docetaxel-resistance in prostate cancer cells (Puhr et al., 2012). 
Reduced E-cadherin expression promotes loss of cell adhesion, cell polarization, and 
gain of cell migration, which leads to invasion and metastases (J. Yang & R. A. 
Weinberg, 2008; Yilmaz & Christophori, 2009).  Moreover, there is growing clinical 
evidence implicating EMT as a cellular mechanism conferring therapeutic resistance, 
development of metastases, and contributing to patient mortality (Puhr et al., 2012).  
Considering that interference with the androgen / AR signaling axis is associated with 
EMT induction (Matuszak & Kyprianou, 2011b; Y. Sun et al., 2011; M. Zhu & Kyprianou, 
2010), Docetaxel administration prior to androgen deprivation with EPI may result in 
improved therapeutic outcomes via navigating the EMT-MET cycling, towards 
cytoskeleton remodeling and sensitizing prostate tumor cells to androgen- depletion 
mediated apoptosis.  An alternative mechanistic scenario is that mutations in tubulin may 
affect the binding sites of taxanes leading to therapeutic resistance (Giannakakou et al., 
1997; Orr et al., 2003). One may argue that when taxanes are structurally unable to 
effectively bind tubulin, the microtubules can no longer become stabilized, an effect that 
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fails to elicit disruption of cell cycle progression, and consequentially the AR is free for a 
nuclear translocation (schematically illustrated on Figure. 2.8.D).  
In subsequent studies (Chapter 3), I focused on the anti-tumor action of 
Cabazitaxel, a 2nd line chemotherapy in models of CRPC. My results provided intriguing 
new insights into the ability of Cabazitaxel not to block AR translocation to the nucleus, 
but to reduce AR expression, both in vitro and in vivo models of androgen sensitive as 
well as CRPC. These observations are in sharp contrast to the effect Docetaxel has on 
inhibiting nuclear translocation of the AR to the nucleus in clinical prostate cancer 
(Darshan, Loftus, Thadani-Mulero, Levy, Escuin, Zhou, et al., 2011; M.-L. Zhu et al., 
2010b).  Moreover, the response and sensitivity of human prostate cancer cells to 
Cabazitaxel was not associated with AR expression status. Thus PC3v567es (AR 
variant) and VCaP (AR full length) exhibited similar resistance to Cabazitaxel treatment 
in prostate cancer cells. These findings resonate with recent evidence indicating that the 
therapeutic anti-tumor effect of Cabazitaxel proceeded via an AR-independent 
mechanism (van Soest et al, 2014). Until recently, the mechanisms driving the 
therapeutic cross-resistance to taxanes and anti-androgens in CRPC included 
microtubule stabilization, AR expression and activity, and decreased nuclear localization 
of AR by interfering with tubulin-AR association via dynein (Darshan, Loftus, Thadani-
Mulero, Levy, Escuin, Zhou, et al., 2011; Mistry & Oh, 2013; M.-L. Zhu et al., 2010a).  It 
was surprising that Cabazitaxel would not inhibit AR nuclear translocation similarly to 
Docetaxel and actually promote nuclear accumulation, but further that translocation of 
ARv567es would not exhibit a similar pattern of nuclear accumulation like that seen for 
full length AR.  PC3v567es cells, harboring the AR variant, demonstrated cytoplasmic 
accumulation of AR in presence of Cabazitaxel which was over ridden by androgen 
treatment.     
 
145 
Compelling mechanistic evidence from recent studies supports two new signaling 
effectors conferring resistance to taxane chemotherapy in CRPC, ERG over expression 
(Galetti et al, 2014) and the GATA2-IGF2 axis (Vidal et al, 2015).  ERG overexpression 
represents one potential contributing explanation for Cabazitaxel resistance among 
prostate cancer cell lines investigated herein. It has been shown that TMPRSS2:ERG 
gene fusions lead to over expression of the transcription factor ERG, but most recently it 
has also been shown that ERG over expression can induce microtubule bending which 
prevents taxanes from efficiently binding and stabilizing β-tubulin subunits within the 
microtubule structure (Galletti et al., 2014; Perner et al., 2006). PC3, LNCaP, DU145, 
and 22Rv1 human prostate cancer cell lines do not possess TMPRSS2:ERG or 
TMRPSS2:ETV1 fusions, but the androgen sensitive prostate cancer line VCaP has 
significant copy number gain of ERG on chromosome 21 (Perner et al., 2006).  
In accordance with existing evidence on the action of this taxane, I found that 
Cabazitaxel can effectively stabilize microtubule structures in androgen-sensitive and 
castration-resistant prostate cancer cells (Azarenko et al., 2014; Vrignaud et al., 2013). 
Cabazitaxel was designed to bind with β-tubulin subunits and stabilize their interaction 
preventing de-polymerization of the microtubule structure. Once assembled, 
microtubules cannot disassemble leading to mitotic blockade. However in contrast to 
Docetaxel that induced microtubule stabilization leading to classic G2M arrest and 
apoptosis as well as preventing AR nuclear import, I report for the first time that 
Cabazitaxel treatment can induce severe multi-nucleation, promote centrosome 
clustering, and lead to the development of mono-astral spindle formation (Nakouzi et al., 
2014). These aberrations of mitosis lent insight that in addition to microtubule 
stabilization, Cabazitaxel treatment could be modulating the function of the mitotic 
kinesins which facilitate this process. Centrosome amplification promotes transient 
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spindle multi-polarity during mitosis and correlates with tumor aggressiveness (Ogden et 
al., 2014). During cell migration in interphase, centrosome-mediated nucleation of a 
microtubule array contributes to a formation of polarized Golgi apparatus, to enable 
directionality. The biological events engaged by cancer cells to navigate their 
supernumerary centrosomes towards directionality during cell migration are not fully 
understood but their potential therapeutic targeting by microtubule-targeting 
chemotherapy such as Cabazitaxel appears promising. The present study supports such 
a notion in CRPC.   
  In my efforts to understand why Cabazitaxel would fail to prevent AR nuclear 
translocation and result in a severe endoreduplication phenotype in prostate cancer 
cells, I identified the mitotic centromere-associated kinesin (MCAK) and HSET as targets 
of Cabazitaxel. MCAK is a member of the kinesin-13 subfamily and is a non-motile, 
microtubule depolymerizing kinesin that targets to microtubule tips and utilizes its’ ATP 
hydrolysis power stroke to “flick” tubulin subunits off the end of the structure during 
mitotic progression (Desai et al., 1999; Ogawa et al., 2004; Rath & Kozielski, 2012). 
HSET is a member of the Kinesin-14 subfamily and like the rest of this subfamily is a 
“minus” end directed motor protein unlike the rest of the Kinesins. HSET promotes 
proper bi-spindle pole formation and facilitates proper cytokinesis. Furthermore, HSET 
has been shown to be overexpressed in Docetaxel resistant tumors (De et al., 2009). 
High expression of HSET has been strongly correlated with metastasis in non-small cell 
lung cancer to the brain (Watts et al., 2013). HSET is an attractive cancer target 
because its’ downregulation does not have any negative consequences in non-malignant 
cells, while interruption of centrosomal clustering is catastrophic for cancer cells with 
supernumerary chromosomes (Watts et al., 2013).  
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The inhibitory effect of Cabazitaxel on protein and mRNA expression of MCAK 
and HSET kinesins provides the first evidence that a microtubule targeting 
chemotherapy can effectively target a mitotic kinesin towards tumor suppression. 
Significantly enough, clinical evidence documented that progression to CRPC in patients 
is correlated with overexpression of MCAK (Sircar et al., 2012). This association 
resonated with our findings in the pre-clinical model of prostate cancer progression 
(Chapter 3). Another kinesin, the kinesin spindle protein (KSP) is a molecular motor that 
crawls along the microtubules to facilitate cell division (also known as Eg5 or KIF11). 
Although an inhibitor specific to Eg5 (KSP) has been evaluated in Phase II clinical trials 
for relapsed multiple myeloma, the clinical data indicate that such KSP inhibitors 
(Ispinesip) might be efficacious in combination with proteasomal inhibitors or immuno-
modulators as frontline therapy for myeloma patients. In prostate cancer, early-phase 
clinical trials in CRPC patients using the first generation Eg5 inhibitor, Ispinesip, have 
met only limited success (Blagden et al, 2008; Beer et al; 2008).  Eg5 is functionally 
involved in prostate cancer cell growth in vitro and in vivo models (Hayashi et al, 2008; 
Davis et al; 2006). In accord with our present findings, MCAK was identified as a mitosis 
phase target in prostate cancer that was overexpressed in CRPC gene expression 
datasets and is associated with disease progression as well as taxanes resistance 
(Ganguly et al., 2011; Sircar et al., 2012).   This work suggests that Cabazitaxel 
chemotherapy targets expression of these mitotic kinesins (MCAK and HSET) which 
confer resistance to Docetaxel chemotherapy, and this evidence is of high mechanistic 
significance as it provides a new molecular platform for Cabazitaxel to impart additional 
increase in survival where Docetaxel chemotherapy fails.  
Targeting the process of EMT by phenotypic reversion to MET in the context of 
the tumor microenvironment acquires an attractive therapeutic value in metastatic 
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tumors. Utilizing a transgenic mouse model of prostate cancer progression driven by 
EMT induction, I analyzed the consequences of Cabazitaxel on EMT in prostate tumor 
progression in vivo. At 18-20wks of age our transgenic mouse model is characterized by 
aggressive and poorly differentiated prostate tumors (Pu et al 2009). The paradoxical 
observation was made that prostate tumors from mice treated with Cabazitaxel alone or 
in combination with castration-induced androgen depletion, exhibited a phenotypically 
differentiated prostate epithelium with intact luminal secretions. One could argue that the 
plasticity afforded to a fully differentiated epithelium by Cabazitaxel treatment, allows 
individual cells to de-differentiate into mesenchymal-like derivatives in reversible 
phenotypic transformative process.  Thus during several rounds of EMT and the reverse 
process, MET, allow for the formation of well-differential glandular epithelial structures in 
response to Cabazitaxel. This is supported indirectly by the observation that the 
incidence of apoptosis in prostate tumors in response to Cabazitaxel, or the combination 
treatment of Cabazitaxel and castration was significantly lower compared to high 
apoptosis induced by castration-induced androgen deprivation. In an interesting twist of 
growth kinetics, Cabazitaxel increased the proliferative activity of prostate tumor cell 
populations compared to castrated mice and was similar to the intact control mice. 
Considering that a dynamic EMT-MET cycling has been functionally implicated in the 
formation of complex epithelial tissues (Moreno-Bueno et al., 2008), my data strongly 
support the ability of Cabazitaxel to induce phenotypic glandular formation of CRPC 
advanced prostate tumors via reversal of EMT.  Thus, I speculate that upon elimination 
of the primary population of prostate cancer cells targeted by Cabazitaxel and androgen-
depletion, a subset population of prostate tumor epithelial cells undergo MET (EMT 
reversal) in response to treatment, reversing the tumorigenic phenotype to well-
differentiated epithelial cells and potentially overcoming phenotypic resistance. This work 
gains support from recent evidence suggesting that resistance to Cabazitaxel 
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chemotherapy can be driven by EMT  (Figure 1.5.G) (Duran et al., 2014). Using gene 
expression profiling techniques it was identified that Cabazitaxel resistant tumor cells 
possessed alterations in the expression of EMT marker profiles. Specifically, they 
demonstrated increased expression of the mesenchymal marker Vimentin and 
decreased expression of the epithelial marker E-cadherin compared to parental controls 
(Duran et al., 2014). Similar effects were documented on Vimentin, E-Cadherin and 
Twist mRNA expression patterns in VCaP cell lines (Cabazitaxel resistant) compared to 
LNCaP (Cabazitaxel sensitive). Thus, Cabazitaxel treatment can induce EMT MET 
cycling which may confer resistance to some prostate cancer cells and may also initiate 
programming to generate a phenotypically differentiated prostate epithelium with intact 
luminal secretions. In Chapter 2 it was described that EPI treatment induced EMT 
MET cycling which sensitized CRPC xenografts to Docetaxel treatment (Figure 
3.15). Here, it is demonstrated that Cabazitaxel resistance can be conferred by EMT 
transcriptional programming highlighting the differences between Docetaxel and 
Cabazitaxel.  
The findings presented herein provide a molecular basis for the emerging role of 
AR variants in predicting therapeutic resistance of advanced CRPC to Enzalutamide 
(Antonarakis et al., 2014) and taxanes in experimental models of CRPC (Thadani-
Mulero, Portella, Sun, Sung, Matov, Vessella, Corey, Nanus, Plymate, et al., 2014). 
Overexpression of AR splice variants may preclude patients from undergoing 
Cabazitaxel and anti-androgen (Enzalutamide, MDV) combination therapy due to 
potential therapeutic resistance. My results showed that combination of Cabazitaxel and 
MDV (at very high doses) leads to a surprising growth stimulatory response in the CRPC 
22Rv1 cells in vitro and in vivo, but not in the androgen-sensitive VCaP cells (harboring 
full length AR) or androgen-independent PC3v567es.  A molecular explanation for this 
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effect is provided by a very recent report indicating that MDV treatment of CRPC 22Rv1 
cells has no effect on AR V7 variant expression, and actually upregulated V7 in VCaP 
cells (Schweizer et al., 2015). Attractive as the potential biomarker value of AR profiles 
might emerge in predicting clinical cross-resistance to Cabazitaxel and anti-androgens in 
CRPC patients, one must consider our present data pointing to the ability of Cabazitaxel 
to overcome phenotypic resistance in prostate tumors in vivo independently of AR 
variant status and nuclear localization. This points to a potential platform to optimize 
sequencing of these therapeutics, tailored to the unique expression profiles of AR and 
the molecular and phenotypic landscape of prostate tumors in individual CRPC patients.  
This dissertation describes the first evidence that Cabazitaxel chemotherapy 
could impair prostate tumor progression to advanced disease by reversing EMT to MET 
and inducing phenotypically normal prostate luminal architecture in CRPC tumors. This 
novel taxane effect proceeds via a mechanism independent of AR variant expression 
status.  My findings are of major therapeutic significance in providing an initial molecular 
insight into mechanisms of cross-resistance between Cabazitaxel and anti-androgens in 
patients with advanced mCPCR that will direct optimization of treatment sequencing for 
CRPC patients towards bypassing such resistance in advanced disease.   
The goal of my dissertation work has been to investigate the mechanisms of 
taxane resistance in CRPC, I have utilized various therapeutic combinations to probe the 
mechanisms behind this resistance towards the sequencing of such strategies for 
effective clinical benefit in CRPC patients. The combination of the microtubule-targeting 
agent, Docetaxel with targeting the AR NTD with EPI leads to enhanced anti-tumor 
action possibly via changes in the EMT landscape and the cytoskeleton of prostate 
cancer cells harboring AR variants.   Moreover, expression of AR variants in CRPC 
patients may contraindicate the use of combination of Cabazitaxel with MDV therapy, 
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and in such cases Cabazitaxel therapy alone would be more efficacious. In CRPC 
patient populations that are screened positive for AR V7 expression, consideration 
should be given for use of Cabazitaxel chemotherapy with intermittent EPI-002 
treatment. As discussed earlier, AR V7 is an AR splice variant which lacks functional 
exons of the ligand binding domain causing it to become constitutively active; over 
expression of AR V7 confers therapeutic resistance to anti-androgens in patients with 
CRPC (Antonarakis et al., 2014).  Where MDV fails to effectively target such 
constitutively active AR splice variants, EPI-002 binds the intrinsically disordered domain 
of the NTD preventing it from initiating transcription activation functions and DNA binding 
(Figure 1.3) (Andersen et al., 2010). EPI small molecule inhibitors bind and inhibit many 
of the AR variant isoforms expressed in advanced prostate cancer tumors such as ARV7 
(Martin et al., 2014; Sadar, 2011).  EPI can still effectively bind and inhibit activation of 
many AR variant isoforms as data generated in this thesis demonstrated (Martin et al., 
2014).  Combining the unique AR targeting features of EPI with the newly revealed 
capability of Cabazitaxel to decrease AR overall expression and modulate mitotic kinesin 
dynamics could offer an effective next generation targeting platform for Docetaxel - 
resistant CRPC patient cohorts with potential therapeutic impact. 
There have been numerous trials investigating the use of mitotic inhibitors in 
combination with additional compounds with mixed results. Inhibition of Eg5 activates 
the spindle check point and induces mitotic arrest and apoptosis therefore, it is an 
attractive therapeutic target (Domenech & Malumbres, 2013). Of clinical significance is a 
recent retrospective study that identified Eg5 nuclear expression and a predictive 
biomarker of Docetaxel response in mCRPC patients and a prognostic biomarker for 
hormone naïve prostate cancer patients (Wissing et al., 2014). One such inhibitor, S-
Trityl-L-Cysteine (STLC) exhibited an effect in Docetaxel-resistant prostate cancer cells 
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that was not impaired by P-Glycoprotein upregulation (Wiltshire et al., 2010). 
Furthermore, Eg5 inhibitors AZD4877, SB-715992, SB-743921, ARRY-520, ARQ621, 
LY2523355, and MK0731 have passed Phase I clinical trials as monotherapy 
(Domenech & Malumbres, 2013).   Treatment with mitotic inhibitors have been well 
tolerated in patients and a Phase I trial investigating combination use of Eg5 inhibitor 
SB-715992 and Docetaxel in solid tumors is ongoing (NCT00169520) (Domenech & 
Malumbres, 2013). With the knowledge of the effect of Cabazitaxel on mitotic kinesin 
expression and apoptosis, promotion by preventing mitotic exit, it is tempting to consider 
exploitation of the combination of Eg5 inhibitors and Cabazitaxel therapies to overcome 
therapeutic resistance in the clinical disease (Domenech & Malumbres, 2013; Martin et 
al., 2015).  
Finally, I would like to reflect on the potential impact of my work in prostate 
cancer. Recently, a lot of attention has surrounded the use of microtubule targeting 
therapeutics in Alzheimer’s disease and other diseases in which neural regeneration is 
compromised (Lu, Lakonishok, & Gelfand, 2015). Specifically, the use of low dose 
vinblastine, another microtubule stabilizing therapeutic, has been shown to facilitate 
microtubule sliding, increase kinesin-mediated  trafficking and enhance neurite repair in 
damaged drosophila neurons (Lu et al., 2015). While these results are extremely 
promising, the results of this study primarily focus on the activity of Kinesin 1, a 
traditional minus end directed, ATP-dependent motor protein. The focus of this highly 
publicized research was on vinblastine treatment but it is certainly possible that use of 
first-generation taxanes and even Cabazitaxel could be similarly worthy of investigation. 
Certainly, neurons do not undergo mitosis and targeting of mitotic kinesins such as 
MCAK and HSET by Cabazitaxel should not be disadvantageous for these populations. 
Future investigations could be directed to the identification of other members of the 
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kinesin superfamily that can be functionally impaired by Cabazitaxel treatment in diverse 
pre-clinical and clinical settings. Thus, tubulin targeting chemotherapy can be recognized 
as a multi-target approach in diseases beyond cancer.   
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